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Abdominal aortic aneurysms (AAAs) are typically fusiform (symmetric) dilations 
of the aortic wall most commonly arising below the renal arteries. The progression is 
typically associated with an activated smooth muscle cell (SMC) phenotype, diminished 
density of mature medial elastic fibers, and an elevated presence of matrix-degrading 
enzymes (e.g., matrix-metalloproteases; MMPs), which may ultimately lead to vessel 
rupture.  Currently, no surgical or non-surgical methods are available to regress AAAs 
via regeneration of new elastin matrices to regain normal vessel contour, particularly due 
to the inherently poor elastin synthesis by adult vascular cells and absence of methods to 
stimulate the same.  Previously, the lab showed that extracellular matrix-derived factors 
based on hyaluronan oligomers (HA-o) and growth factors (TGF-β1) stimulate elastin 
regeneration by healthy vascular cells. Yet, the utility of these factors for matrix synthesis 
by AAA-derived SMCs has not been determined. Thus, the objective of this study was to 
assess the efficacy of these factors on AAA-derived SMCs (peri-adventitial CaCl2 
(aRASMCs) and intralumenal elastase-perfusion AAA models (EaRASMCs)) and further 
compare their responses to human AAA SMCs (aHASMCs). In addition, we assessed 
how the pre-existing elastic matrix content/quality influenced elastogenic inductability of 
SMCs. Finally, we evaluated a mode of factor delivery in vitro using a factor-loaded 
Extracel-HP
™




 ePTFE grafts. 
We generated rat abdominal aortic expansions (~45% and 120% increases in 
diameter for CaCl2 exposure and elastase perfusion, respectively) that had characteristics 





calcification (CaCl2 only) as identified histologically and with scanning electron 
microscopy, and increased elastolytic MMP activity as quantified by zymography. 
Primary cells derived from these expansions had similarities to human AAA-derived 
SMCs in terms of decreased contractile activity (decreased α-actin, SM-22, caldesmon, 
and calponin expression) enhanced proliferation (2.5-fold and 2.8-fold greater aRASMC 
and EaRASMC counts), and reduced elastogenic capacity relative to healthy RASMCs. 
Also, there was significant differential gene expression of EaRASMC relative to 
RASMCs, supporting our hypothesis that the AAA-derived cells maintain altered gene 
expression in vitro. 
Concurrent delivery of HA-o and TGF-β within our tested doses (0, 2, 20 µg/ml 
HA-o and 0, 1, 5, 10 ng/ml TGF-yielded a decrease in aRASMC and EaRASMC 
proliferation and an increase in their tropoelastin (1.5-fold for aRASMC and 1.9-fold for 
EaRASMC) and matrix elastin production (2.2-fold for aRASMC and 1.5-fold for 
EaRASMC) relative to their respective aneurysmal controls. Factors attenuated 
elastolytic MMP-2 activity in aRASMCs; interestingly, no significant decrease was seen 
in aHASMC cultures, yet an overall decrease in MMP and TIMP expression was seen 
with factor supplementation. In support of these findings, differential gene expression 
(e.g., MMP-12, TIMP-3) with supplementation of HA-o and TGF-was observed, yet 
further assessment of functional gene groups is necessary.  Overall, we believe the 
elastase perfusion-injury model of AAAs may be suitable as a surrogate in the context of 
elastin regeneration within advanced human AAAs, yet a shortcoming is the unparalleled 





fold increase in tropoelastin, 8.5-fold increase in matrix elastin relative to aHASMC 
controls).  
Observations from our in vitro elastase-injury studies illustrated the ability of cell 
layers to self-repair and regenerate elastic matrices following their proteolytic damage is 
limited, particularly when elastic matrix injury is severe. Our results also provide 
evidence that HA-o and TGF-β factors together can elastogenically stimulate RASMCs in 
elastin-degraded cultures to restore both elastic matrix amounts and elastic fiber 
deposition to levels of accumulation observed in healthy cultures. Doses of the 
elastogenic factors must be enhanced and optimized based on the severity of elastic 
matrix damage.  





 ePTFE grafts we achieved sustained TGF-β delivery over weeks, 
which is promising. In future work, our delivery approach could be applied to 
endovascular delivery in vivo at the site of AAA for elastin regeneration, elimination of 
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Aneurysms are localized dilations of elastic arteries, typically caused by disease 
or weakening of the vessel wall. They may be associated with atherosclerosis and 
vascular hypertension, or may result from vessel wall architectural changes, trauma, 
infection, enzymatic degradation, or as a result of inherited conditions (e.g., Marfan 
syndrome). The ultimate outcomes of aneurysm progression may be local vessel wall 
dissection (tear) and fatal rupture. Aneurysms are classified by shape, structure, and 
location. Abdominal aortic aneurysms (AAAs) are the most common, occur between the 
renal and iliac bifurcations and are typically associated with atherosclerosis and 
inflammation. AAAs can grow until catastrophic rupture and cause hemorrhage and 
embolisms, leading to shock and stroke 
1
. Most AAAs are asymptomatic and detected 
incidentally during clinical investigation for other conditions (e.g., ultrasound or X-ray). 
Although it is difficult to estimate their prevalence, it is estimated that AAAs are present 
in 1.3–12.7% of the adult population (depending on the age group studied and greatly 
increasing over the age of 70 years) 
2
. Current, clinical AAA treatment methods are 
primarily surgical, and include open repair, wherein the weakened aortic segment is 
replaced with a sutured synthetic mesh graft, and endovascular repair, wherein a woven 
graft mounted on a self-expanding stent is deployed at the site of AAA 
3
.  Despite their 





other surgical and graft-associated complications cause survival rates to drop drastically 
within 10 years post-surgery 
4
. Alternative AAA treatment methodologies are thus 
warranted. 
Within AAAs, vascular elastic matrices are severely disrupted. These elastic 
matrices contain fiber bundles that provide blood vessels the compliance to absorb and 
transmit hemodynamic forces to maintain blood pressure and mechano-transduce smooth 
muscle cell (SMC) behavior through binding to cell surface elastin-laminin receptors to 
regulate cell activity, particularly during vascular morphogenesis and disease. Congenital 
or acquired malformation or degradation of vascular elastin, such as in AAAs, can 
severely compromise vascular homeostasis and therefore must be preserved, replaced, or 
regenerated as a priority.  
Elastin preservative strategies aim to maintain matrix stability by inhibiting 
proteolytic enzyme production or activity. Pharmacologic agents, matrix metalloprotease 
(MMP) and other protease inhibitors, as well as transcription factor regulators, can 
attenuate matrix degradation to slow AAA progression, but do not encourage their 
regression. In the case of severely degraded vascular matrix in which the structural 
stability of the vessel is lost, replacement strategies are considered. Natural or synthetic 
matrices that resemble the size, architecture and mechanical properties of the native ECM 
are harvested or fabricated. Matrix replacement strategies include replacing lost, 
degraded, or malformed tissues using autologous, allogenic, xenogeneic, or polymer/ 





Tissue engineering (also known as regenerative medicine), which is defined as 
restoring, maintaining, or enhancing tissue and organ function, is an emerging 
multidisciplinary field involving biology, medicine, and engineering that is likely to 
revolutionize medicine. It has been proposed as a promising alternative to the 
stabilization and replacement strategies discussed. The foundation of tissue engineering 
for therapeutic applications is the ability to exploit living cells in a variety of ways using 
biomaterial, biomolecule, and mechanical stimuli to repair and/or regenerate tissue. The 




Matrix engineering is an area of expertise within vascular tissue engineering that 
incorporates the broad goals of bioengineering and the specific goals of tissue 
engineering to restore, maintain, and improve defective, damage, or injured extracellular 
matrix (ECM) tissue, which is crucial to improving vascular health and function. Elastin, 
as discussed above, is vital to vascular homeostasis, but has proven to be exceptionally 
challenging to regenerate or restore; therefore, there are specific bioengineering efforts 
being made to address the challenges of vascular elastin matrix engineering. Our 
approach seeks to utilize biological factors to stimulate endogenous cells to regenerate 
elastic matrix in AAA environments in order to restore vascular homeostasis. The 
significance of this approach lies in its potential to overcome the poor elastogenic 
potential of adult cells that deters any regenerative effort.  
The biological factors we are utilizing for elastogenic stimulation of AAA-derived 





transforming growth factor β1 (TGF-β). HA has been chosen due to its potential to 
enhance the synthesis and organization of fibrillin microfibrils, the scaffold for elastic 
fiber deposition 
6
. Specifically, HA‟s intimate binding of the proteoglycan, versican 
7
, has 
been suggested to play an indirect role in elastogenesis by further interacting with 
microfibrillar proteins (fibulin-1, 2) and elastin-associated proteins to form structures 
important for elastic fiber assembly 
7-10
. Evidently, HA brings together soluble 
tropoelastin monomers, to facilitate LOX-mediated crosslinking into matrix elastin 
11-12
, 
and stabilizes elastin fibers against degradation by proteases 
10-12
.  
TGF-β has been chosen in combination with HA because recent studies have 
shown benefits of TGF-β in matrix regeneration and vessel wall re-building in AAAs. 
Specifically, paracrine secretion of TGF-β by endovascularly seeded SMCs in rat AAAs 
decreased proteolysis by reducing MMP expression and up-regulating (tissue inhibitors 
of MMPs) TIMP-1, 2, and 3 mRNA expression, increased matrix production (by various 
cell types (SMCs and fibroblasts), and enhanced production of lysyl oxidase, critical for 
collagen and elastin crosslinking and fiber organization in situ 
13
. Gene therapy 
techniques have also been used to over-express TGF-β within already formed AAAs.  
Results paralleled those above and also qualitatively showed improved elastin 
stabilization, and endoluminal reconstruction, evidenced by generation of a collagen- and 
elastic-fiber-rich intimal lamina 
14
.  Thus, we hypothesize TGF-β and HA availability 
may be useful to trigger matrix regeneration by aneurysmal SMCs and possibly regress 





Numerous animal models exist for the study of AAAs, which recapitulate features 
of the human disease 
15-16
. Human AAAs may result from an inflammatory response 
caused by an insult to the vessel wall (i.e. atherosclerosis involving calcified lipid 
deposits) or congenital abnormalities (i.e. Marfan Syndrome involving defect in fibrillin-
1) and may include medial degradation, inflammation, thrombus formation, and rupture. 
Animal models most commonly implemented are those that have been genetically 
modified or chemically induced to form AAAs. The genetic approaches include 
engineered and spontaneous mutations that generate defects in ECM maturation, 
increased degradation of elastin and collagen, irregular cholesterol homeostasis, and 
enhanced production of angiotensin II (AngII) 
17
. AAA induction via chemical injury can 
be accomplished by the intraluminal infusion of elastase, peri-adventitial exposure of 
calcium chloride (CaCl2), and subcutaneous infusion of AngII 
17
. For the purpose of our 
studies of inflammation-induced AAAs, peri-adventitial CaCl2 and elastase intraluminal 
perfusion are relevant and well characterized rodent models. Peri-adventitial CaCl2 
exposure results in a localized insult to the vessel wall, which induces inflammatory cell 
infiltration leading to high MMP levels and chronic elastin degradation, and calcification 
resulting in time-dependent aorta expansion (e.g., 4 weeks yields ~45% aortic diameter 
increase) 
15-16, 18-19
. With this model, this caustic agent increases inflammatory cell 
infiltration and the subsequent release of matrix degrading proteases, mimicks that of 
human AAA pathology. Whereas with elastase perfusion, there is a combined effect from 
the increased pressure on the vessel wall and the enzymatic attack that play a role in 





media (the increased pressure allows for passage readily through the intima) and degrades 
the elastic matrix 
20
. The matrix degradation products then incite inflammatory response 
and further matrix degradation.  Elastase diffusion through the intima is extremely 
effective and yields more dramatic aneurysms. This results in a larger diameter and more 
elastic matrix degradation in a shorter time frame (e.g., 12 hours yields ~30% and 2.5 
days yields 300% aorta diameter increase 
21
) than the CaCl2 exposure model. Here 
increased pressure and elastase are the primary causes of elastic matrix degradation, 
although secondary degradation and vessel expansion occurs due to MMP over-
expression by late-stage recruitment of inflammatory cells. There are advantages and 
disadvantages to each of these models and both involve a complex sequence of 
biochemical and cellular events that can provide insight into this interesting pathological 
outcome and treatments thereof. Our study results will help ascertain the validity of 
studying aneurysmal SMCs from both models as a surrogate cell type for AAA-derived 
human SMCs in the context of stimulating elastin regeneration, and for developing stand 
alone or combination therapies with existing surgical or pharmacological approaches to 
regenerate elastic matrices within AAAs. 
 
1.2  Study objectives and aims 
The objectives of this project are designed based upon the background 
information presented and preliminary data collected by the lab. Previously, the lab 
showed that extracellular matrix-derived factors based on hyaluronan oligomers (HA-o) 
22-23
 and growth factors (TGF-β1) 
24-25





smooth muscle cells (RASMCs). HA-o and TGF-β1 together, which we term elastogenic 
factors, synergistically attenuated SMC proliferation and dramatically increased elastin 
synthesis, matrix yield, fiber formation, and maturation/stability.  Despite these benefits, 
the utility of these factors for matrix synthesis by AAA SMCs has not been determined. 
Thus, our objective is to assess the efficacy of these factors on AAA-derived SMCs. 
Since cell phenotype can be influenced by the specific means of AAA induction, we will 
compare elastogenic inductability of these cells using two different AAA induction 
models and further compare their responses to human AAA SMCs. In addition, we will 
assess how the pre-existing elastic matrix content/quality influences elastogenic 
inductability of SMCs. Finally, we will evaluate a mode of delivery that can be 
incorporated into current treatment approaches.  In order to achieve these goals, we 
propose the following specific aims.  
 
Specific Aim 1: Compare phenotype and elastogenic inductability of cultured SMCs 
biopsied from human AAAs (aHASMCs) and induced rat AAAs (aRASMCs). 
(A)   Demonstrate that cultured aHASMCs and aRASMCs (derived from peri-adventitial 
exposure of CalCl2 and elastase perfusion) are reliable models of the diseased cells 
in vivo. 
(B)  Compare the elastogenic potential of SMC cultures established from (a) healthy 
aortae (for both human and rat) and (b) human AAAs and the above models of 





(C)  Evaluate dose-specific matrix synthesis responses of the above cultured aRASMC 
and aHASMC populations to elastogenic factors (HA-o and TGF-β1). 
 
Specific Aim 2: Ascertain the impact of pre-existing elastic matrix disruption on 
phenotype and basal/induced elastic matrix (a) repair and (b) regeneration by vascular 
SMCs. 
 
Specific Aim 3: Develop a hydrogel-coated graft system for delivery of elastogenic 
factors.  
(A) Fabricate a hydrogel system incorporating elastogenic factors.  
(B) Assess the hydrolytic stability and factor release from the hydrogel when bound to 
graft material (ePTFE). 
 
1.3 Project significance and innovation 
Aim 1 of this study will identify the AAA induction model, of the two evaluated, 
that most closely mimics the pathology of inflammation-induced human AAAs. This 
model will then serve as the injury model of choice for further in vitro studies aimed at in 
situ regenerative elastic matrix repair by AAA-derived SMCs and isolating the impact of 
pre-existing elastic matrix quality on basal and induced elastogenic response of activated 
SMCs in cell culture models of matrix injury. To support these future studies, this aim 





stimulated, (b) identify a working range of effective elastogenic factor doses, that may 
serve as a basis for model-independent prediction of in vivo delivery doses, and (c) 
demonstrate that clinical translation of this elastogenic induction approach is feasible. 
The benefits of the cell culture approach over studies aimed at elastogenic induction of 
cells within intact aneurysms is that we will able to de-couple behavioral responses of 
cells, including matrix synthesis, from the influence of their ECM, and thus more reliably 
compare cell type-specific differences in these responses. 
Different from aim 1, the 2-D cell culture model of proteolytic injury in aim 2 will 
provide a simple, yet controlled matrix environment that will allow us to isolate the 
impact of pre-existing matrix content/ quality on basal and induced elastic matrix 
regeneration by activated SMCs, in the absence of influencing in vivo parameters such as 
inflammatory cells and thrombi. The outcomes will signify a first step towards predicting 
if and how basal and induced elastic matrix repair and new elastic matrix regeneration by 
activated vascular SMCs depends on their location within AAAs, which exhibit site-
specific differences in ECM content and quality, with more severe, generalized 
proteolysis occurring at the rupture (i.e., proximal) site and milder, predominantly 
elastolytic injury occurring at distal sites. The elastogenic induction outcomes will 
correlate the therapeutic dose of elastogenic factors to the extent of proteolytic injury, and 
will therefore signify a need to deliver a gradient of elastogenic factors across the length 
of aneurysm rather than a single delivery dose, as will be predicted from in vitro dose 





 Finally, aim 3 will provide preliminary data toward developing a strategy for 
localized delivery of elastogenic factors within intact AAAs, and demonstrate the 
feasibility of sustained release of these factors. These studies will serve as the basis for 
more involved studies in the future, directed at delivery of our therapeutic, elastogenic 
factors for in situ elastic matrix regenerative repair within AAAs, optimistically leading 
to AAA regression.  
 
1.4 Organization of dissertation 
In chapter 2, a comprehensive overview of the ultrastructure, composition, and 
distribution of the vascular matrix, elastin distribution, composition, structure, and 
function, abnormalities of vascular matrix elastin, and current strategies for restoration of 
vascular elastin homeostasis is presented.  
Chapters 3, 4, and 5 detail the effect of TGF-β1 and HA-o on elastogenic potential 
of SMC cultures established from (a) healthy aortae (for both human and rat) and (b) 
human AAAs and two different models of AAA induction in rats (i.e., peri-adventitial 
exposure of CalCl2 and elastase perfusion). The benefits of exogenous delivery of these 
factors to elastin production, stabilization, crosslinking, and maturation by aneurysmal 
SMCs will be elaborated upon. Also, we will discuss the efficacy of these models as 
surrogate models for human AAA-derived SMC elastic matrix regeneration.  
Chapter 6 details the impact of pre-existing elastic matrix disruption on phenotype 





Chapter 7 describes a hydrogel-coated graft system for delivery of elastogenic 
factors. The hyaluronan-based hydrogel system incorporating elastogenic factors is 
assessed for hydrolytic stability and factor release when bound to graft material (ePTFE). 
Chapter 8 outlines the overall conclusions derived from this project and identifies 









2.1 Ultrastructure, composition, and distribution of the vascular matrix  
 The vasculature is composed of cells and their surrounding matrix. The 
extracellular matrix (ECM) is a complex network of polysaccharides and proteins 
secreted by cells that provides support and anchorage for cells and regulates intercellular 
communication. Elastin is an ECM protein that crucially maintains structural 
configurations of vascular tissues and regulates cell-signaling pathways involved in 
morphogenesis, injury response, and inflammation. Specifically, elastin matrices contain 
closely arranged fiber bundles (lamellae) that provide vessels the compliance necessary 
to absorb and transmit forces and also provide biochemical and bio-mechanical signals 
that regulate cell proliferation and matrix synthesis. Elastin also mechano-transduces 
smooth muscle cell (SMC) behavior, particularly during vascular morphogenesis and 
disease. Vascular elastic matrices can be damaged by injury or disease, or when 
congenitally malformed or absent, and the failure to reinstate healthy elastic matrices can 
severely compromise vessel homeostasis.  
 
2.1.1 Ultrastructure of an elastic blood vessel 
To understand the role of elastin in vascular homeostasis, vascular ultrastructure 
must first be addressed. Blood vessels are composed of three layers (tunics). Each tunic is 





Moving outward from the lumen, these layers are the tunica intima, tunica media, and 
tunica adventitia. Figure 2.1 is a schematic of the vessel tunics. 
The tunica intima forms the intermost layer of a blood vessel. It consists of axially 
oriented endothelial cells, a thin sub-endothelial layer of areolar tissue, and a basement 
membrane of connective tissue.  The endothelial cells excrete molecules, such as nitric 
oxide, that inhibit platelet activation and thrombus formation. The basement membrane is 
comprised of collagen type IV, laminin, entactin, and proteoglycans (heparin sulfate) and 
is formed by the association of the basal lamina and reticular lamina. The basal lamina 
(collagen IV) and reticular lamina (collagen III and ground substances) act as a molecular 
exchange barrier between the endothelial layer and underlying mass of connective tissue, 
influence cell polarity, proliferation, and differentiation, and metabolism 
26
. 
The tunica media is the location of the majority of vascular elastin. It is bound by 
the internal (IEL) and external elastic laminae (EEL). The IEL separates the intima and 
media (arteries only). The EEL separates the adventitia and the media. This tunic is 
composed of SMCs and elastin arranged in concentric alternating bundles (lamellae). The 
elastic lamellae are surrounded by sheaths of collagen I, III, V fibers. The SMCs are 
responsible for the synthesis of the elastin molecules that compose elastic fibers, which 
organize into lamellae and regulate blood flow by constricting and dilating the vessel 
with varying hemodynamic stresses 
27
.  
The tunica adventitia is the outermost layer of the vessel and consists of a 





over-expansion due to luminal blood pressure. The adventitia is also responsible for 









2.1.2 Composition, distribution & structure of the vascular matrix 
The vascular matrix structure is dependent upon the vessel function. Major, 
conducting (elastic) arteries have thick walls and contain large amounts of elastin, which 
allows them to expand and contract to maintain blood pressure. Smaller, distributing 
arteries are more rigid and contain a greater quantity of collagen.  Venules and veins have 
thinner walls and much less connective tissue than arteries because they encounter much 
lower pressures. Capillaries contain an endothelial layer and basement membrane, which 
allows rapid diffusion of molecules.    
          The vascular matrix is composed of fibers (collagen, elastin, and reticulin), 





and glycosaminoglycans). Table 2.1 identifies the composition of a typical elastic artery, 
the aorta, which is further discussed below.  
 
Collagen Elastin Glycosaminoglycans Water 
5-15 % 7-15 % 0.2-2.5 % 70-75 % 
 




Collagen is an abundant protein of blood vessels and is primarily responsible for 
providing support and tensile strength. It has a helix of 3α-polypeptide chains containing 
glycine, proline, and hydroxyproline and is classified in three groups based on helix size. 
Group I (collagen type I, III, and V) participates in fiber formation. Types I and III are 
the predominant types of collagen in the vasculature. They form fibers by lateral 
aggregation and undergo lysyl oxidase mediated crosslinking. Type V is associated with 
types I and III and regulates collagen fiber formation, as well as connects the basement 
membrane to underlying extracellular matrix (ECM). Group II (types IV, VI, and VII) 
does not participate in fiber formation. Type IV contains helical interruptions that yield a 
greatly flexible molecule, which contributes usefully to the fluid structure of the 
endothelial basement membrane allowing selective passage of molecules through from 
the lumen to the underlying connective tissue. Type VI is microfibrillar collagen 
distributed in the aorta only and is thought to mediate the interaction of collagen fibers 
and cells. In addition to its structural role, collagen is also believed to be involved in 





 In cardiovascular tissues, elastin contributes up to 50% of the tissue dry weight 
31
. 
Within these vessels, particularly, those that may be classified as elastic or conducting 
(e.g., aorta, carotid, subclavian, common iliac arteries), elastin is organized as fibers and 
lamellae that form rings, circumferentially organized around the vessel lumen. These 
elastic lamellae alternate rings of SMCs to form the tunica media of the arterial wall. The 
structure and function of elastin is discussed further below.   
Glycoproteins, such as fibronectin and laminin, are not as abundant as collagen 
and elastin in the vascular matrix, but are vital to vascular homeostasis. They are 
biomolecules composed of a protein and a carbohydrate. Fibronectin is a high molecular 
weight glycoprotein that binds to receptor proteins spanning the cell membrane 
(integrins) and to the ECM. It can also specifically bind to other molecules such as 
collagen and fibrin.  It has a role in matrix deposition and coagulation, as well as 
functions in the activation and migration of inflammatory cells 
32
. Laminin is associated 
with type IV collagen networks. It also binds to cell membranes through integrin 
receptors and other plasma membrane molecules. Through these interactions, laminin 
contributes to cell attachment, differentiation, cell phenotype, and movement. 
          Proteoglycans (PGs) and glycosaminoglycans (GAGs) constitute the amorphous 
ground substance surrounding cells of the vasculature. PGs are complex macromolecules 
that contain a core protein to which at least one GAG chain is covalently bound. They are 
closely associated with collagen and elastic fibers in the ECM, which suggests 
interactions between them 
33
. GAGs (e.g., hyaluronan, chondroitin sulfate, dermatan 





consisting of a repeating disaccharide unit. This unit consists of an N-acetyl-hexosamine 
and hexuronic acid, either or both of which may be sulfated. The availability of sulfate 
groups and carboxylate groups on their uronic acid residues yields these molecules a very 
high density of negative charge. These polysaccharides bind water to become highly 
hydrated gel-like structures that resist compressive forces while permitting rapid 
diffusion of nutrients, metabolites, and hormones between blood and tissue.  
 
2.2 Elastin distribution, composition, structure, and function 
Elastin is a major extracellular matrix (ECM) protein present in dynamic 
connective tissues such as skin, lungs, ligaments, and arteries 
34
. In cardiovascular 
tissues, elastin contributes up to 50% of the tissue dry weight 
31
. Within these vessels, 
particularly those that may be classified as elastic or conducting (e.g., aorta, carotid, 
subclavian, and common iliac arteries), elastin is organized as fibers and sheets (lamellae) 
that form rings, which are circumferentially organized around the vessel lumen. These 
elastic lamellae alternate with rings of smooth muscle cells (SMCs) to form the tunica 
media of the arterial wall.  
 
2.2.1 Chemical composition of elastin  
A single gene on the human chromosome 7q11.23 codes for elastin 
35
. Elastin is 
produced as a hydrophobic protein containing a highly conserved amino acid sequence 
(VGVAPG), rich in proline (10%) and glycine (33%), and contains additional amino 
acids such as OH-proline (1%), alanin, valine, and leucine (40-50%) 
36





soluble monomer, tropoelastin, which has a secondary structure characterized by 
alternating hydrophobic (β-sheet) and hydrophilic (α-chain) regions encoded by separate 
exons 
37
. The secondary structure of elastin consists of 10% α-helices, 40% β-sheets, and 
50% undefined conformations 
38
. Figure 2.2 illustrates the alpha and beta domains 
conserved among many proteins, including elastin. The hydrophilic regions are alanine- 
and lysine-rich, while the hydrophobic domains are rich in proline, valine, and glycine 
39
. 
Lysyl oxidase (LOX), a copper-dependent enzyme, 
36
 crosslinks targeting domains 
40-41
 
of the α-helical regions, via desmosine and isodesmosine linkages
38
, to yield a  















2.2.2 Elastin ultrastructure  
Elastin may be ultrastructurally organized into individual and networked fibers 
(e.g., loose fibers and loose or compact meshes) 
43
 or inter-woven, non-fibrillar matrix 
structures (e.g., continuous sheets, fenestrated sheets) 
43
. Figure 2.3 includes scanning 
electron micrographs of some of the various elastin structures. The fibrillar structures 
Alpha helix 
Alpha helix 







contribute to the elasticity of the tissues that contain them, allowing them to 
characteristically recoil, when distending forces are removed. 
 
Figure 2.3 Scanning electron micrographs illustrating the variability in ultrastructural 




Elastic fibers (~200-900 nm diameter) are major insoluble ECM assemblies 
deposited during early development in elastic connective tissues. They are composed of a 
central core of cross linked, amorphous elastin surrounded by microfibrils 
34
 (Figure 2.4). 
The microfibrils are composed of a number of different glycoproteins, predominately 
fibrillin, which are essential both to maintain the integrity of the fibers and the ability of 
cells to interact and respond to them. Microfibrils are typically 10 nm in diameter with an 
average periodicity of 57 nm 
44
. They form linear bundles and are deposited as pre-
scaffolds onto which soluble tropoelastin monomers then coalesce and are crosslinked. 
During the elastin deposition process, the microfibrils are displaced to the periphery of 
the growing elastin fibers, and typically appear electron-dense, as opposed to the electron 










2.2.3 Biochemical roles of elastin  
In addition to rendering tissues elastic, vascular matrix elastin also regulates 
vascular cell behavior 
28, 46
. Correlative studies have demonstrated large changes in the 
composition and distribution of extracellular matrix (ECM) components during tissue 
development, cell differentiation, and in response to growth factor, hormone, and 
cytokines 
47
. Modulation of a variety of cellular functions, including secretory activities 
and gene transcription, occurs via interaction with the ECM. The ECM also serves as a 
reservoir for growth factors and cytokines 
28
. Therefore, ECM proteins, such as elastin, 
may influence cell development, survival (anchorage-dependent), proliferation, 
phenotype, migration, differentiation, and function 
48
.  
Elastin affects cell-fate. Some cell types are dependent upon anchorage to the 
surrounding ECM for survival. Anchoring junctions, such as adherens junctions and 
hemidesmosomes formed by integrin transmembrane proteins, mechanically attach cells 
and their cytoskeletons to the ECM 
49
.  Therefore, the presence or absence of elastin 
may influence cell viability. The phenotype (the appearance and behavior of cells) also 





fragmented and the fragments may encourage SMCs to change from a contractile to a 
synthetic phenotype. Additionally, cell locomotion is affected by ECM components, 
including elastin, and requires an initial polarization of the cell to promote migration in a 
particular direction. Cell movement is in response to chemical and physical cues in the 
cell environment. Therefore, the physical properties of elastin influence cell movement, 
specifically inflammatory cells in scenarios of disease. These cell-fate processes will be 
discussed further below with regard to elastin and its interaction with the elastin binding 
protein. 
Under healthy conditions, vascular SMCs in the tunica media are quiescent and 
embedded in a network of elastin-rich ECM that acts as a barrier to SMC migration
50
. 
During elastogenesis, the elastin binding protein (EBP), present on the extracellular 
domain of SMC membranes, binds the soluble elastin precursor, tropoelastin 
51
. 




, regulates intracellular 
Ca
2+  53
, and promotes cell adhesion 
54
. Mature elastin also has numerous effects on 
vascular SMCs including inducing actin stress fiber orientation, inhibiting SMC 
proliferation, and regulating cell migration 
55
. In disease states, wherein elastin has been 
broken down, the binding of elastin peptides (the soluble products of elastin 
degradation) via the elastin receptor (EBP and two other integral membrane proteins), G 
protein-coupled receptors (GPCR), or other integrins 
55
 results in activation of G 
proteins and opening of calcium channels 
55
. The Rho signaling cascade can be 
stimulated by elastin and is mediated by GPCRs, the largest family of transmembrane 
receptors 
56-57





which elastin activates a G-protein-coupled pathway, inhibits adenylate cyclase, reduces 
cAMP levels 
58
, and stimulates Rho induced actin polymerization 
57
.  
Under pathologic conditions, such as in atherosclerosis (Figure 2.5) and within 
AAAs, elastin breaks down to generate elastin peptides at an accelerated rate. These 
elastin degradation products up-regulate SMC proliferation and activate phagocytic cells 
55
. Elastin peptides are released and through their interaction with receptors present on the 
surface of fibroblasts, phagocytes, lymphocytes, SMCs, and endothelial cells (ECs) elicit 
a variety of biologic effects such as matrix-metalloprotease (MMP) over-expression, 
greater Ca
2+
 influx, enhanced vasorelaxation and chemotactic activity. In atherosclerotic 
and neointimal lesions, SMCs thus migrate from the tunica media through the internal 
elastin lamina to the intima. Protease release by these SMCs is responsible for further 
elastin destruction in the arterial wall. Elastin is similarly enzymatically degraded by 
MMPs in aneurismal vessels, specifically MMP-2 and MMP-9 released by activated 
SMCs and infiltrated leukocytes, which leads to formation of floppy, de-elastized 
vascular segments, susceptible to rupture 
50
. The degradation of elastin is the result of a 
proteolytic cascade that involves the cooperation of several degradative enzyme types 
such as serine proteases, matrix metalloproteinases, and cysteine proteases
59
.  These may 
be present in latent forms under healthy physiologic conditions, yet become activated 



















Figure 2.5 Schematics to describe SMC response to a vessel injury (A) and 




2.2.4 Contribution of elastin to vascular mechanics  
The mechanical properties of blood vessels stem from their microstructural wall 
components, such as collagen and elastin fibers and smooth muscle cells (SMCs) 
50
. 
Together with collagen, elastin gives vessels the ability to receive and transmit blood at 
high pressures without bursting. Pressure of flowing blood and wall shear stress that a 
vessel encounters critically impact these mechanical properties. Collagen limits the 
distensibility of vascular tissue and prevents tear caused by excessive stretching. Axial 
elastin fibers in intimal and adventitial layers and circumferential medial fibers help 
distribute stresses during vessel contraction and relaxation 
62
. The elastic lamellae 
provide elasticity that arteries need to absorb hemodynamic stress during systole and 






illustrates the contribution of elastin and collagen to vascular mechanics. The average 








Elastin content and organization affect vascular mechanics. Passive stiffness of 
the aortic wall is determined by the individual stiffness, content, and microstructure of 
elastin at low stresses, of collagen at high stresses, and of both elastin and collagen at 
physiologic stresses 
65
. Additionally, elastin organization plays an important role in 
arterial ageing and the development of atherosclerosis. Elastic lamellae grow increasingly 
fragmented and fibrotic with age
66
, which can be seen in Figure 2.7, and in a similar 
manner elastin disruption occurs in the development of atherosclerotic plaque, both of 
which result in arterial stiffening, though for different reasons 
67
. In arterial plaques, 
elastin breakdown generates soluble peptides that interact with cells. There is an 
increased Ca
2+
 influx, which causes calcification and wall stiffening.  
The bulk, as well as nano-scale mechanical properties of ECM/ scaffolds, have 





believe matrix organization (fibrils) provide topographical and/ or mechanical features 
that are important determinants of cell phenotype 
68
. Cells interact with elastin through 
the elastin binding protein (EBP), which binds the tropoelastin
51
. Mechano-transduction 
between elastin and SMCs occurs and transforms mechanical forces created by the ECM 
into intracellular chemical signals.  Intracellular signaling modulates a variety of cellular 





Figure 2.7 SEM micrographs of elastin matrix deposition (1-3), then fragmentation with 
age (4-5), within vascular tissues. Developmental induction of elastin synthesis increases 
7 to 14-fold between 17 and 19 weeks of gestation. (1,2) Fetal elastic tissue contains thin 
strands of amorphous elastin associated with bundles of 10-20 nm wide microfibrils; (3a) 
At 0 years, elastic fibers are thicker, contain a more defined core of amorphous elastin 
surrounded by discontinuous microfibril coat; (3B) At 10 years the diameter of elastic 
fibers has increased to final size (40-300 nm) by deposition of amorphous elastin; (3C) At 





materials; few microfibrils; (3D) At 40 years, electron-dense materials accumulate within 
elastic fibers; (4,5) At 70+ years, electron-dense material disappears leaving „holes‟ and 





2.3 Mechanisms of elastin synthesis, maturation, and breakdown 
Vascular elastin matrix deposition occurs extracellularly in a process directed by 
vascular SMCs. Figure 2.8 illustrates the mechanism of elastic fiber assembly. 
Tropoelastin, the elastin precursor, is secreted from these cells, then crosslinked. The 
tropoelastin first moves through the extracellular space and interacts with glycoprotein 
microfibrils, which guide it to become appropriately aligned for crosslinking
70
. This 
assembly process is mediated at the cell-surface by an elastin-binding complex. The 
complex consists of two membrane proteins (55 and 61 kD), which form a link between 
the extracellular compartment and the cytoskeleton, and the elastin binding protein 
(EBP), a 67 kD protein, which binds the hydrophobic VGVAPG sequence in elastin, the 
cell membrane, and galactosugars. Binding of the galactosugars to the EBP lowers its 
affinity for both tropoelastin and for the cell-binding site, resulting in the release of 
bound tropoelastin and the dissociation of the EBP from the cell membrane. This release 
of the tropoelastin caused by the galactosugar-containing microfibrillar glycoproteins 
allows for congregation and crosslinking of the elastin precursor 
70
. The initial step in the 
crosslinking reaction is the formation of the -aldehyde, through the oxidation of lysine 
amino acid groups by lysyl oxidase (LOX ) 
71





for elastin deposition and organization into fibers; therefore, an abnormality of galactose-
containing microfibrils (e.g., glycoproteins, galactolipids, and glycosaminoglycans) may 
impair elastin assembly 
70
. If alignment and LOX-mediated crosslinking occur 
appropriately, elastin molecules are then connected by formation of desmosine (Des) and 
isodesmosine (IDes) linkages between adjacent elastin molecules. These types of 
crosslinks, specific to elastin, allow the matrix to stretch and recoil as a unit.  
 




2.3.1 Growth factor modulation of elastin synthesis 
Prior studies have shown that elastin matrix synthesis is regulated by numerous 
biochemical factors that may be broadly classified as elastin synthesis inhibitors (e.g., 
absorbic acid 
72
, basic fibroblast growth factor (FGF) 
73







), and elastin synthesis stimulators (e.g., cyclic GMP 
74
, fetal calf serum 
77
, insulin-like growth factor 1 (IGF-1) 
78
, transforming growth factor β1 (TGF β) 
79
, and 
mechanical stretch/cyclic distention) 
80





transcription level and biosynthesis of elastin. Additionally, recent studies have 
implicated the ECM proteoglycan, versican, in mediating increase in cellular tropoelastin 




 Biosynthesis Transcription levels 
Inhibitors   
Absorbic acid
72
 - - 
FGF
73
 - - 
Cyclic AMP
74
 - ? 
Monensin
75
 - - 
Aging
76
 - - 
Stimulators   
Cyclic GMP
74
 + ? 
Fetal calf serum
77
 + + 
IGF-1
78
 + + 
TGF-β
79
 + + 
Mechanical stretch/cyclic distention
80
 + ? 
 
Table 2.2 Effects of various factors on elastin biosynthesis and transcription levels. 
 
 
2.3.2 Impact of GAGs on elastin synthesis and organization 
Other than those listed above, certain ECM molecules such as 
glycosaminoglycans (GAGs) may have elastogenic qualities as well. GAGs contain 
repeating disaccharide units consisting of uronic acid and hexosamine components (e.g., 
glucuronic acid and n-acetyl-d-glucosamine in hyaluronan (HA)). Previous studies 
describe close association between several GAG types (e.g., HA, heparin sulfate) and 







tissues. While some GAGs (e.g., dermatan and chondroitin sulfates) inhibit 
elastic fiber formation 
6, 70, 91





of microfibrils (fibrillin), a precursor for elastic fiber deposition 
6
. HA has been suggested 
to play an indirect role in elastogenesis through its intimate binding of versican 
7
, which 
in turn interacts with microfibrillar proteins (fibulin-1, 2) and elastin-associated proteins 
to form higher-order macromolecular structures important for elastic fiber assembly 
7-10
. 
Evidently, some highly anionic GAGs (e.g., HA) coacervate soluble tropoelastin, to 
facilitate LOX-mediated crosslinking into an insoluble matrix 
85, 86
, and stabilize elastin 
fibers against degradation by elastase 
10-12
. Additional details regarding HA and its effects 
on elastin synthesis and organization can be found in Section 2.6.4.4.1. 
 
2.3.3 Physiologic turnover of elastin 
As seen in Figure 2.8, physiological turnover of elastin is very slow. In healthy 
tissues, very little remodeling of elastin fibers occurs in adulthood. The half life of 
vascular elastin is thus lengthy (approximately 70 years) 
92
 and minimal turnover occurs 
in healthy tissues. However, elastin degradation is greatly accelerated under certain 
pathological conditions. Physiological and pathological vascular remodeling occurs in 
response to a variety of stimuli including mechanical injury or disease induced 
inflammation. The primary ECM receptors mediating ECM remodeling are integrins, 
which act as mechano-transducers, transforming mechanical forces created by the ECM 
into chemical signals. Direct integrin signaling and indirect integrin modulation of 
intercellular signaling pathways regulate matrix remodeling and control subsequent cell 
behavior and tissue organization 
93
. Excessive matrix remodeling occurs in diseased 





arteries, including atherosclerosis and restenosis 
94
. In acquired vascular inflammatory 
diseases (e.g. atherosclerosis and aneurysms) it can be caused by the release of powerful 
elastinolytic proteases released by inflammatory cells or bacteria, matrix-
metalloproteases (MMPs), or cysteine proteases. Additionally, degradation could be due 
to genetic vascular abnormalities, such as those pertaining to elastin or fibrillin, or those 




2.3.4 Role of MMPs in elastin turnover 
 Matrix-metalloproteases (MMPs) are the enzymes typically involved in elastin 
turnover. Vascular smooth muscle cells (SMCs) release numerous MMPs that are capable 
of digesting individual components of the ECM 
94
 and are normally regulated by tissue 
inhibitors of metalloproteases (TIMPs). They are important in maintaining the vessel by 
breaking down matrix while new is being synthesized. Degradation of the matrix scaffold 
by MMPs enables cell movement and general tissue reorganization, yet also contributes 
to cardiovascular pathologic processes 
96-97
. MMPs may be chronically over-expressed 
and insufficiently regulated by TIMPs in pathologically afflicted blood vessels, leading to 
accelerated elastin breakdown and subsequent loss of biochemical and structural 
homeostasis of the vessel. 
 
2.4 Abnormalities of vascular matrix elastin        
 Abnormalities of vascular matrix elastin may be genetic and/or congenital, or may 





outcome of non-inherited, vascular proliferative diseases such as arthrosclerosis and 
restenosis, or due to direct mechanical injury to blood vessels. During injury induced 
inflammation, macrophage-derived proteases degrade the vascular elastin matrix, 
disrupting elastin-smooth muscle cell (SMC) signaling pathways, causing SMCs to 
switch to an activated, synthetic phenotype. Similarly, abdominal aneurysms develop 
when elastin is progressively degraded by matrix-metalloproteases (MMPs), enzymes 
that are involved in normal elastin turnover in healthy vessels, but are pathologically or 
genetically overproduced. Less frequently, genetic disorders can cause aberrations in 
structure or even the formation of vascular matrix elastin. In either of these cases, 
vascular elastin synthesis, structure, and stability may be variably and adversely affected 
to elicit the common downstream effects of SMC hyper-proliferation and medial 
thickening, and to further result in decreased arterial compliance and pathogenesis of 
hypertension.  
 
2.4.1 Genetic abnormalities of vascular matrix 
           Genetic abnormalities of connective tissue matrix structures, specifically elastin, 
affect cardiovascular tissues. These can be categorized into those that impact the elastin 
gene (ELN), and those that target the fibrillin or fibulin genes. Elastogenesis is regulated 
by the presence of the 67-kD elastin binding protein (EBP), which is encoded by the 
elastin gene. Congenital defects in the ELN gene can cause impaired deposition of 
insoluble elastin and accumulation of smaller elastin peptides, which transduces 
intercellular communication resulting in hyper-proliferation 
98





abnormalities affecting the fibrillin and fibulin genes impair elastin organization. 
Impaired elastogensis or elastin organization can lead to the development of potentially 
fatal connective tissue abnormalities.  
William-Beuren syndrome (WBS) affects the elastin gene on chromosome 7q11. 
It is present at birth and is estimated to occur in 1 per 7,500 deliveries 
99
. Peripheral 
arterial stenoses and hypertension result and may be caused by the deletion of 1 allele of 
the elastin gene 
100
. As a result of this deletion, people with WBS are missing one copy of 
the ELN gene, reducing the production of elastin in half, which disrupts the normal 
structure of elastic fibers. Affected patients have abnormally thick, distensible arterial 
walls, which is likely due to the abnormal elastic fiber assembly and SMC de-
differentiation leading to hypertrophy 
98
. WBS is often associated with supravalvular 
aortic stenosis. 
Supravalvular aortic stenosis (SVAS) also affects the elastin gene on chromosome 
7q11. It is caused by point mutations, translocations, and/ or deletions in the ELN gene 
and affects 1 in 13,000 live births and shows extreme clinical variability 
98
. Most ELN 
mutations in SVAS result in premature termination codons, some of which have also 
been shown to cause decay of mRNA products 
101
. The condition is characterized by 
abnormally structured elastin in the arterial walls leading to increased proliferation of 
SMCs and formation of intimal lesions. It results in an increase in elastolytic activity and 
narrowing of the arterial tree.  
Marfan syndrome (MFS) is caused by mutations in a gene on the chromosome 





prevalence of the disorder is 1-3 per 10,000 with an incidence of 25% new mutations 
102
. 
This mutation results in elastin fiber abnormalities primarily in the medial layer of aortic 
wall. Early fragmentation, poor and disorganized deposition of elastic fibers, loss of 
elastin content, and accumulation of amorphous elastin result 
103
. Secondary to fibrillin 
abnormalities are impaired SMC-elastin fiber interactions, which have been shown to be 
mediated by fibrillin-1 microfibrillar components. As discussed previously, such 
impaired interactions enhance local cellular release and activity of MMPs, serine 
proteases, or cysteine proteases, or conversely induce a local deficiency of protease 
inhibitors, including tissue inhibitor of MMPs, -antitrypsin, or cystatin C 
104
, 
exacerbating loss of elastic matrix homeostasis. 
There are additional genetic factors that contribute to elastic matrix abnormalities. 
For example, fibulin, a 6-member protein family, is hypothesized to function as an 
intermolecular bridge that stabilizes the organization of extracellular matrix structures. 
Reduced expression of fibulin-4 leads to aneurysm formation, dissection of the aortic 
wall and cardiac abnormalities 
105
. The lack of fibulin-4 leads to disrupted elastogenesis 
leading to the development of elastic fibers that contain irregular elastin aggregates and 




2.4.2 Acquired elastin disorders 
            In addition to genetic abnormalities that adversely impact the vascular matrix, 
there are acquired inflammatory and vascular cell proliferative pathologies, such as 





ultimate outcomes of severe vessel occlusion. Vascular proliferative disorders share 
common features including the disruption of elastic fibers and the accumulation of 
vascular SMCs within the intima due to a disturbance of homeostatic cues. Elastin 
regulates vascular homeostasis by signaling vascular SMCs through defined pathways to 
localize around the elastic fibers in organized lamellar units and remain in a quiescent, 
contractile state.  The disruption of elastin by inflammation, or direct mechanical injury 
can interrupt cell–matrix signaling and directly activate the SMCs. Degradation of elastin 
by macrophages, T cells, and their proteases during inflammatory disease of vessels, act 
in conjunction with the numerous cytokines and growth factors activated during vascular 
injury to incite SMCs to de-differentiate, proliferate, migrate towards the vascular intima, 
exhuberantly deposit a disorganized matrix prone to calcification, and ultimately form a 
plaque that occludes the vessel lumen. Elastic matrices have additionally been implicated 
as a negative regulator of SMC activity within the arterial wall and are therefore 
important contributors to the pathogenesis of occlusive vascular disease, not simply an 
outcome of inflammation and vascular occlusion.  Therefore, preventing elastic matrix 
degradation following vascular injury or restoring the lost/ degraded vascular elastic 




2.4.3 Abdominal aortic aneurysms (AAAs) 
Aneurysms are progressive, localized dilations of elastic arteries (Figure 2.9) 
caused by pathological weakening of the vessel wall that may have final outcomes of 





hypertension, as a result of vessel wall architectural changes, trauma, infection, chronic 
enzymatic degradation, and certain inherited conditions (e.g., Marfan Syndrome). In 
relatively less-inflammatory environments, abdominal aortic aneurysms (AAAs) develop 
from a diminished quantity of elastic fibers, accumulation of proteoglycans, and loss of 
SMCs 
107
. More commonly, they occur in concurrence with calcified lipid deposits or 
atherosclerotic plaques in the abdominal aortic wall, wherein lymphocytes and 




Figure 2.9 (A) The anatomical position of an AAA. (B) Computed tomography (CT) of 




Current, clinical AAA treatment methods are primarily surgical, and include open 
aneurysm  repair, wherein the weakened aortic segment is replaced with a sutured 
synthetic mesh graft, and endovascular repair, wherein a woven graft mounted on a self-
expanding stent is deployed at the site of AAA 
3
 (Figure 2.10).  Despite their relative 
merits and demerits, long-term cardiac/ pulmonary complications and other surgical and 









Figure 2.10 Current surgical treatment methods for AAA repair. (A) Open repair; (B) 
endovascular repair. 
 
There is great variability in the extracellular matrix of AAAs due to numerous 
influencing parameters such as AAA initiating cause, size and location, proximity to site 
of injury, stage in development, inflammatory cell involvement, thrombus formation, and 
tendency to rupture. For instance, proximal to the site of maximal diameter expansion 
AAAs exhibit great loss of both elastin and collagen, while distal to the site of maximal 
diameter expansion AAAs exhibit rapid loss of elastin with minimal net collagen loss, 
which is attributed to the differential load the vessel experiences at the proximal and 
distal sites. Also, AAAs exhibit an expression/ activity gradient of proteolytic MMPs 1, 
2, 9, and 12 with the greatest concentration at the site of rupture 
110
. MMP expression is 







Additionally, the infiltration of leukocytes has been shown to accompany increased 




2.5 Approaches to restoring elastin homeostasis 
Vascular elastic matrices contain fiber bundles that provide blood vessels the 
compliance to absorb and transmit hemodynamic forces to maintain blood pressure. 
Elastin also mechano-transduces smooth muscle cell (SMC) behavior through binding to 
cell surface elastin-laminin receptors to regulate cell activity, particularly during vascular 
morphogenesis and disease. Therefore, congenital or acquired malformation or 
degradation of vascular elastin can severely compromise vascular homeostasis and 
therefore must be preserved, replaced, or regenerated as a priority.  
 
2.5.1 Elastin stabilization 
Elastin preservative strategies aim to maintain matrix stability by inhibiting 
proteolytic enzyme production or activity. Pharmacologic agents, MMPs and other 
protease inhibitors, as well as transcription factor regulators, can attenuate matrix 
degradation to slow AAA progression, but do not encourage their regression. These 
approaches are further discussed below.  
Pharmacologic inhibition of MMPs 2 and 9 (over-expressed within AAAs by 
SMCs, fibroblasts, and recruited inflammatory cells) using non-antibiotic tetracyclines 
(e.g., doxycycline) have been shown to inhibit AAA formation in rats 
113
. Also, in a 





patients treated with doxycycline 
114
. These promising results have resulted in MMP 
inhibition with doxycycline to proceed toward larger clinical trials to inhibit AAA 
expansion. 
Within AAAs, a marked imbalance in amounts and total activities of MMPs and 
endogenous tissue inhibitors of MMPs (TIMPs) has been noted. Therefore, exogenous 
TIMP delivery is being investigated as a means of arresting AAA growth. MMP 
inhibition may inhibit plaque-stabilizing mechanisms, such as SMC growth, while 
conversely retarding ECM destruction and subsequent vessel rupture. The development 
of selective MMP inhibitors, that do not have inhibitory effects on SMC function, may be 
useful therapies to prevent plaque rupture 
115
. 
Protease inhibitors bind to elastase enzymes to prevent unrestricted and 
potentially harmful effects of proteases on elastin matrices. The most common group of 
protease inhibitors that protect tissues from protease attack, and subsequent matrix 
degradation are serine proteinase inhibitors.  Loss or absence of these elastase inhibitors 
due to inherited genetic defects (e.g., anti-trypsin deficiency) can lead to elastin 
degradation.  Exogenous delivery of alternative elastase inhibitors, or transfection of 
vascular SMCs with genes (e.g., -1 antitrypsin gene) can help regulate in vivo 
production of these elastase inhibitors and inhibit elastin degradation 
116
. 
Transcription factors regulate formation of RNA that codes for assembly of 
proteins in the cell cytoplasm.  Transcription factors can be selectively activated or 
deactivated.  In the vascular context, inflammation is specifically regulated by 





degradation of matrix components.  Therefore, inhibition of such transcription factors is 
an approach to treat matrix degradation 
117
. 
Chemical stabilization of vascular elastin is a novel approach to limit elastin 
degradation. Specifically, Isenburg et al. has shown pentagalloyl glucose (PGG), a 
polyphenolic tannin produced from tannic acid, decreases elastin loss and preserves 
integrity of elastic lamellae 
118
. In a rat model of CaCl2 –induced AAA, PGG has been 
shown to inhibit elastin degeneration, limit aneurysm expansion, and hinder AAA 
development without increasing inflammation, calcification, and MMP activity 
118
. This 
is a promising technique to preserve vascular elastin.  
Despite the promise of these techniques, active regression of AAAs is limited or 
non-existent due to lack of new elastin regeneration and existing matrix disruption. 
Emerging studies in the field have sought to address this problem. 
 
2.5.2 Elastin replacement strategies  
In the case of severely degraded vascular matrix in which the structural stability 
of the vessel is lost, replacement strategies are considered. Natural or synthetic matrices 
that resemble the size, architecture and mechanical properties of the native ECM are 
harvested or fabricated. Characteristics of an ideal blood vessel substitute include: strong, 
compliant, kink restistant, good suture retention, non-toxic, non-immunogenic, low 
thrombogenicity, biocompatible, readily available, and low processing or manufacturing 
costs 
5
. Matrix replacement strategies include replacing lost, degraded, or malformed 





Autologous grafts (e.g., greater saphenous vein or internal mammary artery) are 
the most viable clinical option for replacement of a vessel, but are limited by a lack of 
quality and availability. The major benefit of using autologous grafts is no immune 
response. Many patients simply do not have enough appropriate blood vessels for use as 
grafts. Typically, the blood vessels are diseased or the blood vessels were used in a 
previous surgery 
119-120
. In such cases, allogenic, xenogenic, or synthetic graft materials 
are implemented.  
Allogenic tissue grafts are an attractive substitute for replacing vessel segments 
due to identical structural makeup, mechanical properties and size-matches.  They may be 
sourced from vessels from deceased fetuses, cadavers, and umbilical cords
121
. Allogenic 
tissue may produce an immune response from the recipient and graft rejection may occur. 
Therefore, lifelong immuno-suppression is required to ensure allograft survival.  More 
recently, techniques have been developed to extract immunoreactive epitopes and 




Xenogenic (e.g., bovine or porcine) materials present problems of end-stage organ 
failure, different lifespan of recipient and donor, disease transmission, and permanent 
alteration to the genetic code.  The biggest challenge for xenografted tissue is immune 
rejection due to cross-species transplants being more likely to produce host-graft 
reactions than same-species transplants.  Processing of xenografts (e.g., SDS treatment) 
to remove immunoreactive molecules and cells is the most commonly utilized method to 





integrity of the resulting acellular matrix composed of elastin and collagen.  Compliance 
mismatch, elastic degradation, and mechanical stiffening are resulting problems 
122
. 
Additionally, due to the lack of endothelium of decellularized grafts, they are 
thrombogenic. To overcome this problem researchers have done autologous vascular cell 
seeding of the luminal surface establishing a confluent monolayer of cells 
123
. 
Synthetic polymers provide an alternative to natural polymers for vessel 
replacement. Dacron (polyethylene terepthalate, PET), Teflon (expanded 
polytetrafluoroethylene, ePTFE), and polyurethanes (PUs) are typical, readily available 
synthetic conduits 
124
. Problems associated with synthetic polymer grafts are early post-
operative thrombosis, long-term intimal hyperplasia and graft infections. Material 
properties of the grafts greatly influence the resulting problems. Dacron has a tensile 
strength of 170-180 MPa 
124
, which is much greater than that of the aorta (800-1000 kPa) 
63
. These properties contribute to its resistance to biodegradation, but also reduce its 
compliance. Dacron is produced in either woven or knitted forms. Woven grafts are 
stronger with smaller pores while knitted grafts have larger pores that promote greater 
tissue ingrowth and are more compliant. This porous nature also increases its 
susceptibility to the infiltration of hyperplasic medial SMCs and formation of a neointima 
consisting of a fibrin, macrophages, and connective tissue. Dacron has been shown to 
remain intact for more than 10 years, yet its most common failure mode is dilation 
124
.   
Teflon is highly crystalline and has a tensile strength of 14 MPa, which is slightly 
greater than that of a native human aorta (800-1000 kPa) 
63, 124
. It has an electronegative 





addition, its porous structure provides favorable cellular reaction. Inflammatory response 
and formation of a neointima, similar to that which occurs with Dacron, occurs with 
implantation of Teflon 
124
. 
PU has shown significant applicability as a vascular graft. The porosity and 
therefore the radial compliance of the graft can be regulated 
125
. The material has hard 
domains dispersed within a soft segment matrix. The hard segment accounts for the 
strength and rigidity, while the soft segment provides flexibility. Depending on the ratio 
of the hard and soft segments, tensile strengths range between 20 MPa and 90 MPa, 
which is slightly greater than that of a native human aorta (800-1000 kPa) 
126
. PU has a 
viscoelastic and compliant nature, which is essential for blood and tissue compatibility. 
PUs have also shown thromboresistance, rapid ingrowth of living tissue and minimal 
anastomotic hyperplasia 
127
. The major problem associated with PU is the degradation of 
the soft segments. To overcome this problem, PUs with poly(carbonate) soft segments 




2.5.3 Elastin regenerative strategies 
Tissue engineering (and its in vivo counterpart, regenerative medicine), defined as 
restoring, maintaining, or enhancing tissue and organ function, is an emerging 
multidisciplinary field involving biology, medicine, and engineering that is likely to 
revolutionize medicine. It has been proposed as a promising alternative to the 
stabilization and replacement strategies discussed. The foundation of tissue engineering 





biomaterial, biomolecule, and mechanical stimuli to repair and/or regenerate tissue. The 
major goal for vascular tissue engineering is maintenance of viable and self-renewing 
vessel components 
5
. Ideally, engineered tissues should provide nutrient transport, 
mechanical stability, coordination of multi-cellular processes, and a cellular 
microenvironment that promotes phenotypic stability. 
129
 
Thus far, scientists have not created a viable vascular graft that possesses the 
necessary complex mechanical properties and mimics the biological function of a native 
artery, specifically elastin, but much progress has been made. Table 2.3 illustrates the 
progress of vascular tissue engineering conduit technology and some major contributors 
from 1906 to present. The table is not comprehensive, but illustrates the field‟s 
continuing advancement in biomaterials, cell sources, and mechanical stimuli. 
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Table 2.3 History of tissue engineered blood vessels. 
 
2.6 Matrix engineering 
 Matrix engineering is an area of expertise within tissue engineering that 
incorporates the broad goals of bioengineering and the specific goals of tissue 
engineering to restore, maintain, and improve defective, damage, or injured ECM tissue, 
which is crucial to improving health and function. The elastic matrix, though vital to 
vascular homeostasis, has proven to be exceptionally challenging to regenerate or restore. 
Therefore, there are specific bioengineering efforts being made to address the challenges 
of vascular elastin matrix engineering. The following sections will discuss the successful 
approaches that have been explored and the challenges that still exist. 
 
2.6.1 In vitro tissue engineering approaches 
In vitro approaches are those that are completely conducted in a controlled 
environment outside the body, typically in a petri dish. These approaches are important 
for preliminary investigation as a proof of concept for elastic matrix engineering 
techniques, but further investigation in vivo is necessary to verify the effectiveness of a 





investigation of the effects of specific elastogenic stimuli. Additionally, they minimize 
the number of animals sacrificed for experimentation and give a starting point for 
appropriate exposure doses of factors.  
An example of an in vitro tissue engineering approach for increasing elastin 
matrix is the work conducted by Kim and Mooney 
141
. They tested poly(L-lactic acid)-
bonded polyglycolide fiber-based scaffolds and type I collagen sponges under cyclic 
strain conditions. They found tissues engineered with type I collagen sponges subject to 
cyclic strain had greater elastin than control tissues, and the SMCs in these tissues 
exhibited a contractile phenotype. In contrast, SMCs in control tissues exhibited more of 
a synthetic phenotype. These studies indicate that a natural scaffold material and a 
mechanical stimuli are elastogenic 
141
. Many other research groups have conducted in 
vitro studies to up-regulate elastin production in vascular cell and tissue culture systems. 
It is a necessary starting point prior to in situ and in vivo elastin regeneration and repair. 
 
2.6.2 In situ elastin regeneration and repair 
Although a great deal of experimentation has been performed in vitro, in vivo 
studies are needed to better understand the technique or therapeutic approach being tested 
in physiologic conditions. An important intermediate between in vitro and in vivo is in 
situ experimentation. In situ investigation compensates for some of the limitations of in 
vitro while still allowing for greater control of the test environment.  
 Ex vivo vascular models are those in which elastic vessels are explanted from a 





physiologic environment than that of explanted cells growing in an in vitro culture 
system. The native cells and ECM structure are intact. The effects of elastogenic stimuli 
can be investigated on the vessel as a whole. This is extremely important in studies 
focusing on aneurysm repair as outlined below. 
 In situ sustained delivery of factors is more challenging than that of in vitro 
studies in which the therapeutic stimuli can be directly incorporated into culture media 
and the exposure dose of the agent to the cells is known throughout the culture period. In 
in situ and in vivo models the complex environment may decrease the exposure of the 
cells and ECM to the therapeutic agent, so more direct, controlled delivery is necessary. 
Systemic injection, peri-adventitial injection, delivery via catheterization or osmotic 
pump, and stent graft delivery are some options currently under investigation.  
 
2.6.3. Animal models for matrix engineering 
 There are numerous considerations for selection of animal models for vascular 
tissue engineering including: size match, hemodynamics, blood reactivity, calcification 
potential, endothelialization potential, pharmacokinetics (drug metabolism), 
developmental pattern, life span, ethical consideration, and cost. A list of animal models 
currently utilized for cardiovascular tissue engineering is included in Table 2.4 below. A 
few examples of the research use for each animal model, as well as the advantages and 
disadvantages of each, are listed.  
 The rat model of aortic aneurysms is well-established. This model involves a 





increased MMP levels, and eventually causes vessel expansion similar to that that occurs 
in human aneurysm formation 
142-143
. Adult rat vascular SMCs additionally poorly repair 
disrupted vascular elastin matrices in situ, in a similar manner to that of human vascular 
SMCs. Therefore, regenerative outcomes in rats may imply a similar response in humans.  
Animal 
Model 
Advantages Disadvantages Examples of Research Use 
 
Primate 
Anatomical size & lifespan 
similar to human 
Ethical concerns, 
cost 
Demonstrate chronic EC & 




Similar anatomy & 
physiology to humans 
 
Uncooperative 
without full general 
anesthetic, capable 
of rapid growth, 
cost 
Test durability & functionality 
of various TE conduits & 
small intestinal submucosa 





Large size, easy 
access to the carotid artery, 
adult animals do not grow 
Cost Evaluate a tissue-engineered 
vascular constructs, animal of 
choice for assessment of 
cardiac valves (sheep) 
 
Canine 
Convenient size, ready supply, 




Test a vascular prostheses in 





Convenience of anatomical 
Size, lower cost 
Smaller size of the 
vasculature 
 
Assess in vivo vascular 
engineering in the reduction 
of atherosclerosis post-





Cheap, easy to 
anaesthetize & work with, 
vascular healing mechanisms 
parallel that in humans, yet 
highly accelerated 
Small size presents 
quite a technical 
challenge 
 
Compare graft patency, study 
vascular pathogenesis, injury 
response, remodeling, & test 
therapies for preserving 
existing vascular matrices 
 
Mouse 




Too small for vascular use 
typically 
 





2.6.3.1 Animal models for study of AAA                                                                       
 Numerous animal models exist for the study of AAAs, which recapitulate features 
of the human disease 
15-16





caused by an insult to the vessel wall (i.e. atherosclerosis involving calcified lipid 
deposits) or congenital abnormalities (i.e. Marfan Syndrome involving defect in fibrillin-
1, an elastin associating microfibril) and may include medial degradation, inflammation, 
thrombus formation, and rupture. Animal models most commonly implemented are those 
that have been genetically modified or chemically induced to form AAAs. The genetic 
approaches are engineered and spontaneous mutations including defects in ECM 
maturation, increased degradation of elastin and collagen, irregular cholesterol 
homeostasis, and enhanced production of angiotensin 
17
. The chemical approaches 
include intraluminal infusion of elastase, peri-adventitial exposure of calcium chloride 
(CaCl2), and subcutaneous infusion of AngII 
17
.        
For the purpose of our studies of inflammation-induced AAAs, peri-adventitial 
CaCl2 injury and elastase perfusion of rodent aortae are relevant and well characterized 
models. Peri-adventitial CaCl2 exposure results in a localized insult to the vessel wall, 
which induces inflammatory cell infiltration leading to high MMP levels and chronic 
elastin degradation and calcification resulting in time-dependent aorta expansion 
15-16, 18
. 
With this model, this caustic agent increases inflammatory cell infiltration and the 
subsequent release of matrix degrading proteases, mimicking that of human AAA 
pathology. Whereas with elastase perfusion, elastase penetrates the vessel wall from the 
intima to the media and enzymatically degrades the elastic matrix 
20
. The matrix 
degradation products then incite inflammatory response and further matrix degradation.  
Elastase diffusion through the intima is extremely effective and yields more dramatic 





degradation in a shorter time frame (e.g., 12 hours yields ~30% and 2.5 days yields 300% 
aorta diameter increase 
21
). Here, elastase is the primary cause of elastic matrix 
degradation, although secondary degradation and vessel expansion occurs due to MMP 
over-expression by late-stage recruitment of inflammatory cells. There are advantages 
and disadvantages to each of these models and they both involve a complex sequence of 
biochemical and cellular events that can provide insight into this interesting pathological 
outcome and treatments thereof. A notable advantage of peri-advential treatment is the 
easy access to arterial segments, minimal mechanical damage to the arterial wall or direct 
injury of the vascular endothelium or elastic lamellae, and no systemic or metabolic 
changes to blood profile or blood pressure. 
 
2.6.4 Parameters influencing matrix engineering outcomes 
 There are numerous parameters influencing the outcomes of vascular matrix 
engineering techniques including whether the approach is acellular or cellular. In the case 
of cellular approaches, cell source, cell signaling, biomaterial selection, mechanical 
conditioning, and growth factors influence the success of the strategy greatly. These 
parameters are discussed further below.  
Acellular approaches utilize biologic scaffold materials that provide a 
regenerative tissue matrix, but do not incorporate cells. The biologic scaffold serves as a 
mechanical reinforcement for the soft tissues and provides an area for parenchymal cell 





Incorporating cells in a natural or synthetic scaffold is another method being 
thoroughly investigated for vascular matrix engineering. Numerous cell sources are being 
considered including embryonic stem cells, adult progenitor and stem cells, vascular 
endothelial cells, and vascular smooth muscle cells. The cell donor can be the recipient 
(autologous), a different animal of the same species (allogenic), or a different species all 
together (xenogenic). Cell based therapies have promise as a regenerative strategy, but 
continued expansion of biological and biomaterial knowledge is necessary to bring cell-
based therapies forward. Key topics being addressed are how cells assemble the 
architecture of vascular tissues and what signals guide the molecular assembly.  
 There are issues that must be kept in mind for cellular approaches, specifically in 
clinical studies. First, the manpower, cost, and time associated with harvesting cells, 
allowing them to proliferate in vitro for weeks, then implanting them in the recipient, is 
large. Second, there is variability that will exist between patients; remodeling that will 
take place within a body can be extremely different, depending on the individual. Also, 
the therapy, in whatever form it takes, must overcome the disease state of the individual 
(e.g., pathophysiological conditions) 
145
. Finally, if the cells are not autologous, there is a 
key issue of immunogenicity 
145
.  
The following sections discuss the many parameters that influence cellular 
approaches to vascular elastic matrix engineering including: cell sources, cell signaling, 
biomaterials, mechanical stimuli, growth factors, and matrix/substrate impact. Successful 
results of approaches that take these parameters into account in their experimental design 





2.6.4.1 Cell sources 
The use of autologous cells eliminates the issues involved in immune acceptance, 
but has a large time constraint; they cannot be used in emergency scenarios because they 
do not have off-the-shelf availability. Autologous cells must be harvested, propagated for 
a number of weeks to acquire adequate cell numbers, and returned to the donor. Off-the-
shelf availability is important because it will make the clinical treatment or therapy 
available to the wide population of patients in need
145
. Alternatively, the use of allogeneic 
and xenogenic cells does provide for off-the-shelf availability; however, these cells 
require a strategy for immune acceptance. Further issues involve cell isolation and 
procurement, expansion, differentiation, and movement to specific sites. The cell lineage 
is important as well. Vascular smooth muscle cells (SMCs) are commonly used for 
vascular elastin matrix engineering because of the native role of SMCs in elastin 
synthesis as discussed previously. Primary cell lines are typically used to encourage 
matrix production similar to in vivo. 
The goal of cell-based tissue engineering is to encourage tissue regeneration, 
regardless of the cell source or lineage. Cells sense soluble factors and their physical 
environment including growth factors, cell- substrate (matrix) interactions, and cell-cell 
interactions. The key to regenerative medicine is to deliver the correct signals at the right 
place and at the ideal time 
145
. The ability of cells to perceive and correctly respond to 
their microenvironment is the basis of tissue repair and homeostasis and thus is vital to 





Cells receive information from their environment through receptors, which are 
proteins present on the extracellular membrane. Receptor ligands activate or, in some 
cases, inhibit the receptors, which may be hormones, neurotransmitters, cytokines, or 
growth factors. The ligand-receptor interactions are fundamental to cell signaling. In 
some cases, receptor activation is directly caused by ligand-receptor binding, whereas in 
other cases, the activated receptor must first interact with other proteins inside the cell 
before the ultimate physiological effect of the ligand on the cell's behavior is produced. 
Often, the behavior of a chain of several interacting cell proteins is altered following 
receptor activation (signal transduction pathway). Cell biology advancements in cell 
signaling pathways will greatly aid bioengineers in designing cell-based therapies. 
 
2.6.4.2 Biomaterials selection  
If the key to success of cell-based regenerative medicine approaches are the 
signals that are delivered, then “smart” instructive biomaterials 
145
 are of vital importance 
to a successful tissue engineering approach. These can be biologic or synthetic and have 
instructive influence on cells due to their chemistry, architecture, and scale of surface 
features. Material surface modification or controlled release of biologically active 
materials could provide the necessary signals or cues to facilitate cell-mediated tissue 
regeneration. 
Biologic scaffold materials include collagen, elastin, fibrin, and 
glycosaminoglycans (GAGs). The most popular biopolymer in vascular engineering is 





component in the ECM wall, making it a natural cell substrate. Bovine collagen I  has 
been approved by the Food and Drug Administration (FDA) 
146
.  Scaffolds can be 
constructed in the form of a hydrogel within a hollow cylindrical mold and the mild 
fabrication conditions allow direct cellularization by cell entrapment. Also, 
electrospinning techniques can be implemented to obtain scaffolds with controlled 
characteristics (e.g., fiber size, porosity). Additionally, pure tubular elastin and pure 
collagen scaffolds prepared from porcine carotid arteries have been investigated 
147-148
. 
Elastin stabilization by tannic acid (TA), a polyphenol capable of protecting elastin from 
enzymatic degradation, in conjunction with glutaraldehyde (Glut) treatment has been 
shown to increase the stability of fixed aorta against elastin digestion by 15-fold and 
decrease  calcification in the rat subdermal model by 66% 
149
. Biologic scaffolds are a 
promising matrix engineering scaffold material. 
The most commonly used synthetic degradable polymers are polyglycolic acid 
(PGA), poly-L-lactic acid (PLLA), poly-D,L-lactic-co-glycolic acid, and polyurethanes. 
PGA and PLLA and its copolymers are biodegradable. Synthetic scaffolds have the 
advantages of industrial-scale replication and controllable biochemical and mechanical 
qualities including degradation products, degradation time, compliance, tensile strength, 
and size. Alteration of the polymers is common. For example, PGA, the most common 
synthetic scaffold, is copolymerized to improve its long-term mechanical stability with 






, polycaprolactone-co-polylactic acid 
153








Hybrid vascular grafts have also been created by combination of natural and 
synthetic polymers. For example, hybrid vascular prostheses have been developed using 
SMCs and collagen reinforced with a knitted, segmented polyester mesh. The grafts have 
been successfully seeded with endothelial cells and exhibit similar compliance to native 
tissue under pulsatile flow conditions 
155
. Table 2.5 illustrates various scaffold materials 
and cell type combinations that have been published. The list is not comprehensive, but it 
illustrates some of the major advancements over the last 20 years. 









Collagen Bovine aortic 
SMCs 
Poor Not tested  








cord vein SMCs 
& ECs 
Poor Not tested  







SMCs & ECs 
Poor Canine posterior 
vena cava 
65% at 6 
months 




None Human umbilical 
vein SMCs & 
ECs, human 
dermal fibroblasts 
Good Canine femoral 
artery 
50% at 7 
days 







SMCs, ECs, & 
fibroblasts 
Good Ovine infrarenal 
aorta 
100% at 5 
months 




PGA Bovine aortic 
SMCs & ECs 
Good  Bovine 
saphenous artery 
100% at 4 
weeks 







vein SMCs & 
fibroblasts 
Moderate Canine inferior 
vena cava 
 100% at 
13 months 







cord cells & 
human dermal 
fibroblasts 
Good Canine femoral 
artery 
50% at 7 
days 











& smooth muscle 
cell 
Good Canine carotid 
artery 
100% at 6 
months 
 








Whether investigating natural or synthetic scaffold materials, cellularization is 
necessary and can be accomplished by cell infiltration or cell seeding techniques 
141
. The 
scaffold initially acts as a mechanical support until infiltrating cells are able to produce a 
significant amount of ECM to maintain the mechanical stability. For synthetic, 
biodegradable scaffolds, the polymer resorption and tissue infiltration should occur at the 
same rate. Cellular interaction with the scaffold  can be accomplished by incorporating 









2.6.4.3 Mechanical Conditioning 
Mechanical conditioning is another consideration for tissue engineering vascular 
grafts. Blood vessels experience shear stress, luminal pressure, radial stretch, and 
longitudinal stretch. Table 2.6 outlines shear stress and cyclic strain and their effects on 
vascular cells. These forces act independently and synergistically to control the behavior 
of vascular tissues 
160, 164-165
. Bioreactors have been designed to imitate these mechanical 
stresses and have been found to increase matrix production and cell and fiber alignment.  
 
2.6.4.4 Growth factors and other biomolecules 
As discussed previously in Section 2.3.1, studies have shown that elastic matrix 
synthesis is regulated by numerous biochemical factors that may be broadly classified as 
elastin synthesis stimulators (e.g., cyclic GMP
74
, fetal calf serum
77
, insulin-like growth 
factor 1 (IGF-1)
78
, and transforming growth factor β1 (TGF β)
79





implicated the ECM proteoglycan versican in mediating increase in cellular tropoelastin 
production, as well as in encourage elastic fiber formation 
81-82
. These growth factors can 
be added to the scaffold materials to promote desirable cellular activities. For instance, 
TGF β1 has been shown to increase lysyl oxidase enzyme activity and mRNA in rat 
aortic SMCs 
166
. Also, IGF-1 has been shown to regulate transcription of the elastin 
gene
78
 and stimulate elastin synthesis by bovine pulmonary arterial SMCs 
167
. 
Shear stress mediated EC response Cyclic strain mediated EC response 
Response Effect Response Effect 
Morphology Alignment & elongation   
Actin stress fiber Formation & alignment   
DNA synthesis Stimulated (if turbulent)   
Apoptosis ↓   
G proteins Acivation   




Endothelin 1 ↓ Endothelin 1  
VCAM-1 ↓ VCAM-1 ↓ 
ICAM-1 ↑   
Nitric oxide ↑ Nitric oxide ↑ 
pH ↓   
  Platelet derived 
growth factor 
No change 
Shear stress mediated SMC response Cyclic strain mediated SMC 
response 
Morphology No alignment   
Proliferation ↓ Proliferation ↑ 
Tissue plasminogen 
activator 
↑   
Nitric oxide ↑   
pH ↓ Platelet derived 
growth factor 
↑ 
  MMP 1 ↓ 
 




Recent studies have shown benefits of transforming growth factor- β1 (TGF-β) in 





by endovascularly seeded SMCs in rat AAAs decreased proteolysis by reducing MMP 
expression and up-regulating TIMP-1, 2, and 3 mRNA expression, increased matrix 
production (primarily collagen) by various cell types (SMCs, fibroblasts), and enhanced 
production of lysyl oxidase, critical for collagen and elastin crosslinking and fiber 
organization in situ 
13
. Gene therapy techniques have also been used to over-express 
TGF-β within already formed AAAs.  Results paralleled those above and also 
qualitatively showed improved elastin stabilization, and endoluminal reconstruction, 
evidenced by generation of a collagen- and elastin-fiber-rich intimal lamina 
14
.  Thus, 
TGF-β over-expression/availability may be useful to trigger matrix regeneration and 
AAA regression. It is important to note that these outcomes are specific to abdominal 
AAAs, which differ in cause, etiology, and pathology from thoracic AAs (TAAs). In 
TAAs, TGF-β over-expression is thought to be a pathological factor. Thus, TAAs are 





2.6.4.4.1 Glycosaminoglycans as elastogenic factors 
Glycosaminoglycans (GAGs) are negatively charged polysaccharides containing 
repeating disaccharides containing uronic acid and hexosamines. Variable elastogenic 
effects have been shown by different GAGs, both inhibition (e.g., dermatan and 
chondroitin sulfates) of elastic fiber formation 
6, 70, 91
 and facilitation (e.g., hyaluronan; 
HA) of the synthesis and organization of fibrillin microfibrils, the scaffold for elastic 
fiber deposition 
6
. In tissues, GAGs are closely associated with proteoglycans (e.g., 
versican) 
69, 83-90
. Specifically, HA‟s intimate binding of versican
7





play an indirect role in elastogenesis by further interacting with microfibrillar proteins 
(fibulin-1, 2) and elastin-associated proteins to form structures important for elastic fiber 
assembly 
7-10
. Evidently, HA brings together soluble tropoelastin monomers, to facilitate 
LOX-mediated crosslinking into matrix elastin
85, 86
, and stabilizes elastin fibers against 
degradation by proteases 
10-12
. Additional details on HA are below. 
Originally named hyaluronic acid due to its naturally glassy state and high uronic 
acid content, hyaluronan (encompassing the acid and salt forms) is a GAG synthesized as 
a large, negatively charged, unbranched polymer, which is composed of repeating 
disaccharides of glucuronic acid and N-acetylglucosamine 
170
 (Figure 2.11) that provides 
compressive strength, lubrication, and hydration within the ECM and regulates cell 
adhesion and motility and mediates cell proliferation and differentiation
171-172
. It is 
synthesized as an unmodified polysaccharide by transmembrane enzymes, hyaluronan 
synthases (HAS1, HAS2 and HAS3) 
173
, and has extraordinary biophysical properties that 
contribute to extracellular matrix structure and interstitial homeostasis. It also influences 
cell behavior by binding to cell surface receptors (e.g., CD44 and RHAMM) or through 
attachment to a hyaluronan synthase across the plasma membrane 
174-175
. It has been 
shown in studies of embryonic development, tissue regeneration, and healing that 
proliferating and migrating cells are in an environment highly enriched in hyaluronan 
174
. 
In disease processes, such as atherosclerosis and restenosis, altered hyaluronan-cell 
interactions causing aberrant cell behavior have also been shown 
176
. There is yet to be a 
detailed mechanistic understanding of hyaluronan and its influences cell behavior, yet 







. Interestingly, RHAMM gene expression has been shown to be 
markedly elevated when cells are exposed to TGF-β and there is evidence indicating 









HA is known to be involved in many fundamental physiological and pathological 
processes (morphogenesis, embryonic development, tissue stability, cell proliferation, 
remodeling, migration, differentiation, angiogenesis, and wound healing), yet the 
functions appear to be molecular weight dependant. High molecular weight HA 
(HMWHA) binds cells and extracellular hyaladherins (proteins capable of binding to 
HA) to maintain the structural stability and integrity of tissues with few stimulatory 
effects on cells. In contrast, low molecular weight HA, or HA oligomers (HA-o) interact 
with cellular receptors resulting in a multitude of cell signaling cascades. In addition, the 
large strands of HMWHA are capable of blocking biomolecules from stimulating the cell 





HA-o (0.75–10 kDa) are capable of binding to cell surface receptors in a monovalent 
manner, therefore communicating directly with cells and influencing their metabolic 
functions.  This results in the stimulation of specific cell signaling cascades. An example of 
such a signaling cascade results in an up-regulation of ECM production and is of interest to 
our group. It has been shown, SMCs cultured in the presence of HA-o, have highly up-
regulated production of ECM, specifically elastin 45. Recently our group has shown, in the 
presence of exogenously supplemented HA-o, there is an increased production of 
tropoelastin, desmosine, and crosslinked elastin. In addition, the elastic fibers are laterally 
aggregated and larger than those produced by SMCs cultured with HA of higher MW. These 
findings encourage further study into the utility of HA-o for elastic matrix tissue engineering 
180-181.   
 
 










2.6.4.5 Matrix/ substrate  
Cell phenotype and matrix synthesis are affected by the substrate in which they 
are grown upon or within. The chemical composition of the substrate, as well as its 
geometric properties, plays a role. For example, 2-D substrate monolayers and 3-D 
substrates may promote different or exaggerated cell responses. There is evidence that 3-
D, ECM-based scaffolds are superior to 3-D synthetic scaffolds or 2-D monolayer cell 
cultures in their efforts to simulate the chemical and physical environment of tissues 
150, 
183-184
. Cells within a natural 3-D scaffold exist in a more natural environment in which 
they contact other cells and ECM and interact with cell adhesion molecules, growth 
factors, and mechanical stimuli similarly to that of native tissues. Integrin-ECM 
interactions and cell phenotype are also preserved 
150
. Cell phenotype and matrix 
synthesis can be greatly affected by the substrate; therefore, selection of scaffold that 
facilitates elastogenesis in vivo is important.  
   
2.7 Challenges to elastin matrix regeneration and repair  
 Tissue engineering elastic matrices to mimic that of healthy vasculature is a 
critical challenge. The ability to regulate the amount, quality, ultrastructure and higher 
scale organization of the elastin matrix are significant problems. Providing cells suitable 
biomechanical and biochemical cues may alleviate these problems, but further 
investigation is needed to create an effective tissue engineering approach that replicates 






2.7.1 Tropoelastin production 
Tropoelastin production is the initial step for producing stable, organized matrix 
elastin. As discussed previously, vascular elastin matrix deposition occurs extracellularly 
in a process directed by vascular SMCs. First, tropoelastin, the elastin precursor, is 
secreted from these cells. The tropoelastin then moves through the extracellular space and 
interacts with glycoprotein microfibrils, which guide it to become appropriately aligned 
for crosslinking 
70
. Numerous studies have shown, adult SMCs do not inherently 
regenerate elastin 
185-186
, therefore stimulation of tropoelastin production is necessary.  
 
2.7.2 Matrix elastin yield 
After the tropoelastin is appropriately aligned on the cell membrane, it is released 
and crosslinked. The initial step in the crosslinking reaction is mediated by lysyl oxidase 
(LOX) 
71
. Microfibrils serve as a scaffold template for elastin deposition and organization 
into fibers; therefore, an abnormality of galactose-containing microfibrils (e.g., 
glycoproteins, galactolipids, and glycosaminoglycans) may impair elastin assembly 
70
. If 
alignment and LOX crosslinking occurs appropriately, elastin molecules are then 
connected by formation of desmosine (Des) and isodesmosine (IDes) linkages between 
adjacent elastin molecules. Obtaining healthy quantities of crosslinked matrix elastin is a 








2.7.3 Organization of elastin matrix 
Matrix elastin content and organization affects vascular biochemistry and 
mechanics. For example, studies have led researchers to believe matrix organization 
(fibrils) provide topographical and/ or mechanical features that are important 
determinants of cell phenotype 
68
 and ECM production. Cells interact with elastin 
through the elastin binding protein (EBP), which binds the tropoelastin 
51
. Intracellular 
signaling modulates a variety of cellular functions including cell phenotype, secretory 
activities, and gene transcription 
28
. Therefore, elastic matrix organization into a native, 
healthy structure (lamellae) is vital. 
 
2.7.4 Matrix stability 
 Vascular matrix stability is necessary and is disrupted in many pathologic 
vascular conditions. Excessive matrix remodeling occurs in diseased states and is thought 
to be the primary cause of the most prevalent vascular pathologies of arteries, including 
atherosclerosis and restenosis 
94
. In acquired vascular inflammatory diseases (e.g. 
atherosclerosis and aneurysms) it can be caused by the release of powerful elastinolytic 
proteases released by inflammatory cells or bacteria, matrixmetalloproteinases (MMPs), 
or cysteine proteases. Additionally, degradation could be due to genetic vascular 
abnormalities, such as those pertaining to elastin or fibrillin, or those in the gene coding 
for the in the naturally present elastase inhibitor 1-antitrypsin 
95
. Therefore, a vascular 
matrix that does not stimulate these elastolytic proteases is necessary and should be 





2.7.5 Delivery of elastogenic factors 
 In situ sustained delivery of factors is more challenging than that of in vitro 
studies in which the therapeutic stimuli can be directly incorporated into culture media 
and the exposure dose of the agent to the cells is known throughout the culture period. In 
in situ and in vivo models the complex environment may decrease the exposure of the 
cells and ECM to the therapeutic agent, so more direct, controlled delivery is necessary. 
Systemic injection, peri-adventitial injection, delivery via catheterization and osmotic 
pump, and graft delivery are described below.  
Sytstemic injection is a method of putting liquid into the body with syringe and 
hollow needle, which is pierced through the dermis, then forced into the body. The effect 
is not typically local to the area in which the injection is administered. It is systemic. 
Therefore, if a therapeutic agent is meant for only a small region of the body (e.g., 
aneurysm site) alternative methods of specific delivery to the target are necessary.  Peri-
adventitial injection of factors directly into the adventitia of the vessel is a technique used 
to obtain targeted delivery of therapeutics. The agent distributes both longitudinally and 
circumferentially at the same rate and penetrates from the adventitia to the intima within 
1-2 hours after the delivery 
187
. 
Controlled delivery can be achieved via subdermal osmotic pumps. Osmotic 
pumps are miniature, infusion pumps for the continuous dosing of laboratory in situ and 
in vivo models. They provide a convenient and reliable method for controlled agent 
delivery and typically require no external connections or researcher intervention during 





injection schedules and have proven valuable in predictably sustaining compounds at 
therapeutic levels, avoiding potentially toxic or misleading side effects, and ensuring 
accurate exposure doses. An assortment of sizes, flow rates and durations is available to 
meet a variety of research needs. Osmostic pumps can be used to deliver a variety of 
agents. For example, Meyer et al. used the Alzet mini osmotic pump subdermally in the 
thoracic region of a rabbit model to deliver an agent continuously and locally to the 
carotid artery 
188
. The study investigated how the expression of inducible nitric oxide 
synthase (iNOS) affected intimal thickening.  
Graft delivery is a mode of factor delivery that expands upon the current clinical 
endovascular aneurysm repair (EVAR). Factors are incorporated in or coated on a stent 
graft that is endovascularly introduced into the vessel; this facilitates slow, localized 
release of the factors.  Kajimoto et al. demonstrated the release of basic fibroblast growth 
factor (bFGF) from a gelatin hydrogel sheet, which was coated on a stent graft 
189
. This 
biodegradable and biocompatible material was coated on an ePTFE graft that covered a 
stainless steel stent. This delivery system was introduced in the canine thoracic aortic 
aneurysm model with endoleaks and the ePTFE graft diameter (outer) was doubled to 
10% to 20% larger than those of both the proximal and distal landing zones (measured in 
preoperative aortography) upon delivery with a balloon catheter. They showed locally 
and persistently delivery of bFGF 
189
. This is a promising mode of delivery. 









ELASTOGENIC INDUCTIBILITY OF EARLY-STAGE RAT ABDOMINAL AORTIC 
ANEURYSM-DERIVED SMCS 
3.1 Introduction  
In past work, our lab identified and optimized extracellular matrix-derived 
biomolecules based on hyaluronan (HA) fragments 
22-23
 and growth factors (TGF-β1, 
IGF-1) 
24-25
, for stimulating elastin regeneration by healthy vascular cells.  Specifically, 
our lab showed that a combination of HA oligomers (HA-o; 4-6 mer; MW ~ 756-1221 
Da; 0.2 g/mL) and TGF-β1 (1 ng/mL), referred as elastogenic factors, synergistically 
attenuated vascular SMC proliferation and dramatically increased elastin synthesis, 
matrix assembly, maturation, and stability.  Despite their benefits to elastin synthesis by 
healthy adult SMCs, it is yet unknown if these factors will suppress pro-calcific and 
elastolytic activities of diseased vascular cells, such as those within AAA segments, and 
enable synthesis and assembly of new elastic matrices. 
To ascertain this, in this study, we adopted an established abdominal aorta injury 
protocol involving application of calcium chloride to induce an expansion/ aneurysm 
within rats over 4-weeks 
190
.  We then investigated the standalone and combined 
elastogenic benefits of TGF- and HA-o factors on SMCs isolated and cultured from 








3.2 Materials and methods 
 
3.2.1 Induced aortal injury by calcium chloride application 
All animal studies were approved by the IACUC at Clemson University.  Adult 
Sprague-Dawley rats (300-350 g in weight) were procured and acclimatized for one-week 
before surgery.  The rats were placed under general anesthesia (2-4%
 
isoflurane) and the 
infrarenal abdominal aorta exposed surgically.  The aortae were treated using a protocol 
adopted by various groups 
190-191
 (Figure 3.1), wherein sterile cotton gauze presoaked 
with 0.5 mol/L CaCl2 was placed on the aorta for 15 min.  Sufficient care was taken not 
to expose other organs to this caustic treatment.  Following treatment, the abdominal 
cavity was thoroughly washed with sterile saline to remove the residual CaCl2.  The 
cavity was then closed, subcutaneously sutured and stapled, and the rats were allowed to 
recover.  After 28 days in rehabilitation, the animals were humanely euthanized by CO2 
asphyxiation.  The abdominal aorta was excised and processed for SMCs isolation.  The 
abdominal aortae were photographed before surgery and after 28 days to compare the 
changes in aortic diameter.  Detailed histological/ biochemical analysis of these 
expansions was not performed, as prior work by Vyavahare et al. 
190, 192
 rigorously 
characterized the aneurysms induced by this method. 
 
3.2.2 Isolation and culture of aRASMCs 
The isolated aortae (n = 3) were opened lengthwise and the intima was scraped 





chopped into ~ 0.5 mm-long sections, and washed twice with warm PBS.  The resulting 
tissue slices were pooled, enzymatically degraded in DMEM-F12 (Invitrogen, Grand 
Island, NY) containing 125 U/mg collagenase and 3 U/mg elastase for 30 min at 37C, 
centrifuged at 400 g for 5 min, and cultured in T-75 flasks with DMEM-F12 containing 
10% fetal bovine serum over 15 days.  Aneurysmal rat aortic SMCs (aRASMCs) derived 
by outgrowth from these tissue explants were cultured over 2 weeks, and the cells 
passaged when confluence was attained.  Passage 2 SMCs were then seeded onto 6-well 
tissue culture plates (area = 10 cm
2
) at a seeding density of 2 × 10
5
 cells/well and cultured 
in DMEM-F12 medium containing 10% FBS and 1% Penstrep.  The total volume of 
medium added per well was 5 mL. 
 






HA-o mixtures supplemented to aRASMC cultures were prepared in-house by 
digestion of long-chain HA (MW: 2×10
6
 Da; Genzyme Biosurgery, Cambridge, MA) 
with testicular hyaluronidase (Sigma Aldrich, USA), as previously reported
23
.  The 
mixtures contained 75 ± 15% w/w of HA 4-mers (henceforth referred to HA-o), with 6-
mers and 8-mers forming the balance.  The experimental groups were aneurysmal SMCs 
cultured with no-additives (controls), and aneurysmal cells cultured with supplements of 
HA-o alone, TGF- alone, or TGF-β and HA-o together.  TGF- (PeproTech Inc., Rocky 
Hill, NJ) was added at a final concentration of 1 ng/mL, while oligomers were added at a 
final dose of 0.2 μg/mL.  Medium aliquots were replaced twice weekly, and spent media 
from each well was pooled and stored at -20 
o
C.  At 21 days, these pooled aliquots from 
each well and their corresponding cell layers were biochemically assayed. 
 
3.2.3 DNA assay for cell proliferation 
The DNA content of cell layers was quantified at 1 and 21 days of culture to 
assess the proliferation of SMCs over the culture period.  Briefly, cell layers were 
detached with 0.25% v/v trypsin-EDTA (Invitrogen), pelleted by centrifugation, re-
suspended in NaCl/ Pi buffer, and assayed using a fluorometric assay
193
, with the cell 




3.2.4 Hydroxy-proline assay for collagen 
A hydroxy-proline assay was used to estimate the collagen content within test and 







cell layers were homogenized in distilled water after 21-days of culture, pelleted by 
centrifugation (10000 g, 10 min) and digested with 1 mL of 0.1 N NaOH (1 h, 98ºC).  
The digestate was then centrifuged to isolate a mass of insoluble, crosslinked elastin.  The 
supernatant containing solubilized collagen and uncrosslinked matrix elastin was 
neutralized with an equal volume of 12 N HCl, and divided into two equal volumetric 
halves.  One half-volume was hydrolyzed at 110°C for 16 h, and dried in a constant 
stream of N2 gas overnight and 20 μL aliquots of the reconstituted residue were assayed 
for hydroxy-proline content.  The total and matrix collagen amounts were then calculated 
on the basis of the 13.2% hydroxy-proline content of collagen, and normalized to DNA 
content of corresponding cell layers. 
 
3.2.5 Fastin assay for elastin 
The amounts of matrix elastin (alkali-soluble and insoluble fractions) and soluble 
tropoelastin (in pooled spent medium) were quantified using a Fastin assay (Accurate 
Scientific Corp, Westbury, NY), according to manufacturer‟s recommendations.  Since 
the Fastin assay quantifies only soluble α-elastin, the insoluble elastin was first reduced 
to a soluble form by digesting with 0.25 N oxalic acid (1 h, 95°C), and filtering the 
pooled digestate in microcentrifuge tubes fitted with low molecular weight cut-off 
membranes (10 kDa).  The insufficiently crosslinked, soluble elastin fraction retained in 
the oxalic acid-free fraction and in the water-reconstituted hydrolysate (from the collagen 
assay above) were also quantified using the Fastin assay.  Spent fractions of media 





processed for tropoelastin using the Fastin assay.  The measured elastin amounts were 
normalized to corresponding DNA amounts to provide a reliable basis of comparison 
between samples. 
 
3.2.6 Von Kossa staining 
After 21 days of culture, aRASMCs were incubated with 1% silver nitrate 
solution and placed under UV light for 20 min.  After several changes of distilled water, 
the unreacted silver was removed with 5% sodium thiosulfate for 5 min, and the cells 
were rinsed.  The slides were counterstained with hematoxylin.  The presence of black 
stain confirmed the presence of calcium phosphate deposits. 
 
3.2.7 Desmosine assay for elastin crosslinks 
The desmosine crosslink densities within elastin matrices were quantified using 
ELISA to determine if any of the provided factors enhanced elastin crosslinking 
efficiency 
22
.  The 3-week old cell layers were digested with collagenase (12 h, 37ºC) and 
elastase (12 h, 37ºC), the digestates acid-hydrolyzed (6 N HCl, 110ºC, 16 h), and 
desmosine content in the reconstituted dried residue determined by ELISA, and compared 
to corresponding trends in insoluble matrix elastin. 
 
3.2.8 Lysyl oxidase (LOX) enzyme activity 
Spent culture medium pooled over 21 days of culture were assayed for LOX 





based on measurement of H2O2 released when LOX oxidatively deaminates alkyl 
monoamines and diamines
194
.  The fluorescence intensities were recorded with excitation 
and emission wavelengths at 560 and 590 nm, respectively. 
 
3.2.9 Elastase assay 
Elastase activity in the cell cultures was assayed using an EnzChek® Elastase 
Assay kit (Molecular Probes, Eugene, OR).  Briefly, 50 L of supernatant was mixed 
with 50 L of diluted bovine neck ligament elastin, incubated for 30 min incubation at 
37ºC, and the fluorescence intensity measured at 485 nm excitation and 510 nm emission 
wavelengths.  One unit of elastase was defined as the amount of porcine pancreatic 
elastase required to solubilize 1 mg of elastin at pH 8.8 and 37ºC. 
 
3.2.10 Western blot analysis for LOX 
Western blot analysis was performed to semi-quantitatively assess LOX protein 
synthesis, as described earlier
25
.  Briefly, the spent medium from cultures pooled over the 
21 day period were lyophilized, assayed for protein content using a DC protein assay kit 
(Bio Rad Laboratories, Hercules, CA), to further optimize sample volumes for SDS 
PAGE/ western blot.  Protein bands were detected with primary rabbit anti-rat polyclonal 
antibodies to the 31 kDa active LOX protein (Santa Cruz Biotechnology, Santa Cruz, 







3.2.11 Gel zymography for MMP activity 
MMP-2, 9 activity was detected in the culture medium by gelatin zymography 
methods described elsewhere
195
.  Briefly, aliquots of culture medium were assayed for 
protein content using the BCA assay, and all lanes were loaded in triplicate with 15 μg of 
protein from each extract alongside with prestained molecular weight standards (Bio Rad 
Laboratories).  After development and staining, densities of MMP-2 and 9 bands on a 
dark background of stained gelatin were measured using Gel Pro Analysis software 
(Media Cybernetics, Bethesda, MD), and reported as relative density units (RDU). 
 
3.2.12 Immunoflourescence detection of elastin, fibrillin and LOX 
Immunofluorescence techniques were used to confirm the presence of elastin 
within the cultured cell layers.  aRASMCs were cultured in 4-well sterile chamber slides 
under identical conditions at an initial seeding density of 5  10
3
 cells/ well.  At 21 days, 
the cell layers were fixed with 4 % v/v paraformaldehyde for 10 min, and labeled with a 
monoclonal antibody against rat SMC -actin (Abcam Inc, Cambridge, MA; 1:200 
dilution; 30 min, 25°C).  Elastin and fibrillin were detected with polyclonal antibodies 
(Elastin Products Company) as well as LOX (Santa Cruz Biotech) visualized with a 
Rhodamine-conjugated donkey anti-rabbit IgG secondary antibody (Abcam Inc.).  Cell 
nuclei were visualized with the nuclear stain 4, 6-diamino-2--phenylindole 







3.2.13 Matrix ultrastructure 
Transmission electron microscopy (TEM) was used to characterize the 
ultrastructure of matrix elastin.  aRASMC layers at 21 days of culture in the absence of 
any supplements (controls) and in the presence of TGF- and HA-o factors were fixed 
with 2.5% v/v glutaraldehyde, post-fixed in 1% v/v osmium tetroxide (1 h), dehydrated in 
graded ethanol, embedded in Epon 812 resin, sectioned, placed on copper grids, stained 
with uranyl acetate and lead citrate, and visualized on a Hitachi H7600T TEM. 
 
3.2.14 Statistical analysis 
Since experimental data (n = 3/case) was determined to exhibit a near Gaussian 
distribution, they were analyzed using Student‟s t-test, assuming unequal variance.  
Statistical significance was deemed for p < 0.05.  Asterisks in figures denote statistical 




3.3.1 Aneurysm progression and SMC phenotype 
Figures 3.2A and B show representative rat abdominal aortae before and 28 days 
after CaCl2 injury. It was observed that an ~45% local increase in aortic diameter was 
attained over this period, agreeing with prior observations. Images pre and post-treatment 
confirmed increased size of CaCl2 injured aortae relative to those treated with NaCl 





indicated that CaCl2 injury caused extensive breakdown of medial elastin, visible as 
gaping holes in the elastic lamellae (see arrows); these outcomes were confirmed via IF 
labeling of medial elastin (green), which appeared intact in NaCl-treated aortae, but again 
exhibited holes within CaCl2-treated aortae (Figure 3.3). As shown in Figures 3.4A and 
B, aRASMCs outgrowing from aneurysmal aortic explants initially appeared rounded, 
then more spindle-shaped, and thereafter somewhat more spread attaining 50% 
confluence by 15 days. In contrast, SMCs isolated from healthy rat aortae exhibited more 
spread morphology on day 7 after seeding (Figure 3.4C). The SMC phenotype was 
confirmed by staining for SMC α- actin (Figure 3.4D). 
 
 
Figure 3.2 Representative images of abdominal rat aortae before calcium chloride 
(CaCl2) treatment (A) and 28 days post-injury (B), when significant elastin degradation 







Figure 3.3 Histological analysis of rat aortae are shown 28 days post-treatment with 
0.5M CaCl2 and 0.5M NaCl (treatment control).The solutions were applied for 15 min, 
postadventitially. Hematoxylin and eosin–stained sections of l2-treated aortae showed 
extensive breakdown of elastic lamellar structures (see arrows) in the tunica media layer, 
in contrast to those within NaCl-treated aortae, which remained intact. These results were 
confirmed by comparison of elastin (black structures) within Verhoeff- Van Gieson–
stained sections, and using immunofluorescence (note holes in green fluorescing elastic 





with CaCl2, but not NaCl, confirming the induction of an abnormal, disease-like 
microenvironment in the former case. 
 
 
Figure 3.4 Significant rounding of the smooth muscle cells isolated from the aneurysmal 
segment (aRASMCs) was observed on day 1 (A) and more spindle-shaped by day 7 (B). 
SMCs isolated from healthy aortae showed more spread morphology on day 7 of seeding 
(C). The cells were stained with SMC-a actin to confirm the SMC phenotype (D).  
 
3.3.2 aRASMC proliferation and matrix synthesis 
Figure 3.5A shows the proliferation ratios of passage 2 aRASMCs cultured in the 
presence of TGF- alone, HA-o alone, or both.  Non-additive control aRASMCs 
proliferated 2.5 ± 0.32– fold over 21 days.  Addition of TGF- to SMC cultures had no 
effect on these proliferation ratios (0.97 ± 0.08– fold at 21 days vs. controls; p = 0.56).  
However, HA-o supplemented alone or together with TGF- suppressed cell 
proliferation ratios significantly, relative to non-additive control aRASMCs (0.81 ± 0.1 







Figure 3.5 (A) Proliferation ratios of aRASMC cultures supplemented with HA-o alone, 
TGF-β alone, or factors together. Data shown represent mean ± SD of DNA content of 
cell layers after 21 days of culture, normalized to initial seeding density, and further 
normalized to aRASMC control cultures that received no additives (n = 3/ case). (B) 
Effects of HA-o alone, TGF-β alone, and factors together, on total collagen synthesis by 
aRASMCs. Data shown (mean ± SD) are normalized to cellular DNA content at 21 days 
of culture and represented as fold change in protein production relative to aRASMCs 
controls (n = 3/ case). p < 0.05 represents significant differences from controls (*). 
 
When HA-o or TGF- alone were provided to SMCs, significant increase in 
collagen synthesis (1.4 ± 0.07 and 1.33 ± 0.05–fold, respectively; Figure 3.5B) was 
observed, relative to control cultures (p = 0.008 and 0.005, respectively).  Addition of 
both the factors furthered collagen synthesis to 1.78 ± 0.18–fold relative to controls (p = 
0.008). 
As shown in Figure 3.6A, addition of HA-o alone or together with TGF- 
promoted tropoelastin synthesis by 1.17 ± 0.02–fold and 1.47 ± 0.05–fold, respectively, 





However, addition of TGF- alone had no effect on tropoelastin synthesis (0.94 ± 0.02-
fold; p = 0.13).  Interestingly, collagen and tropoelastin synthesis (779 ± 62 ng/ng DNA 
and 3516 ± 149 ng/ng DNA, respectively) observed within additive-free aRASMC 
cultures were much lower than that we previously measured within healthy RASMC 




As explained earlier, elastin protein incorporated into the extracellular matrix was 
measured as a sum of two individual fractions, i.e., a highly cross-linked, alkali-insoluble 
elastin (which represents structural elastin), and an alkali-soluble fraction.  As shown in 
Figure 3.6B and C, the trends in matrix elastin protein production mirrored those 
observed for tropoelastin synthesis under identical conditions.  Addition of 0.2 g/mL of 
HA-o to aRASMC cultures increased soluble and insoluble matrix elastin synthesis by 
1.5 ± 0.11 and 1.23 ± 0.09–fold respectively, relative to that measured in control 
aRASMC cultures (157 ± 26 ng/ng DNA and 216 ± 54 ng/ng DNA; p = 0.017 and 0.031, 
respectively).  However, addition of TGF- (1 ng/mL) alone had no effect on basal 
matrix elastin synthesis levels (soluble elastin: p = 0.56, insoluble elastin: p = 0.54).  On 
the other hand, HA-o and TGF- factors together increased production of soluble and 
insoluble matrix elastin fractions by 1.78 ± 0.29 and 1.56 ± 0.34–fold, respectively, 
relative to controls (p = 0.014 and 0.026, respectively).  Overall, relative to controls, the 
total elastin output (sum of tropoelastin and matrix elastin fractions) increased by 1.19 ± 
0.03, 0.96 ± 0.03 and 1.49 ± 0.06–fold, respectively, upon addition of HA-oalone, TGF-






Figure 3.6 Effects of HA-o alone, TGF-b alone, and both factors together, on 
tropoelastin (A), alkali-soluble (B), crosslinked matrix elastin (C), and total elastin (D) 
produced by aneurysmal SMCs. Data shown (mean ± SD) are normalized to cellular 
DNA content at 21 days of culture and represented as fold change in protein production 
relative to aneurysmal controls (n = 3/ case). p < 0.05 represents significant differences 










3.3.3 LOX protein expression and functional activity 
Figure 3.7A compares outcomes of western blot analysis of LOX protein 
expression with trends in biochemical quantification of matrix elastin.  LOX protein 
expression increased significantly in cultures supplemented with TGF- alone or together 
with HA-o (1.59 ± 0.05 and 1.72 ± 0.04–fold, relative to controls; p < 0.001 in both the 
cases).  However, addition of HA-o alone promoted only 1.03 ± 0.14–fold increase in 
LOX protein expression relative to controls (p = 0.73).  In all the cases, no significant 
differences in the cellular LOX activities were observed, relative to non-additive controls 
(data not shown). 
 
 
Figure 3.7 (A) Sodiumdodecyl sulfate (SDS) polyacrylamide gel electrophoresis/ 
Western blot analysis of tropoelastin and lysyl oxidase (LOX) proteins within the pooled 
medium of aRASMC cultures at the end of 21 days. Data shown represent mean ± SD of 
three repeats/ case and are shown normalized to controls. (B) Desmosine amounts 
measured in test cell layers were normalized to corresponding DNA amounts (ng/ ng), 
and further a similar ratio obtained for the healthy nonadditive controls. Comparable 





elastin/ DNA for selected cases. *Represents significance of differences in values relative 
to cultures of healthy additive-free cells, deemed for a p < 0.05. 
As shown in Figure 3.7B, aRASMCs, alone or in the presence of HA-o, did not 
show any significant increase in desmosine synthesis (0.78 ± 0.01 and 0.92 ± 0.08-fold) 
relative to healthy SMC layers (11.85 ± 0.37 pg desmosine/ ng DNA), while TGF- 
alone or together with HA-o enhanced the desmosine synthesis by 1.07 ± 0.07–fold and 
1.21 ± 0.03–fold, respectively (p = 0.06 and p < 0.001 vs. healthy RASMCs controls). 
 
3.3.4 Activity of proteolytic enzymes 
As shown in Figures 3.8A and B, gel zymography analysis revealed that the 
MMPs-2 and 9 activity was significantly higher within non-additive aRASMC cultures 
relative to healthy cell cultures (1.67 ± 0.16 and 2.07 ± 0.35–fold, respectively; p = 0.03 
and 0.01), confirming their activated/ diseased phenotype.  Addition of either HA-o or 
TGF- alone to aRASMCs did not alter their basal MMP activity levels.  However, in the 
presence of both HA-o and TGF-, production of MMPs-2 and 9 was marginally lower 
than those in aRASMC control cultures (p = 0.08 and 0.03), and not different than those 
in healthy SMC cultures (p = 0.67 and 0.71).  Similarly, as shown in Figure 3.8C, 
elastase activity within additive-free aRASMC cultures was 1.19 ± 0.09–fold higher than 
those in healthy SMC cultures (0.23 ± 0.02 U/mL; p = 0.04).  Addition of HA-o or TGF-
 supplements to aRASMC cultures also increased elastase activity by 1.29 ± 0.08 and 
1.39 ± 0.18–fold, respectively, (p = 0.015 and 0.03), relative to healthy SMC cultures, 





cultures.  In the presence of both the factors, elastase activity however was almost 
identical to additive-free aRASMC cultures (1.01 ± 0.06–fold vs. aRASMC non-additive 
cultures; p = 0.82). 
Figure 3.8C shows the images of Von Kossa stained aRASMC cultures.  
Untreated aRASMC cultures (panel D) exhibited multiple large calcific deposits (black); 
supplementing cultures with TGF- alone (panel F) did not alter patterns of matrix 
calcification, while addition of HA-o (panel E) appeared to decrease the density of these 
deposits.  However, the presence of both the factors significantly suppressed formation of 
calcific deposits (panel G), though complete inhibition was not observed. 
 
 
Figure 3.8 Gel zymography analysis revealed the activity of MMP-2 (A) and MMP-9 (B) 
within aRASMC cultures treated with or without factors. Data were shown normalized to 
the respective values observed in healthy non-additive treatment controls (n = 3/case). 
(C) Elastase enzyme activity within aRASMC cultures treated with HA-o alone, TGF-b 
alone or together with HA-o. Data are shown normalized to the corresponding values in 





aRASMC cell layers (D) or those treated with TGF-b alone (E), HA-o alone (F), or 
factors together (G), and healthy RASMC layers (H). Significant calcific deposits were 
evident in control cultures and those treated with TGF-β alone or HA-o alone, while 
cultures that received factors together showed a decrease in the calcific mineralization, 
almost to levels exhibited in healthy SMC layers. *Indicates significance of differences 
relative to healthy, additive-free control cell cultures, deemed for p < 0.05. 
 
3.3.5 Immunodetection of elastin, fibrillin, and LOX in cell layers 
Figure 3.9 shows immunofluorescence micrographs of cell layers stained for 
elastin, fibrillin, and LOX after aRASMC culture for 21 days with HA-o alone, TGF- 
alone or both the factors together.  Non-additive aRASMC cultures and negative 
immunolabeling controls (untreated with primary antibodies) are also shown for 
comparison.  While featureless amorphous elastin deposits were seen in non-additive 
aRASMC cultures and TGF--treated cultures, more organized fibrous elastin were 
visible in cell layers cultured with either HA-o alone, or together with TGF-.  
Fluorescence intensity of elastin matrices within cell layers supplemented with both 
TGF- and HA-o was much greater than in the absence of the factors, or either of the 
factors alone.  Fluorescence intensity due to fibrillin microfibrils was similarly greater in 
cultures supplemented with HA-o alone, or together with TGF-, compared to non-
additive aRASMC cultures or those cultured with TGF- alone.  The fibrillin appeared 





together, than in non-additive control cultures.  However, in all cases, LOX was rather 
faintly expressed and was sparsely distributed. 
 
 
Figure 3.9 Immunodetection of elastin, fibrillin, and LOX within control aRASMC and 
factor supplemented aRASMC layers after 21 days of culture. For each labeled protein, 
images of each of the treatment control (no additives) and supplemented layers were 
collected under identical image capture settings and were identically brightness/ contrast 
enhanced. An average of 15 random locations were imaged on each of the three replicate 
cell layers/ case/ set. An increase in matrix elastin, fibrillin, and LOX is evident in 
aRASMC cultures that received both TGF-b and HA-o, relative to non-additive 
aRASMC cultures (treatment controls). Cultures that received TGF-b alone or HA-o 





factors. Lack of fluorescence in cultures untreated with primary antibodies (negative 
immunofluorescence controls) confirms lack of nonspecific binding of the fluorophore-
conjugated secondary antibody.  
 
3.3.6 Ultrastructure of matrix elastin 
Figure 3.10 shows representative transmission electron micrographs of 21-day 
cell layers of aRASMCs cultured in absence and presence of elastogenic factors.  Similar 
to that previously observed in healthy control RASMC cultures 
24
, non-additive 
aRASMCs also deposited aggregating clumps of amorphous elastin protein that were 
overall sparse and rather localized within the cell layers (panels A, B).  When TGF-1 
and HA-o together were provided to these cultures, mature elastin fiber formation was 
favored, with the matrix containing numerous fully-formed bundles (100-200 nm 
diameter) of aggregating fibrils (panels C, D).  Fibrillin (immunogold particle-stained) 
appeared as darkly stained nodules, and was located at the periphery of aggregating 
elastin fiber bundles, signifying normal elastic fiber assembly. 
 
 
Figure 3.10 Representative transmission electron micrographs of 21-day-old aRASMC 





100000 X) and those cultured with both TGF-β and HA-o ((C) 50000 X; (D) 100000 X). 
Aggregating amorphous elastin clumps leading to the formation of elastin fibers can be 
clearly seen in aneurysmal cell cultures treated with the factors (C, D), while aRASMC 
cultures that received no additives (A, B) showed amorphous elastin deposits with sparse 
fiber formation. In all cultures, immunogold labeling showed presence of fibrillin 
microfibrils (black dots), indicative of normal mechanisms of elastic matrix assembly. 
 
3.4 Discussion 
The long-term goal of this project is to develop technologies to enhance elastic 
matrix regeneration within AAAs, to stabilize and even possibly regress their growth, 
thus eliminating the need for surgical intervention.  This is specifically challenging 
because elastin turnover is slow, and minimal remodeling of elastin fibers occurs in 
adults 
196
.  Our elastogenic factors are novel in stimulating elastin regeneration and repair 
in vitro,  which raises the possibility that they may also have a future in vivo role as a 
stand alone or combination therapy for AAAs. 
Rats, which we have chosen to investigate as a model for elastic matrix 
regeneration, are widely used to study AAAs 
197-198
.  Among the several models available 
to induce AAAs are genetic manipulation (deficiencies in LOX, TIMP-1, LDL-receptor, 
etc) and surgical/chemical induction (intraluminal elastase infusion and peri-adventitial 
injury with CaCl2) 
191, 199
.  In particular, peri-adventitial injury of the abdominal aorta with 
CaCl2 has been shown to induce several characteristics of human AAAs, such as medial 
layer disruption, inflammation, matrix calcification, thrombus formation
18





MMP activity at the site of application 
190, 192
 associated with  significant and progressive 
local aortic dilation within 4 weeks
200
.  Since cells isolated from diseased and healthy 
tissues can be propagated in culture, limitations to tissue procurement do not restrict 
rigorous evaluation of parameters that influence cell phenotype and matrix regenerative 
potential in each case; further, the standalone effects of each of these parameters on the 
outcome of interest can be isolated.  However, conditions of culture do not mimic the 
arterial conditions of cyclic stress, pressure, and interaction with circulating blood, nor 
with any paracrine effects of neighboring tissues, including the intima or adventitia. 
However, although a 2-D cell culture model may not replicate the physiologic 3-D matrix 
microenvironment, it is nevertheless valuable to study biochemical regulation of cell 
phenotype by supplemented biomolecules.  
Though the CaCl2-injury-derived rat aortic SMCs (aRASMCs) isolated from our 
rat aortal expansions expressed smooth muscle -actin confirming a SMC-phenotype, a 
significant number amongst them exhibited decreased volume/ spreading especially in the 
first 10-days after seeding, which was different from the spread morphology observed in 
healthy RASMC cultures.  Such differences in phenotype between healthy and 
aneurysmal vascular SMCs have also been reported by others 
201
.  In general, these 
aRASMCs generated greater amounts of MMPs and elastases than did healthy control 
RASMCs, and promoted deposition of a greater number of calcific deposits than in 
healthy RASMC cultures, suggesting an activated phenotype.  Interestingly, the 
aRASMCs proliferated more slowly than healthy RASMCs 
24
 over the 21 day period (33 





healthy RASMCs; p < 0.001), collagen (3.4 ± 0.5 % of healthy SMCs; p < 0.001) and 
matrix elastin (11 ± 2 % of healthy RASMCs; p < 0.001) than did healthy control 
RASMCs
24
.  These results were supported by a significant decrease in the production of 
elastin crosslinking proteins (LOX and desmosine), as gauged from our biochemical 
analysis, and a visible decrease in elastin matrix density within these cultures relative to 
healthy RASMC controls 
24
.  Overall, these observations point to the activated state of 
these isolated „aneurysmal‟ aRASMCs when cultured in vitro. 
In our recent studies exploring the elastogenic benefits of HA-o (0.2 g/mL) to 
elastin synthesis by RASMCs 
24
, we found tropoelastin synthesis to be modestly 
enhanced (48.5 ± 23%), while elastin yield was increased multi-fold (2.57 ± 0.3-fold vs. 
non-additive healthy RASMC cultures), though matrix elastin synthesis on a per cell 
basis remained unchanged.  In this study, addition of HA-o alone (0.2 g/mL) suppressed 
aRASMC proliferation, promoted tropoelastin and insoluble matrix elastin synthesis (~ 
1.2–fold), and increased collagen and soluble matrix elastin synthesis (~ 1.5-fold).  
However, the elastin matrix yield remained similar to that in non-additive aRASMC 
cultures (10.8 ± 0.8 vs. 9.6 ± 2.1 %), which might be due to the lack of any significant, 
parallel increase in desmosine and LOX protein content within these cultures.  
Interestingly, the production of the MMPs-2 and 9 and the levels of elastase activity and 
matrix calcification in these cultures remained similar to that within additive-free 
(control) aRASMC cultures, and significantly higher than that within additive-free 
healthy RASMC cultures.  In contrast to factor benefits of deposition of a fibrillar rather 
than amorphous elastin matrix deposition by healthy RASMCs 
23





no particular advantage to the quality of elastin matrix deposited by aRASMCs, since the 
elastin matrix was still largely non-fibrillar (not shown).  These results lead us to 
speculate that much higher doses of HA-o may be necessary to stimulate aRASMCs to 
enhance elastogenesis and elastin fiber deposition, in a similar manner as that of healthy 
RASMCs, which respond HA-o at low doses (0.2 g/mL). 
Though in a previous study, we found TGF-1 ng/mL) to significantly 
suppress healthy SMC proliferation and increase synthesis of matrix elastin (~2.5-fold) 
and collagen (~1.3-fold) 
24
, the same dose of TGF- had no effect on aRASMC cultures, 
except for collagen synthesis (~ 1.3-fold).  Also, TGF- had no impact on elastin yield 
within aRASMC cultures (11.2 ± 1.8% vs. 9.6 ± 2.1% in additive-free aRASMC; p = 
0.72), although the same dose of TGF- enhanced elastin matrix yield in healthy 
RASMC cultures.  The lack of elastogenic impact of TGF- on aRASMCs when 
provided at doses optimized for healthy RASMCs, similar to that with HA-o, suggests 
attenuated sensitivity of aRASMCs to these factors and thus the necessity to likely 
increase and re-optimize doses of these factors to up-regulate elastogenesis by these 
diseased cell types.  Nevertheless, attenuated TGF--induced elastic matrix effects on 
aRASMC cultures also appear to directly correlate with increases in production of 
MMPs-2 and 9 and elastase activity, and greater distribution of non-fibrillar elastin, 
suggesting higher elastolytic activity within these cultures.  Thus, the presence of either 
HA-o or TGF- alone could be inciting increased elastolytic activity within aRASMC 
cultures to rapidly generate soluble elastin peptides, and thereby discouraging 





When aRASMCs were exposed to both TGF- and HA-o factors, their impact 
on aRASMCs differed from that on healthy RASMCs.  The factors suppressed 
proliferation of aRASMCs, though not as severely as they did healthy SMCs 
24
.  The 
suppression in proliferation of aRASMCs has vital implications in deterring hyper-
proliferation of these activated cell types when factors are delivered to an intact AAA 
site.  Again, in both aRASMC and RASMC cultures, the factors enhanced tropo- and 
matrix elastin synthesis and that of collagen matrix, although the level of increase in 
aRASMC cultures was far less compared to the healthy RASMC cultures.  Previously, 
we showed that the factors improved elastin matrix yields in healthy RASMC cultures, 
quite possibly by increasing LOX protein synthesis and desmosine content 
24
.  Based on 
these outcomes, we expected similar improvements in elastin matrix yields within 
aRASMCs cultures that received these factors, which was not the case (10.7 ± 2.1% yield 
with factors vs. 9.6 ± 2.1% for additive-free aRASMC cultures) despite measured 
increases in production of the elastin crosslinking enzyme, LOX, and desmosine.  
Relative to healthy RASMC cultures, the lack of net increase in matrix yield may not be 
due to the lack of factor-derived benefits of recruitment and crosslinking of tropoelastin 
precursors, but rather due to innately enhanced elastolytic activity within aRASMCs 
cultures.  Regardless, on a positive note, these elastogenic factors reduced matrix 
calcification and MMP activity by aRASMCs, results that were not observed when either 







3.5 Conclusions  
1.   Calcium chloride-treatment was successful in inducing expansions in the abdominal 
aorta of a rat within 4 weeks (~45% diameter increase). The model yielded medial 
layer disruption, inflammation, matrix calcification, and enhanced MMP activity. 
 
2.   aRASMCs isolated from the medial portion of the expansions had SMC phenotype, 
yet they exhibited significant rounding within the first few days of culture and an 
increase released MMP-2 and 9 activity, relative to healthy RASMCs.  
 
3.  Compared to healthy RASMCs, aRASMCs proliferated less and produced less 
collagen, tropoelastin, and matrix elastin. The protein synthesis within aRASMC 
cultures was not up-regulated by adding either HA-o or TGF-β alone. 
 
4.   Relative to control aRASMC cultures, concurrent delivery of the factors resulted in 
slight suppression of proliferation, significant increases of LOX, desmosine, collagen, 
tropo- and matrix elastin production by aRASMCs, and reduced calcification and 
MMP activity, which was not achieved by the presence of either factor alone. 
 
5.   The factors significantly promoted crosslinking and deposition of matrix elastin, as 
evident from immunofluorescence and ultrastructural analysis, yet optimization of the 







EVALUATION OF ELASTIC MATRIX REGENERATION BY EARLY-STAGE RAT 
ANEURYSM-DERIVED SMCS AS A SURROGATE FOR HUMAN AAA SMCS 
 
4.1 Introduction 
In chapter three, we observed that the elastogenic factors provided at doses 
optimized for healthy cells (2 μg/ml HA-o and 1 ng/ml TGF-β) were effective in 
stimulating elastogenesis by SMCs derived from CaCl2-induced rat AAAs (aRASMCs) 
19
. This study provided preliminary evidence that such SMCs continue to exhibit a 
diseased/ activated phenotype in culture and that they can be elastogenically stimulated, 
though factor doses must be re-optimized (likely increased) separately for diseased cell 
types since induced elastic matrix amounts were still an order of magnitude lower than 
that by healthy RASMCs. This is addressed in the present study. 
   While demonstration of the therapeutic efficacy of biomolecular factors in 
animal models of disease must necessarily precede testing in human subjects, it is vital to 
ascertain that outcomes with the surrogate model/ cell type parallel outcomes in humans. 
In this study, we thus compare dose-specific elastogenic effects of HA-o and TGF-β in 
cultures of SMCs, isolated from CaCl2-induced rat AAAs and SMCs isolated from a 
biopsied atherosclerotic human AAA tissue (aHASMCs). The study results will help 
ascertain the validity of studying aRASMCs from CaCl2-injured aortae as a surrogate for 





alone or combination therapies with existing surgical or pharmacological approaches to 
regenerate elastic matrices within AAAs. 
 
4.2 Materials and methods 
 
4.2.1 Aortal injury by peri-adventitial application of CaCl2 
All animal studies were approved by the IACUC at the Medical University of SC.  
Adult Sprague-Dawley rats (250-300 g in weight) were procured and acclimatized for 




isoflurane) and the infrarenal abdominal aortae exposed surgically.  The aortae were 
treated using a protocol adopted by various groups 
190-191
, wherein sterile cotton gauze 
pre-soaked with 0.5 mol/L CaCl2 was placed peri-adventitially on the aorta for 15 min.  
Sufficient care was taken not to caustically injure surrounding organs.  The abdominal 
cavity was then thoroughly washed with sterile saline to remove the residual CaCl2, the 
cavity closed, subcutaneously sutured and stapled, and the rats allowed to recover.  After 
28 days in rehabilitation, the animals were humanely euthanized by CO2 asphyxiation.  
The expanded infrarenal abdominal aortae were then excised and processed for isolation 
of SMCs.  The abdominal aortae were photographed before surgery and at 28 days to 
compare the changes in aortic diameter.  Detailed histological analysis and MMP 
release/activity within these expansions confirmed they were representative of early-stage 







To verify medial disruption and thinning, and calcific deposition within the aortic 
wall of CaCl2-treated animals, standard hemotoxylin and eosin staining (H & E; for 
nuclear and intracellular and extracellular protein visualization), modified Verhoff Van 
Gieson staining (VVG; for elastin visualization; ScyTek Laboratories, Logan, UT), Von 
Kossa staining (for calcific depostion; ScyTek Laboratories, Logan, UT), and scanning 
electron microscopy (SEM; for aortic cross-section ultrastructural visualization) were 
conducted on no treatment control and CaCl2-treated aortae (n = 3 animals/ group). 
Aortae from respective animals harvested at 28 days post-op (or at a time-matched stage 
for un-operated control animals) were rinsed in sterile saline, embedded in optimum 
cutting temperature (OCT) medium, and stored at -20 °C until cryosectioning. Sections 
(5µm) were processed for histology or SEM. Standard histological protocols were 
followed. For SEM, samples were fixed in 2% v/v gluteraldehyde in phosphate buffer, 
rinsed in phosphate buffer, DI water, then dehydrated in graded ethanol and finally 
hexamethyldisilazane (Sigma Aldrich, St. Louis, MO) (3 min). The histological and SEM 
samples were imaged on an Olympus BX41 (Olympus, Center Valley, PA) and a Hitachi 
SEM TM1000 (Hitachi Technologies, Pleasanton, CA), respectively, and are shown in 
Figure 4.1. 
 
4.2.2 Isolation and culture of aRASMC and aHASMC 
 Expanded aortae isolated from adult, male Sprague Dawely rats (n = 3) subject to 
caustic aortal injury with CaCl2 were opened lengthwise, and the intima was scraped off 





adventitia, chopped into ~ 0.5 mm-long sections, and washed twice with warm 
phosphate-buffered saline (PBS).  The tissue slices were then pooled, enzymatically 
degraded in DMEM-F12 (Invitrogen, Grand Island, NY) containing 125 U/mg 
collagenase (Worthington, Biochemicals Lakewood, NJ) and 3 U/mg elastase 
(Worthington Biochemicals) for 30 min at 37C, centrifuged (1400 RPM; 5 min), and 
cultured in T-75 flasks with DMEM-F12 containing 10% v/v (PAA Laboratories, 
Etobicoke, Ontario) fetal bovine serum over 15 days.  Primary aneurysmal rat aortic 
SMCs (aRASMCs) derived by outgrowth from these tissue explants were cultured for up 
to 2 weeks, and the cells passaged when confluence was attained.  Passage 3 SMCs were 
then seeded onto 6-well tissue culture plates (growth area of 9.6 cm
2
) at a seeding density 
of 2 × 10
4
 cells/well and cultured in DMEM-F12 medium containing 10% v/v FBS and 
1% v/v penstrep (South Logan, UT).  The total volume of medium per well was 5 mL. 
 Waste human AAA tissue, generated during open AAA repair (Figure 4.3B), 
was procured with IRB approval at the Medical University of South Carolina (HR# 
18387, 07/2008).  The tissue source was a 6 cm diameter AAA from a 62 year old male 
patient with hypertension, coronary disease, and hyperlipidemia. The tissue was collected 
from the anterior wall of the aneurysm near the origin of the inferior mesenteric artery; it 
had significant thrombus formation. After explanting the aneurysmal tissue, the AAA 
was successfully repaired in a standard fashion. To isolate primary aHASMCs, the 4 x 1-
cm-sized aortic tissue explant was opened lengthwise, the intima scraped with a scalpel 
blade, the medial layer dissected from the adventitia, then chopped it into ~ 0.5 mm-long 





(PBS), pooled, and enzymatically degraded in DMEM-F12 medium (Invitrogen) 
containing 357 U/mg collagenase (Worthington Biochemicals) and 4.5 U/mg elastase 
(Worthington Biochemicals) over 45 min, at 37 C. The digestate was centrifuged (1400 
RPM; 5 min) and the tissue segments then re-constituted, and cultured for up to 6 weeks 
in 6-well plates with minimal volumes of DMEM-F12 medium containing 10% v/v FBS 
(PAA Laboratories).  Primary aneurysmal human aortic SMCs (aHASMCs), derived by 
outgrowth from these tissue explants, were cultured until confluence was attained, and 
then passaged.  Passage 3 aHASMCs were then seeded onto 6-well tissue culture plates 
(growth area of 9.6 cm
2
) at a density of 2 Χ 10
4
 cells/well and cultured in DMEM-F12 
supplemented with 5% v/v FBS, 1% v/v penstrep, 5 μg/ml human insulin (Sigma, St. 
Louis, MO), 2 ng/ml of human recombinant fibroblast growth factor (huFGF) (Peprotech, 
Rocky Hill, NJ), and 0.5 ng/ml of human recombinant epidermal growth factor (huEGF) 
(Assay Design, Ann Arbor, MI). Passage-matched healthy human aortic SMCs derived 
from the tunica media of a healthy and fibrous plaque-free aorta of a 48 year old 
Caucasian male (HASMCs; Cell Applications, San Diego, CA) were also cultured under 
identical conditions. 
 
4.2.3 Experimental design and time points 
Passage 3 aRASMCs, aHASMCs, and healthy HASMCs were cultured in media 
supplemented with elastogenic factors (0-20 μg/ml HA-o and 0-10 ng/ml TGF-β) within 




) for 21 days, over which time the cells deposited a 





twice-weekly medium change, were pooled with previously removed aliquots, frozen at –
20˚C, then biochemically assayed together with their corresponding cell layers when 
harvested at 21 days of culture. 
 
4.2.4 DNA assay for cell proliferation 
The DNA contents of each group of cell cultures were compared to determine the 
impact of the factors and factor doses on SMC proliferation. For analysis, the cell layers 
were harvested at 21 days of culture, resuspended in NaCl-Pi buffer, sonicated on ice, 
and their respective DNA contents quantified using a fluorometric assay described by 
Labarca and Paigen
202




4.2.5 Immunoflourescence detection of SMC phenotypic markers 
Immunofluorescence techniques were used to visualize contractile and synthetic 
phenotypic markers of both human and rat aortic SMCs.  SMCs were cultured in sterile, 
2-well Permanox
®
 chamber slides (4.2 cm
2
/ well; Nalge Nunc International, Rochester, 
NY) under identical experimental conditions as described for cultures intended for 
biochemical analysis, though the cell seeding density and treatment doses were adjusted, 
to account for the reduced substrate surface area and cell number, respectively.  Cell 
layers were fixed with acetone for 10 minutes at -20 °C and blocked with 5% v/v goat 
serum (30 min). α smooth muscle actin, SM22α, calponin, and caldesmon (contractile 
phenotype markers), and thrombospondin and osteopontin (synthetic phenotype markers) 





Cambridge, MA), which show cross-reactivity with human antigens, and visualized with 
FITC-conjugated IgG secondary antibodies (1:1000 v/v; Chemicon, Temecula, CA). The 
cell layers were cover-slipped with Vectashield mounting medium containing the nuclear 
dye 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA), which 
labeled the cell nuclei.  
 
4.2.6 Flow cytometry  
 Flow cytometry analysis of the SMCs (Passage 4) was performed.  Cells were 
trypsinized, centrifuged (1500 RPM; 10 min), reconstituted at 1 Χ 10
6
 cells per sample, 
fixed with 4% w/v paraformaldehyde in PBS (37 °C; 10 min), washed, then 
permeabilized with 0.1% v/v Triton X-100 in PBS for 1 min. The immunoflourescence 
detection of SMC phenotypic markers was conducted with the antibodies outlined above. 
The samples were blocked (30 min; 4 °C), then incubated with primary antibodies (30 
min; 4 °C), followed by a FITC-conjugated secondary antibody (20 min; 4 °C; in the 
dark). After labeling, cells were resuspended in 0.5 ml of PBS and kept at 4 
°
C protected 
from light until analysis. Cytometric analysis was performed using a Becton Dickinson 
FACSCalibur Analytical Flow Cytometer and data were processed using Cell Quest Pro 
5.2 (BD Biosciences, Franklin Lakes, NJ). 
 
4.2.7 Fastin assay for elastin 
The Fastin assay (Accurate Scientific and Chemical Corporation, Westbury, NY) 
was used to quantify the total amount of elastin deposited within cell layers (matrix 





For each treatment group, tropoelastin in the spent medium was collected and pooled 
over the culture period and frozen at -20 ˚C.  To isolate matrix elastin following either 21 
days the cell layers were trypsinized, then scraped off, re-suspended in NaCl/Pi buffer, 
and centrifuged (2500 RPM, 10 min). The cell pellet was digested with 0.1 N NaOH (98 
˚C, 1 h), and centrifuged to yield a less crosslinked, alkali-soluble supernatant fraction 
(soluble elastin), and a mature, highly crosslinked, insoluble pellet (insoluble elastin). 
Since the Fastin assay quantifies only soluble α-elastin, the insoluble elastin was 
converted to a soluble form prior to quantification. To do this, the insoluble elastin pellet 
was dried, solubilized with 0.25 M oxalic acid (95 ˚C, 1 h), and the pooled digests then 
centrifuge-filtered (3000 RPM, 10 min) in microcentrifuge tubes fitted with low 
molecular weight (10 kDa) cut-off membranes (Millipore, Bedford, MA). All three 
elastin fractions (tropoelastin, and soluble and insoluble matrix elastin) were quantified 
using the Fastin assay.  
 
4.2.8 Von Kossa staining 
Van Kossa staining was used to visualize calcific deposition by the aneurysmal 
SMCs. SMCs were cultured in sterile, 2-well Permanox
®
 chamber slides (Nalge Nunc 
International, Rochester, NY) under identical experimental conditions as described for 
cultures meant for biochemical analysis, though the cell seeding density and treatment 
doses were adjusted, to account for reduced the substrate surface area and cell number, 
respectively. After 21 days of culture, SMCs were incubated with 1% w/v silver nitrate 





distilled water, the un-reacted silver was removed by rinsing cells with 5% w/v sodium 
thiosulfate for 5 min, then PBS.  The slides were counterstained with hematoxylin.  The 
appearance of black stained masses in the cell layers confirmed the presence of calcium 
phosphate deposits. 
 
4.2.9 Gel zymography 
Matrix metalloprotease (MMP) activity was detected from the cell culture 
medium by gelatin zymography methods described elsewhere
19
.  Briefly, aliquots of 
culture medium were assayed for protein content using the BCA assay, and all lanes were 
loaded in multiplicate with equal amounts of protein. A pre-stained molecular weight 
standard (BioRad, Hercules, CA) and MMP-2 and 9 standards (Anaspec, San Jose, CA) 
were loaded alongside.  After development, staining, and destaining, bands from the 
various MMP-2 and 9 isoforms appeared on a dark background of stained gelatin and 
were measured using ImageJ software (NIH, Bethesda, MD), and quantified as relative 
density units (RDU). 
 
 
4.2.10 MMP array 
To assess the MMPs and tissue inhibitors of MMPs (TIMPs) released by 
aHASMCs as compared to aHASMCs treated with an optimal dose of elastogenic 
factors, an MMP array was used. Proteins from factor-supplemented and non-factor 
supplemented aHASMC cultures were extracted in a RIPA buffer (Thermo Scientific, 





ELISA-based MMP antibody array (RayBiotech, Norcross GA). The array identified 
MMPs-1, 2, 3, 9, 10, 13 and tissue inhibitors of MMPs (TIMPs)-1, 2, 4. The 
manufacturer‟s protocol was followed and the array was imaged on the UVP EC3 
BioImaging System (Upland, CA). An MMP array is not commercially available for rat 
tissues/ cells, and was thus not conducted for those cell types.  
 
4.2.11 SEM of elastic matrix 
Scanning electron microscopy (SEM) was used to visualize elastic matrix 
architecture. Spent medium was removed from atop cell layers after 21 days of culture. 
The cell layers were rinsed with PBS, and fixed with 4% w/v paraformaldehyde in 0.1 M 
phosphate buffer (4 ˚C, 15 min). After fixation, the cell layers were rinsed several times 
with 0.1M phosphate buffer, then submersed in 25% w/v KOH (60 ˚C, 5 min) to remove 
cellular and ECM debris and yield relatively pure, matrix elastin structures. Following a 
phosphate buffer rinse, the isolated elastic structures were then treated with 1% w/v 
tannic acid (1 h) and stained with osmium tetroxide (1 h), then dehydrated successively in 
graded ethanol (70-100% v/v; 1 min each) and finally hexamethyldisilazane (Sigma 
Aldrich, St. Louis, MO) (3 min), under a fume hood. The samples were finally mounted 









4.2.12 TEM of elastic matrix 
Transmission electron microscopy (TEM) was used to characterize the 
ultrastructure of the elastic matrix.  At 21 days post seeding, all control and test groups 
were fixed with 2% w/v cacodylate glutaraldehyde (12 h), post-fixed in 1% w/v osmium 
tetroxide (1 h), dehydrated in a graded ethanol series (50-100% v/v), embedded in Epon 
812 resin, sectioned, placed on copper grids, stained with uranyl acetate and lead citrate, 
and visualized on a Hitachi TEM H7600T (High Technologies, Pleasanton, CA). 
 
 
4.2.13 Statistical analysis 
The experimental data (n = 3/case) was analyzed using Student‟s t-test.  Statistical 
significance was deemed for p < 0.05.  Asterisks in figures denote statistical significance 
(p < 0.05) for each group compared with controls (cells in medium alone). 
 
 
4.3 Results  
 
 
4.3.1 Aneurysm progression and SMC phenotype 
An ~45% local increase in rat aortic diameter representing early aneurysm 
expansion, was attained over a 28 day period following peri-adventitial CaCl2 exposure, 
agreeing with our prior observations
19
.  Detailed histological analysis demonstrated 
significant medial thinning, elastic matrix disruption, matrix calcification, and 
involvement of inflammatory cells in the etiology of the expansion (Figure 4.1), similar 
to our previous publication
19





comprise a mixed cellular population with a significant number amongst them exhibiting 
decreased volume/ spreading. Expression of α-actin, SM-22, caldesmon, and calponin 
was reduced compared to healthy RASMCs, as illustrated in Figures 4.2A and 4.2B 
suggesting a loss of contractile phenotype. The aRASMCs also exhibited increased 
expression of osteopontin, a marker indicative of a switch to a synthetic phenotype, 
which SMCs typically express in response to injury.  
 
Figure 4.1 Representative SEM (50 X and 500 X magnification) and histological 
micrographs (VVG, H&E, and Von Kossa; 20 X magnification) of CaCl2-treated aortae 






Figure 4.2 (A) Immunofluorescence images of RASMC and aRASMC phenotypic 
marker expression. (B) Flow cytometry data of RASMC and aRASMC phenotypic 
marker expression (total intensity of marker expression per 100 cells). (C) aRASMC 
count following 21 days of culture with or without HA-o and TGF-β factor 
supplementation (n = 3/case). * indicates P < 0.05. § indicates p < 0.05 as compared to 
other specified conditions. 
 
aHASMCs derived from atherosclerotic human AAA (Figure 4.3A) tissue 
initially appeared less spread and more spindle-shaped relative to healthy human aortic 
SMCs (Figure 3B), although no differences were noted at confluence. Compared to 





expression indicating a loss of contractile phenotype and increased expression of 
osteopontin suggesting assumption of a synthetic phenotype, as illustrated in Figures 
4.3C and 4.3D.  
Figure 4.3 (A) Phase contrast images of primary HASMCs 1 and 21 days post seeding. 
(B) Phase contrast images of primary aHASMCs 1, 4 14, 21, and 28 days post seeding. 
(C) Immunofluorescence images of HASMC and aHASMC phenotypic marker 
expression. (D) Flow cytometry data of HASMC and aHASMC phenotypic marker 





following 21 days of culture with or without HA-o and TGF- factor supplementation (n 
= 3/case). * indicates p < 0.05. 
 
4.3.2 aRASMC and aHASMC proliferation  
The aRASMC count following culture with variable doses of TGF-and-is 
shown inFigure 4.2C.  Over 21 days of culture, non-supplemented control aRASMCs 
proliferated 2.5-fold relative to healthy RASMCs
19
.  Addition of TGF- and HA-o had no 
significant effects on aRASMC proliferation except at a dose of 2 µg/ml  HA-o and 10 
ng/ml TGF- which increased proliferation was noted (p = 0.002). At higher doses of 
HA-o (20 µg/ml), attenuation of cell proliferationwas observedwith increasing TGF- 
dose; there was significant decrease in cell count as compared to the control at the highest 
provided TGF-dose (10 ng/ml TGF- p = 0.01) and a significant difference between 
the cell counts at lowest and highest TGF-doses (1 and 10 ng/ml TGF-p = 0.023).   
Figure 4.3E shows the count of aHASMCs cultured with variable doses of TGF-
and-over 21 days.  Addition of TGF- and HA-o to aHASMC cultures again, 
had no statistically significant effects on cell proliferation. 
 
4.3.3 Matrix synthesis 
As shown in Figure 4.4A, most dose combinations of HA-o and TGF-had no 
effect on tropoelastin production by aRASMCs; at the highest dose of 20 µg/ml  HA-o 





seen (p = 0.043). Matrix elastin synthesis at this provided dose was also increased, but 
was not deemed significant from a statistical standpoint. As seen in Figures 4.4A and 
4.4B, when HA-o and TGF- were provided to aRASMCs at a moderate dose of 2 µg/ml 
HA-o and 10 ng/ml TGF-, no increase in tropoelastin production over controls was 
measured, though a significant increase in matrix elastin (including both highly cross-
linked, alkali-insoluble structural elastin and an alkali-soluble fraction) was observed, 
relative to control cultures (p = 0.016).  The matrix yield (percentage of total elastin in 
the matrix form, normalized to DNA) increased significantly from 1.39% (control) to 






Figure 4.4 Effects of HA-o and TGF- factor supplementation on tropoelastin (A) and 
matrix elastin (B) produced by aRASMCs.  Data shown are normalized to cellular DNA 
content at 21 days of culture (n = 3/case).  * indicates P < 0.05; § indicates p < 0.05 as 
compared to other specified conditions. (C-F) Tropoelastin and matrix elastin production 
trends (based on mean values) associated with increased in HA-o or TGF-. 
 
Figure 4.5 Effects of HA-o and TGF- factor supplementation on tropoelastin (A) and 
matrix elastin (B) produced by aHASMCs.  Data shown are normalized to cellular DNA 
content at 21 days of culture (n = 3/case).  * indicates p < 0.05: § indicates p < 0.05 as 
compared to other specified conditions. (C-F) Tropoelastin and matrix elastin production 






There were significant increases in tropoelastin production by aHASMCs (Figure 
4.5A) at doses of 2 µg/ml HA-o and 5 ng/ml TGF-and higher, in general,  relative to 
control cultures (p < 0.01 in all cases). At these higher dose combinations, a significant 
increase in matrix elastin production was observed, relative to unsupplemented aHASMC 
cultures (Figure 4.5B; p < 0.02 in all cases).  The matrix yield enhanced from 0.19% 
(control) to 0.31% (2 µg/ml HA-o and 5 ng/ml TGF- p = 0.039).  
 
4.3.4 Ultrastructure of matrix elastin 
Figures 4.6 (low magnification) and 4.7 (high magnification) are representative 
transmission electron micrographs (TEM) of aRASMC layers following 21 days of 
culture in the absence and presence of elastogenic factors.  Similar to that previously 
observed in healthy cultures of RASMCs, untreated control aRASMCs deposited 
aggregating clumps of amorphous elastin protein that were overall sparse and rather 
localized within the cell layers (panel A).  When TGF-1 and HA-o together were 
provided to these cultures, mature elastin fiber formation was favored, with the matrix 
containing numerous fully-formed bundles (100-200 nm in diameter) of aggregating 
fibrils (panel B).  Fibrillin (immunogold particle-stained) appeared as darkly stained 
nodules, and was located at the periphery of aggregating elastin fiber bundles, signifying 
normal elastic fiber assembly. 
In the case of human SMC cultures, the rather slow proliferation of healthy 
HASMCs deterred their retention as an intact cell layer when subject to processing for 





results have been omitted from this manuscript; comparison has instead been made using 
SEM alone. 
 
Figure 4.6 Representative TEM images of 21-day old aRASMC cultures with (B) or 
without (A) HA-o and TGF- factor supplementation (7300 X magnification; scale bar = 
2 µm). Black arrows indicate elastic matrix. 
 
Figure 4.7 Representative TEM images of 21-day old aRASMC cultures with (B) or 
without (A) HA-o and TGF- factor supplementation (30,000 X magnification; scale bar 






Representative scanning electron micrographs of elastic matrices isolated from 21 
day cultures of treated and no-additive control rat and human aneurysmal SMCs are 
shown (Figures 4.8 and 4.9, respectively). Enhanced cellular deposition of crosslinked 
elastic fibers relative to control cultures was observed. 
 
Figure 4.8 Representative SEM images of elastic matrix produced by 21-day old 
aRASMC cultures with (B) or without (A) HA-o and TGF- factor supplementation 
(1,000X magnification; scale bar = 20 µm). White arrows indicate fibrillar elastic 
structures. 
 
Figure 4.9 Representative SEM images of elastic matrix produced by 21-day old 
aHASMC cultures with or without HA-o and TGF- factor supplementation (1,000X 






4. 3.5 Von Kossa staining 
 Calcific deposits were minimal or absent in all of the culture groups (aRASMC, 
aRASMC +factors, aHASMCs, aHASMCs +factors) following 21 days of culture 
indicating there was no/ minimal calcific deposition due to uptake of Ca
2+ 
from culture 
medium or the exogenous supplementation TGF-β.  
 
4.3.6 Proteolytic enzyme activity 
We previously showed a significant increase in MMP-2 and 9 activity in untreated 
aRASMC cultures relative to healthy RASMC cultures (1.67-fold and 2.07-fold, 
respectively; p = 0.03 and 0.01)
19
, confirming their activated phenotype. As shown in 
Figure 4.10 gelatin zymography run in triplicate on spent medium samples derived from 
aRASMC cultures supplemented with factors (2 μg/ml HA-o, 10 ng/ml TGF-β) revealed 
decreased MMP-2 activity (22% decrease in MMP-2) and MMP-9 activity (4% decrease 
in MMP-9) as compared to untreated control aRASMCs.  
 
Figure 4.10 (A) Gel zymography analysis revealed the activity of MMP-2 and MMP-9 





o and TGF- factor supplementation.  (B) Data are shown normalized to the respective 
values observed in non-supplemented aRASMC controls (n = 3/case). The factor dose 
assessed was 2 µg/ml HA-o and 10 ng/ml TGF- 
 
 
Figure 4.11 Gel zymography (C) revealed the activity of MMP-2 and MMP-9  
(numerous isoforms/ many bands) released by aHASMCs as compared to HASMCs (A) 
and the activity of MMP-2 and MMP-9 within aHASMC cultures treated with or without 
HA-o and TGF- factor supplementation (B). Data are shown normalized to the 
respective controls (n = 3/case).  (D) MMP array revealed MMPs (MMPs-1, 2, 3, 9, 10, 












The CaCl2-injury model is frequently used for accelerated study of human AAA 
pathology. The model has been shown to induce several characteristics of human AAAs, 
such as medial layer disruption, inflammation, matrix calcification, thrombus 
formation
18
, and enhanced MMP activity at the site of application 
190, 192
 associated with  
significant and progressive local aortic dilation within 4 weeks
200
.  Despite the 
similarities human AAAs, in the context of investigating elastic matrix regeneration and 
induction of the same by human AAA-derived SMCs, the utility of the CaCl2-injury 
model in rats remains unproven. From the standpoint of assessing the efficacy of our 
elastin regenerative factors for AAA treatment in animal models of disease, it is vital to 
ascertain that observations with the surrogate model/cell type parallel observations in 
humans. Therefore, in this study we compared the elastogenic potential of cultured SMCs 
from CaCl2-induced model of rat AAAs (aRASMCs) and from a biopsied atherosclerotic 
human AAA tissue (aHASMCs) to evaluate the rodent disease cell culture model as an 
appropriate surrogate.  
In this study, at 4 weeks post-injury, CaCl2-treated rat abdominal aortae generated 
many of the characteristic findings typical of human AAAs, such as medial elastic matrix 
disruption, medial thinning, calcification, increased MMP activity, and an approximate 







Although, we refer to these dilatations of the aortic wall as induced-AAAs throughout 
this paper, we acknowledge that they may be different pathological processes.  
Differences in phenotype between healthy and aneurysmal vascular SMCs have 
been reported by others 
201
. As found in those studies, we also observed that aRASMCs 
derived from CaCl2-injured aortae exhibited decreased volume/spreading and SM22, 
caldesmon, and calponin expression as compared to healthy RASMCs (Figures 4.2A and 
4.2B). SM22, a protein found extensively in adult SMCs, is implicated in restricting 
phenotypic changes from a contractile to a synthetic phenotype 
203
; it is homologous to 
calponin and can be functionally compensated by calponin in maintenance of SMC 
homeostasis 
204-205
. Caldesmon plays a key role in SMC contraction by binding to acto-
myosin contractile units like actin, tropomyosin, myosin and calmodulin 
206
 and may 
have a regulatory role in the contractile apparatus; it has been reported to inhibit the 
Mg
2+
-ATP-ase activity and hence inhibit smooth muscle contractility 
207
. Calponin binds 
with actin light chains depending on the presence of Ca
2+
 thereby regulating the 
contractile apparatus of SMC‟s 
208-209
; due to this binding, it has also shown to inhibit 
actin-activated Mg
2+-
ATP-ase activity in-vitro 
210
. Together, a decrease in expression of 
these markers signifies a loss of contractile SMC phenotype. In addition, the aRASMCs 
also exhibited increased expression of osteopontin, a multi-functional pro-inflammatory 
cytokine implicated with vascular disease and enhanced inflammatory response 
211
; 
osteopontin has been shown to induce chemotaxis of macrophages and monocytes, which 
stimulates calcification 
212
 and enhances MMP activity, thereby promoting vascular wall 
deterioration 
213





aRASMCs exhibited enhanced MMP and elastase activity over healthy control RASMCs, 
suggesting an activated phenotype
19
.   
A comparison of the effects of the factors on aRASMCs and aHASMCs revealed 
that HA-o and TGF-β1 together had only a limited impact on proliferation of either of 
these cell types, which in general proliferated more rapidly than their healthy 
counterparts. In aRASMC cultures, unlike in healthy RASMC cultures, low dose 
combinations of HA-o (< 2 μg/ml) and TGF-β (< 5 ng/ml) together had no effect on 
tropoelastin and matrix elastin production. This agrees well with our prior findings that 
diseased SMCs require higher doses of these factors for elastogenic stimulation. Also 
apparent from our results, are that HA-o and TGF-β1 in general, appear to more 
sensitively influence the elastin crosslinking/ matrix assembly machinery than cellular 
tropoelastin synthesis, which is increased only at the highest dose combination. At the 
factor doses assessed in this study, effects of TGF-β on tropoelastin production by 
aRASMCs were dependent on the concentration of HA-o. At low HA-o doses (2 μg/ml), 
increased doses of TGF-β (1-10 ng/ml) decreased tropoelastin production, whereas at 
high HA-o doses (20 μg/ml), increased doses of TGF-β increased tropoelastin production 
(Figure 4.4D). For a given dose of HA-o to aRASMCs, increased doses of TGF-β 
resulted in an increase in matrix elastin production (Figure 4F). At the higher doses of 
TGF-β, there was minimal effect of HA-o on matrix elastin production (see convergence 
of trend curves in Figure 4.4F). These trends are also clearly apparent in Figure 4.4E, 
where dose increases in HA-o most significantly enhance elastic matrix synthesis at the 





aRASMCs suggest that (a) the predominant effects of HA-o lie in the enhancement of 
elastic matrix deposition rather than improvement of tropoelastin production, which 
corroborates inferences from our prior studies 
214-215
, (b) the effects of HA-o on matrix 
elastin production are most pronounced at lower tested TGF-β doses, indicating that at 
the highest tested TGF-β  dose, TGF-β  effects dominate over that due to HA-o and (c) 
increase in tropoelastin and matrix elastin synthesis with increasing TGF-β dose are more 
pronounced at higher HA-o doses.  
Similar to aRASMCs, cultured aHASMCs demonstrated a loss of contractile 
phenotype relative to healthy HASMCs, but exhibited a marginal increase in expression 
of markers typical of injured/activated SMCs (e.g., osteopontin; Figures 4.3C and 4.3D). 
These cells were also similar to aRASMCs in that they proliferated much faster than their 
healthy counterparts and that exposure to HA-o and TGF-β at any tested dose 
combination did not impact cell proliferation. Overall, these results show that SMCs 
obtained by passaging primary cell isolates from both CaCl2-injury generated rat AAAs 
and human AAAs maintain an activated phenotype in culture and demonstrate 
morphological and phenotypic similarities. 
The aHASMCs showed similarities to aRASMCs in their matrix synthesis 
responses to the provided factors, specifically in that tropoelastin and matrix elastin 
synthesis was only enhanced at the higher dose combinations, and no effects were seen at 
the lowest doses. However, two important differences are worthy of notice. The first is 
that the minimal dose(s) for significant elastogenic up-regulation, particularly for 





determined for aRASMCs (20 µg/ml HA-o; 10 ng/ml TGF-β). The second is that at the 
respective doses that induce maximal elastogenicity, the increases in tropoelastin and 
matrix elastin was far greater in the aHASMC cultures (5.08-fold increase in tropoelastin/ 
DNA vs. 8.4 -fold increase in matrix elastin/ DNA at 2 µg/ml HA-o; 5 ng/ml TGF-β) 
than for aRASMCs (16% decrease in tropoelastin vs. 2.15-fold increase in matrix elastin 
at 2 µg/ml HA-o; 10 ng/ml TGF-β). Both these observations strongly suggest that the 
intracellular signaling mechanisms that form the basis for downstream outcomes of 
increased elastin precursor and matrix synthesis in aHASMCs are more sensitive to cell 
interaction with HA-o and TGF-β than in the case of aRASMCs. This is suggested from 
the trend curves which show elastin synthesis to have much stronger HA-o dose 
dependency in aHASMC cultures (at a given TGF-β dose) than in aRASMC cultures, 
especially at the lowest TGF-β doses (Figures 4.5C and 4.5E). It is also noteworthy that 
at the lowest HA-o dose, TGF-β effects on elastic matrix deposition dominate, as deemed 
from the classic biphasic TGF-β-dose response, with an initial increase in tropo/ matrix 
synthesis with TGF-β dose, and a sharp decrease when TGF-β dose is increased still 
further; such a biphasic response to TGF-β was not observed in aRASMC cultures, at 
least within the tested dose range (Figures 4.5D and 4.5F). Our results also suggest that 
the provided factors encourage elastic fiber organization in aHASMC cultures similar to 
aRASMC cultures, in a manner similar to that observed in healthy cells (Figures 4.8 and 
4.9). 
At the factor dose combinations deemed most elastogenic, absolute elastic matrix 





amounts generated by their respective healthy cultures (with no factor supplementation), 
respectively. This reveals that although elastic matrix yield is enhanced significantly, that 
additional elastogenic stimulation of human aneurysmal cells, particularly, may be 
necessary to coax the elastogenic capacity to level at least that of healthy SMCs. There is 
a strong potential for increasing matrix elastin further. Future studies to address this 
challenge may incorporate combination therapies that would increase elastin crosslinking 
into mature matrix (e.g., exogenous supplementation of lysyl oxidase (LOX) to initiate 
covalent crosslinking of elastin precursors 
216
 or copper nanoparticles to increase LOX-
mediated elastin crosslinking machinery to enhance matrix yield and maturation, as we 
have previously demonstrated 
217-218
).  
Similar to aRASMCs, which we showed in a prior publication  to demonstrate 
enhanced MMP-2 and 9 activity relative to healthy RASMCs 
19
, cultured aHASMCs 
exhibited higher activity of elastolytic MMP-2 (but not MMP-9) relative to healthy 
HASMCs confirming their activated phenotype. However, HA-o and TGF-β factors, 
provided at the „most effective‟ doses identified for the respective cell types, had very 
different effects on MMP activity in aRASMC and aHASMC cultures; the factors 
attenuated MMP-2  (minimal change in MMP-9) activity in aRASMC cultures (Figure 
10), but enhanced the same in aHASMC cultures (Figures 4.11B and 4.11C), although in 
the latter the factors induced an across-the-board decrease in concentration of elastogenic 
(MMP-2 and 9) and other MMPs relative to non-supplemented aHASMC cultures 







1. The peri-adventitial CaCl2-injury model of AAAs exhibits the pathological 
characteristics of human AAAs, including similarities in terms of decreased 
contractile activity, enhanced proliferation, and reduced elastogenic capacity (relative 
to healthy SMCs) when isolated and expanded in culture, the model differs from 
human AAAs in cellular responses to elastogenic stimulation.  
 
2.   aRASMCs appear to be less sensitive to TGF-β and HA-o relative to aHASMCs  in 
the context of elastin regenerative responses, though trends are maintained. At the 
respective doses that induced maximal elastogenicity, the increases in tropoelastin 
and matrix elastin was far greater in the aHASMC cultures (5-fold increase in 
tropoelastin/ DNA vs. 8-fold increase in matrix elastin/ DNA at 2 µg/ml HA-o; 5 
ng/ml TGF-β) than for aRASMCs (16% decrease in tropoelastin vs. 2-fold increase in 
matrix elastin at 2 µg/ml HA-o; 10 ng/ml TGF-β). 
 
3.   Concurrent delivery of factors attenuated elastolytic MMP-2 activity in aRASMCs 
(as shown previously). Interestingly, no significant decrease was seen in aHASMC 
cultures, yet an overall decrease in MMP and TIMP expression was seen with factor 
supplementation. 
 
4.  Differences in cell responses may likely be due to differences in the stage in 





barely qualifying as an aneurysm and the human AAA at pre-rupture stage. We also 
acknowledge that aHASMCs were isolated from AAA tissue from a single patient, 
and thus may not adequately represent phenotypic diversity of aHASMCs.  
 
5.   Further study of SMCs from stage-matched CaCl2-injury generated aortal expansions 
and human AAAs will be necessary to more rigorously evaluate their basal and 
induced elastogenic responses.  
 
6.   The CaCl2-injury model of AAAs exhibits distinctive short-comings as a surrogate in 
the context of elastin regeneration within human AAAs; alternate models, such as an 
elastase-perfusion model of AAAs, require similar investigation as to their suitability 







EVALUATIION OF ADVANCED RAT AAA- DERIVED SMCS FOR 
ELASTOGENIC POTENTIAL 
5.1 Introduction 
In the previous chapter, we presented our observations on the dose-specific effects 
of the factors (0-20 μg/ml HA-o and 0-10 ng/ml TGF-β) on elastogenesis by SMCs 
derived from CaCl2-induced rat aortal expansions (aRASMCs) 
19
, which are 
representative of early stage inflammatory human AAAs; we showed aRASMCs to 
maintain a diseased/activated phenotype in culture and that they are amenable to 
elastogenic stimulation, though much greater factor doses were required for these 
diseased cell types than that by healthy RASMCs. However, it is also important to 
recognize that AAAs are frequently diagnosed at relatively advanced stages of maturation 
when matrix deterioration is severe. From the standpoint of a clinically applicable 
paradigm for AAA regression, we must assess elastogenic up-regulation of SMCs derived 
from late-stage AAAs (>100% diameter expansion). This is the subject of the present 
study. 
 
5.2 Materials and methods 
 
5.2.1 Induction of aortal injury via elastase perfusion  
 All animal studies were approved by the IACUC at the Medical University of SC 





Dawley rats (250-300 g in weight) were acclimatized for one-week before surgery.  The 




isoflurane) and the infrarenal 
abdominal aortae surgically exposed, and injured via elastase perfusion, using a 
published method adapted for our purposes 
219-220
. The posterior lumbar aortic branches 
and the inferior mesenteric arteries were ligated with 9-0 suture (Surgical Specialties 
Corp., Reading, PA) if they were within the area of interest.  The aortae were 
circumferentially dissected at the proximal and distal ends to allow placement of vascular 
clamps (Fine Science Tools, Foster City, CA) and distal silk ties.  The aortic diameters 
were measured using an eyepiece micrometer fitted on a stereoscope (Olympus SZ61, 
Olympus, Center Valley, PA).  The proximal and distal microclips placed at the renal 
junctions and iliac junctions, and small aortotomies made using the tip of a 27
1
/2-guage 
needle.  PE-10 catheters (Scientific Commodities Inc., Lake Havasu City, AZ) were 
inserted into the vessel lumen and the distal silk ties tightened to hold these intraluminal 
catheters in place.   The aortae were slowly perfused with elastase (20 U/ml; 25 min) 
until the aortal section between the clamps ballooned to 200% of the original diameter as 
measured by the eyepiece micrometer. Following perfusion, the distal ties were released, 
the catheter tubing removed, the aortotomies closed with 9-0 suture, and the proximal and 
distal clamps removed (Figure 5.1).  Following confirmation of re-perfusion to the lower 
limbs, and collection of post-perfusion measurements, the intestines were replaced and 
the incision sites closed in two layers with 4-0 Vicryl suture and 4-0 Ethilon suture 
(Ethicon, New Brunswick, NJ).   The rats were then placed on a heat pad until they 







analgesic (0.03 mg/ml; Buprenorphine) was injected subcutaneously. The animals were 
monitored for a few days with administration of Buprenex every 12 hours if necessary. 
The aneurysmal aorta was harvested at 14 days post-op. 
 
Figure 5.1 Elastase perfusion (20 U/ml; 25 min) procedural images. (A) Abdominal aorta 
prepared for catheterization with clamps on the proximal and distal aorta and a silk tie in 
place, yet loose, to secure the catheter upon placement.  (B) Abdominal aorta with a PE-
10 catheter introduced in the lumen. (C) Secured catheter and perfused aorta. (D) Closure 







5.2.2 Histological and biochemical characterization of aortal expansions  
Diameter expansion measurements were conducted on aortae pre- and post-
perfusion and 14 days post-op (n = 12) from photographs taken at the respective time 
points and analyzed via Image J software (NIH, Bethesda, MD). Histological and 
biochemical analysis of these expansions was performed. Standard hemotoxylin and 
eosin staining (H & E; for nuclear and intracellular and extracellular protein 
visualization), modified Verhoff Van Gieson staining (VVG; for elastin visualization; 
ScyTek Laboratories, Logan, UT), and scanning electron microscopy (SEM; for 
ultrastructural visualization aortic cross-sections) were conducted on untreated control 
aortae, sham (saline-perfused) aortae, and elastase-perfused aortae (n = 3 animals/ group). 
Aortae from respective animals were harvested 14 days post-op (or at a time-matched 
stage for un-operated control animals), rinsed in sterile saline, embedded in optimum 
cutting temperature (OCT) medium, and stored at -20 °C until cryosectioning. Sections 
(5µm) were processed for histology or SEM. Standard histological protocols were 
followed. For SEM, samples were fixed in 2% v/v gluteraldehyde in phosphate buffer, 
rinsed in phosphate buffer, DI water, then dehydrated in graded ethanol and finally 
hexamethyldisilazane (Sigma Aldrich, St. Louis, MO) (3 min), under a fume hood. The 
histological and SEM samples were imaged on an Olympus BX41 (Olympus, Center 
Valley, PA) and a Hitachi SEM TM1000 (Hitachi Technologies, Pleasanton, CA), 
respectively. 
MMP activity within elastase-perfused aortae was assessed by gelatin 
zymography methods 
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tissue was homogenized in RIPA buffer and then assayed for protein content using the 
BCA assay (Thermo Scientific, Waltham, MA). All lanes were loaded in multiplicate 
with 25µg of protein in each lane. A pre-stained molecular weight standard (Invitrogen, 
Grand Island, NY) was loaded alongside.  After development, staining, and destaining, 
densities of MMP-2 and 9 bands on a dark background of stained gelatin were quantified 
using ImageJ software (NIH,  Bethesda, MD), and reported as relative density units 
(RDU). 
 
5.2.3 Isolation and culture of EaRASMC  
 Expanded abdominal aortae segments from adult, male Sprague Dawely rats (n = 
3), 14 days post perfusion with elastase, were opened lengthwise and the intima scraped 
gently with a scalpel blade.  The medial layer was dissected from the underlying 
adventia, chopped into ~ 0.5 mm-long sections, and washed twice with warm phosphate-
buffered saline (PBS).  The tissue slices were then pooled, enzymatically degraded in 
DMEM-F12 (Invitrogen, Grand Island, NY) containing 125 U/mg collagenase 
(Worthington, Biochemicals Lakewood, NJ) and 3 U/mg elastase (Worthington 
Biochemicals) for 30 min at 37 C, centrifuged (400 g; 5 min), and cultured in T-75 
flasks with DMEM-F12 containing 10% v/v fetal bovine serum (PAA Laboratories, 
Etobicoke, Ontario) over 15 days.  Primary aneurysmal rat aortic SMCs (EaRASMCs) 
derived by outgrowth from these tissue explants were cultured over 2 weeks, and the cells 
passaged when confluence was attained.  For experiments, passage 2 SMCs were seeded 
onto 6-well tissue culture plates (Area = 10 cm
2







and cultured in DMEM-F12 medium containing 10% v/v FBS and 1% v/v Penstrep 
(South Logan, UT).  The total volume of medium added per well was 5 mL. 
  
5.2.4 Experimental design and time points 
Passage 3 EaRASMCs were cultured in medium containing supplemented factors 
(0, 0.2, and 20 μg/ml HA-o and 1, 5, and 10 ng/ml TGF-β; n = 6/ condition) within 6-well 




) for 21 days, over which time the cells deposited a robust 
matrix. Spent medium aliquots were removed from each well, at the time of each, twice-
weekly medium change, pooled with previously removed aliquots, frozen at –20 ˚C, then 
biochemically assayed together with their corresponding cell layers when harvested at 21 
days of culture. 
 
5.2.5 DNA assay for cell proliferation 
The DNA contents of the cell cultures groups were compared to determine the 
impact of the factors and factor doses on SMC proliferation. For analysis, the cell layers 
were harvested at 21 days of culture, resuspended in NaCl-Pi buffer, sonicated on ice, 
and their respective DNA contents quantified using a fluorometric assay described by 
Labarca and Paigen
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5.2.6 Immunoflourescence detection of SMC phenotypic markers 
Immunofluorescence techniques were used to visualize SMC contractile and 
synthetic phenotypic markers.  RASMCs and EaRASMCs (n = 3/marker/cell type) were 
cultured in sterile, 2-well Permanox
®
 chamber slides (Nalge Nunc International, 
Rochester, NY) under identical experimental conditions as described for cultures 
intended for biochemical analysis, though the cell seeding density and treatment doses 
were adjusted, to account for the reduced substrate surface area and cell number, 
respectively.  Cell layers were fixed with acetone for 10 minutes at -20 °C and blocked 
with 5% v/v goat serum (30 min). α smooth muscle actin, SM22α, calponin, and 
caldesmon (contractile phenotype markers), and thrombospondin and osteopontin 
(synthetic phenotype markers) were then detected with polyclonal antibodies against rat 
antigens (1:100 v/v; Abcam, Cambridge, MA), which show cross-reactivity with human 
antigens and visualized with FITC-conjugated IgG secondary antibodies (1:1000 v/v; 
Chemicon, Temecula, CA). The cell layers were cover-slipped with Vectashield 
mounting medium containing the nuclear dye 4',6-diamidino-2-phenylindole (DAPI; 
Vector Laboratories, Burlingame, CA), which labeled the cell nuclei. 
 
5.2.7 Flow cytometry  
 Flow cytometry analysis of the SMCs (Passage 4) was performed.  Cells were 
trypsinized, centrifuged (1500 RPM; 10 min), reconstituted at 1 Χ 10
6
 cells per sample, 
fixed with 4% w/v paraformaldehyde in PBS (37 °C; 10 min), washed, then 





detection of SMC phenotypic markers was conducted with the antibodies outlined above. 
The samples were incubated with primary antibodies (30 min; 4 °C), followed by a FITC-
conjugated secondary antibody (20 min; 4 °C; dark). After labeling, cells were 
resuspended in 0.5 ml of PBS and kept at 4 
°
C protected from light until analysis. 
Cytometric analysis was done using a Becton Dickinson FACSCalibur Analytical Flow 
Cytometer and data were processed using Cell Quest Pro 5.2 (BD Biosciences, Franklin 
Lakes, NJ). 
 
5.2.8 Fastin assay for elastin 
A Fastin assay (Accurate Scientific and Chemical Corporation, Westbury, NY) 
was used to quantify the total amount of elastin deposited within cell layers (matrix 
elastin), and that released into the culture medium as a soluble precursor (tropoelastin). 
For each treatment group, tropoelastin in the spent medium was collected and pooled 
over the culture period and frozen at -20 ˚C.  To isolate matrix elastin following either 21 
days the cell layers were trypsinized, then scraped off, re-suspended in NaCl/ Pi buffer, 
and centrifuged (2500 RPM, 10 min). The cell pellet was digested with 0.1 N NaOH (98 
˚C, 1 h), and centrifuged to yield a less crosslinked, alkali-soluble supernatant fraction 
(soluble elastin), and a mature, highly crosslinked, insoluble pellet (insoluble elastin). 
Since the Fastin assay quantifies only soluble α-elastin, the insoluble elastin was first 
converted to a soluble form prior to quantification. To do this, the insoluble elastin pellet 
was dried, solubilized with 0.25 M oxalic acid (95 ˚C, 1 h), and the pooled digests then 





molecular weight (10 kDa) cut-off membranes (Millipore, Bedford, MA). All three 
elastin fractions (tropoelastin, and soluble and insoluble matrix elastin) were quantified 
using the Fastin assay.  
 
5.2.9 Von Kossa staining 
Van Kossa staining was used to visualize calcific deposition by the aneurysmal 
SMCs. SMCs (n = 2/ condition) were cultured in sterile, 2-well Permanox
®
 chamber 
slides (Nalge Nunc International, Rochester, NY) under identical experimental conditions 
as described for cultures meant for biochemical analysis, though the cell seeding density 
and treatment doses were adjusted to account for reduced the substrate surface area and 
cell number, respectively. After 21 days of culture, the SMCs were incubated with 1% 
w/v silver nitrate solution and placed under UV light (λ = 254 nm; 20 min).  After several 
changes of distilled water, the un-reacted silver was removed by rinsing cells with 5% 
w/v sodium thiosulfate for 5 min, then PBS.  The slides were counterstained with 
hematoxylin.  The appearance of black stained masses in the cell layers confirmed the 
presence of calcium phosphate deposits. 
 
5.2.10 Gel zymography 
Activity of MMPs-2 and 9 were detected in the culture medium by gelatin 
zymography methods.  Briefly, aliquots of culture medium were assayed for protein 
content using the BCA assay, and all lanes were loaded in multiplicate with equal 





Hercules, CA) and MMP-2 and 9 standards (Anaspec, San Jose, CA) were loaded 
alongside.  After development, staining, and destaining, densities of MMP-2 and 9 bands 
on a dark background of stained gelatin were quantified using ImageJ software (NIH,  
Bethesda, MD), and reported as relative density units (RDU). 
 
5.2.11 TEM of elastic matrix 
Transmission electron microscopy (TEM) was used to characterize the 
ultrastructure of the elastic matrix.  At the 21 days post seeding, all control and test 
groups outlined in Table 1 were fixed with 2% w/v cacodylate glutaraldehyde (12 h), 
post-fixed in 1% w/v osmium tetroxide (1 h), dehydrated in a graded ethanol series (50-
100% v/v), embedded in Epon 812 resin, sectioned, placed on copper grids, stained with 
uranyl acetate and lead citrate, and visualized on a Hitachi TEM H7600T (High 
Technologies, Pleasanton, CA). 
 
5.2.12 Statistical analysis 
The biochemical data were analyzed using Student‟s t-test.  Statistical 
significance was deemed for p < 0.05.  Asterisks in figures denote statistical significance 
(p < 0.05) for each group compared with controls (cells in medium alone). 
 
5.2.13 DNA microarray 
To assess differences in gene expression patterns between healthy, untreated 





elastogenic factor supplements (2 µg/ml HA-o and 5 ng/ml TGF-β), DNA microarray 
analysis was conducted using an adaptation of a published method  
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. Primary, passage 
3 SMCs (derived from 3 different animals/ culture condition and passaged separately) 
were cultured for 7 days under the conditions specified above. Total RNA was prepared 
from cell layer samples by RLT buffer extraction followed by purification using RNeasy 
columns (Qiagen, Valencia, CA). Quality and purity of the RNA preparations were 
assessed by spectrophotometric determination of the ratio of absorbance at 260/280 nm 
and by quantification of 28S:18S ribosomal RNA ratios using a Bioanalyzer 2100 
(Agilent Technologies, Palo Alto, CA).  
Synthesis of double-stranded cDNA, in vitro transcription of biotin-labeled cRNA 
targets, and fragmentation of target cRNA were performed as outlined by Affymetrix 
protocols (Affymetrix, Santa Clara, CA). Fragmented cRNA samples were hybridized 
overnight at 45 °C to Affymetrix Rat Expression 230 2.0 GeneChips. Post-hybridization 
washing and phycoerythrin-streptavidin staining and fluorescence scanning were 
performed using Affymetrix instrumentation in accordance with manufacturer protocols. 
Gene hybridization intensities were normalized using Robust Multichip Average 
implemented with Affymetrix Expression Console. Normalized hybridization values 
were compared using dChip 2009 software or the Significance Analysis of Microarray 
Addin for Microsoft Excel. Genes differentially expressed in response to elastase 
perfusion injury or supplementation of HA-o and TGF-β factors were identified using 





following review of gene ontology annotations as well as functional information 
available through NCBI Entrez Gene.  
 
5.3 Results  
 
5.3.1 Aneurysm progression and SMC phenotype 
A local increase in rat aortic diameter (~122%), typical of a late-stage aneurysmal 
expansion, was induced over a 14 day period following elastase-perfusion (Figure 5.2A-
D).  SEM and histological assessment (H & E and VVG) of the elastase-perfused aortae 
revealed a collapsed lumen and disruption in the elastic medial layer of the vessel wall 
compared to the no treatment control and the treatment sham (saline perfusion) (Figure 
5.3A).   Assessment of sham-treated aortae revealed minimal elastic matrix degradation 
relative to elastase-perfused aortae, yet mild disruption and disorganization of the elastic 
structures was observed relative to healthy, control aortae (Figure 5.3A). These results 




Morphologically, EaRASMCs derived from elastase perfusion-injured aortae 
appeared represent a mixed population and in general appearing smaller and less spread 
than healthy RASMCs. Phenotypic analysis using immunofluorescence revealed the 
EaRASMCs to exhibit decreased α-actin, caldesmon, and calponin expression as 
compared to healthy RASMCs, as illustrated in Figure 5.4A, suggesting a loss of 





osteopontin. Flow cytometry analysis (total intensity of marker expression per 100 cells; 
Figure 5.4B) indicated that there was a decrease in α-actin, caldesmon, and calponin 
contractile marker expression as compared to healthy RASMCs; there was no notable 
difference in SM22, osteopontin, and thrombospondin expression as compared to 
RASMCs. 
 
Figure 5.2 (A) Representative images of an aorta pre-perfusion, (B) elastase-perfused, 
and (C) post-perfusion. A vascular clip is pictured as a scale marker. (D) Aortic diameter 
measurements.  
 
5.3.2 EaRASMC proliferation  
Figure 5.4C shows the count of EaRASMCs cultured with different dose 
combinations of TGF-and-.  EaRASMCs proliferated more rapidly relative to 





RASMCs. Addition of TGF- and HA-o to EaRASMC cultures significantly decreased 
cell proliferation, with maximum attenuation observed for doses of 20 µg/ml HA-o and 
10 ng/ml TGF- (75% of untreated control EaRASMCsp = 0.0001).   
 
 
Figure 5.3 (A) Representative SEM (1000 X magnification) and histological 
micrographs (VVG and H&E; 2 X and 20 X magnification) of elastase-perfused aortae as 
compared to control and sham aortae. Black arrows indicate intact, healthy elastic media; 
white arrows indicate disrupted elastic media. (B) Gel zymography analysis revealed the 








Figure 5.4 (A) Immunofluorescence images of RASMC and EaRASMC phenotypic 
marker expression. (B) Flow cytometry data of RASMC and EaRASMC phenotypic 
marker expression (total intensity of marker expression per 100 cells). (C) EaRASMC 
count following 21 days of culture with or without HA-o and TGF- factor 







Figure 5.5 Effects of HA-o and TGF- factor supplementation on tropoelastin (A) and 
matrix elastin (B) produced by EaRASMC.  Data shown are normalized to cellular DNA 
content at 21 days of culture (n = 3/case).  * indicates P < 0.05. (C-F) Tropoelastin and 
matrix elastin production trends (based on mean values) associated with increased in HA-
o or TGF-.  
 
5.3.3 Matrix synthesis 
As shown in Figure 5.5A, at the high dose combination of 20 µg/ml HA-o and 10 
ng/ml TGF-a significant increase in tropoelastin production by EaRASMCs was seen 





(1.49-fold increase; p = 0.006). At moderate doses of 2 µg/ml HA-o and 5 ng/ml TGF-
2 µg/ml HA-o and 10 ng/ml TGF- and 20 µg/ml HA-o and 1 ng/ml TGF- there was 
no significant increase in tropoelastin, yet there was an increase in elastin crosslinked into 
the matrix form. As shown in Figure 5.5B, when HA-o and TGF- were provided to 
aRASMCs at an optimal dose (least amount supplement needed for greatest elastogenic 
benefit) determined as 2 µg/ml HA-o and 5 ng/ml TGF-, a significant increase in matrix 
elastin (including both highly cross-linked, alkali-insoluble structural elastin and an 
alkali-soluble fraction) was observed, relative to control cultures (1.40-fold increase; p = 
0.049).  At this optimal elastogenic dose, EaRASMC cultures produced 112% of the 
absolute matrix elastin of that produced by healthy RASMCs (with no factor 
supplementation). 
 
5.3.4 Ultrastructure of matrix elastin  
                          
Figure 5.6 TEM of elastic fibers produced by EaRASMCs with (B) and without (A) 






5.3.5 Von Kossa staining 
 In all culture groups, calcium deposits were absent or minimal indicating there 
was no/ minimal calcific deposition due to uptake of Ca
2+ 
from culture medium or the 
exogenous supplementation TGF-β.  
 
5.3.6 Production of proteolytic enzymes 
Gelatin zymography run in triplicate on homogenized aortic tissue and spent 
medium samples, respectfully, revealed that the MMP activity was increased (9 % 
increase in relative density units) in tissues that underwent elastase perfusion as 
compared to untreated control aortae (Figure 5.3B). MMP activity of cells derived from 
these elastase-perfused aortae was minimally affected by the addition of the factors 
(Figure 5.7).  
 
Figure 5.7 (A) Gel zymography analysis revealed the activity of MMP-2 and MMP-9 
within aRASMC cultures treated with or without HA-o and TGF- factor 
supplementation.  (B) Data are shown normalized to the respective values observed in 





5.3.7 DNA microarray 
Differential gene expression was measured using DNA microarray and 
preliminary analysis was conducted.  Differential gene expression of EaRASMCs relative 
to healthy RASMCs was noted; Figure 5.8A is a heat map of these differentially 
expressed genes (criteria of p < 0.05 for unpaired Student‟s t-test and a fold change > 2) 
with red representing up-regulation and green representing down-regulation. Further 
assessing the effects of HA-o and TGF-on gene expression (with the same criteria), we 
found a small set of genes that returned to „healthy levels‟ following treatment of factors 
(Figure 5.8B). A gene of interest from that subset was pro-collagen type VI, which was 
down-regulated in EaRASMCs relative to RASMCs and returned to healthy levels in 








Figure 5.8 Differential gene expression as measured by DNA microarray. (A) 
Differentially expressed genes in elastase-perfusion-derived EaRASMCs relative to 
healthy RASMCs (p < 0.05 for unpaired Student‟s t-test and fold change > 2). (B) Gene 
expression that returned to „healthy‟ levels following 7 days of culture with factors (2 
µg/ml HA-o and 5 ng/ml TGF-). Shown is a subset of genes differentially expressed 
between treatment groups as defined by Significance Analysis of Microarrays, multiclass 
analysis, with delta adjusted for false discovery rate > 5%.  
 
 We utilized gene ontology functional categories (AmiGO 
223
) for analysis of 
differential gene expression. The AmiGO functional group search terms of interest to us 
included smooth muscle cell, extracellular matrix, apoptosis, inflammation, matrix-
metalloproteases, and TGF-β. The criterion we implemented was a fold change > 1.5; the 
output is represented in Appendix A. There are numerous genes of interest to further 
* Indicate genes (probe sets) on 
the microarray that did not have 
an assigned identity but which 
were subsequently conditionally 
identified based on homology 







investigate; here, we will highlight only a few. Of note, bone morphogenic protein-4 
(BMP-4) expression was decreased in EaRASMCs relative to RASMCs and HA-o and 
TGF-appeared to have no effect on that expression level. Interestingly, elastin 
expression was decreased in EaRASMCs relative to RASMCs and the factors seemed to 
suppress this further. On a promising note, tissue inhibitor of MMP (TIMP)-3 expression 




We previously showed that healthy RASMCs
215
 and peri-adventitial CaCl2-
derived aneurysmal RASMCs, representing early-stage aneurysmal cells, can be 
elastogenically stimulated in vitro with our HA-o and TGF-factorsThe relevance of 
this study lies in the fact that we seek to evaluate the elastogenic inductibility of cells 
isolated from AAA models that exhibit severely-degraded, late stage AAA matrix 
environment. 
In the current study, at 2 weeks post-injury, elastase-perfused rat abdominal 
aortae generated many of the outcomes typical of human AAAs, such as medial elastic 
matrix disruption, increased MMP activity, and an approximate 120% increase in aortic 
diameter, similar to more advanced human AAAs. SMCs isolated from the abdominal 
aortic expansions can be propagated in culture, therefore limitations due to tissue 





phenotype and matrix regenerative potential. Our in vitro model is thus valuable for study 
of biochemical regulation of cell phenotype by supplemented biomolecules.  
In this elastase-perfusion AAA model, we see increases in the activity of 
elastolytic MMPs in intact elastase-perfused aortae compared to untreated aortae (Figure 
3), and in cultures of EaRASMCs relative to healthy RASMCs, indicating that elastase 
injury induces an activated phenotype. Morphologically, we found EaRASMCs exhibited 
decreased volume/ spreading as compared to healthy RASMCs. Phenotypic analysis 
using immunofluorescence and flow cytometry revealed a significant number of 
EaRASMCs exhibited decreased α-actin, caldesmon, and calponin expression as 
compared to healthy RASMCs. Caldesmin plays a key role in SMC contraction by 
binding to acto-myosin contractile units like actin, tropomyosin, myosin and 
calmodulin
206
 and may have a regulatory role in the contractile apparatus; it has been 
reported to inhibit the Mg
2+
-ATP-ase activity and hence inhibit smooth muscle 
contractility
207
. Calponin binds with actin light chains depending on the presence of Ca
2+
 
thereby regulating the contractile apparatus of SMC‟s 
208-209
; due to this binding, it has 




. Together, these 
suggest a loss of contractile phenotype. In addition, the aRASMCs also exhibited an 
increased expression of osteopontin, a multifunctional pro-inflammatory cytokine 
implicated with vascular disease and enhanced inflammatory response 
211
; osteopontin 
has been shown to induce chemotaxis of macrophages and monocytes, which stimulates 
calcification 
212
 and enhances MMP activity, thereby promoting vascular wall 
deterioration 
213





exhibited enhanced MMP and elastase activity over healthy control RASMCs, suggesting 
an activated phenotype 
19
. However, Von Kossa staining showed no visible matrix 
calcification in either the elastase-perfused aortal segments or in cultures of isolated 
EaRASMCs, indicating that the treatment did not induce a significant osteogenic 
phenotype amongst the EaRASMCs.  
EaRASMCs in general proliferated much faster than that of healthy RASMCs. A 
comparison of the effects of the factors on EaRASMCs revealed that HA-o and TGF- 
suppressed cell proliferation significantly, relative to non-additive, control EaRASMCs. 
In EaRASMC cultures, unlike in healthy RASMC cultures, low dose combinations of 
HA-o (< 20 μg/ml) and TGF-β (< 10 ng/ml) together had no effect on tropoelastin 
production. This agrees well with our prior findings that diseased SMCs require higher 
doses of these factors for elastogenic stimulation. Also apparent from our results, are that 
HA-o and TGF-β1 in general, appear to more sensitively influence the elastin 
crosslinking/ matrix assembly machinery than cellular tropoelastin synthesis, which is 
increased only at the highest dose combination. Also, observations from this study 
suggest that the predominant effects of HA-o lie in the enhancement of elastic matrix 
deposition, which corroborates inferences from our prior studies 
214-215
 and increases in 
tropoelastin and matrix elastin synthesis with increasing TGF-β dose are more 
pronounced at higher HA-o doses.  
We saw attenuated MMP-2 (minimal change in MMP-9) activity in EaRASMC 
cultures that received the maximum factor dose tested (20 μg/ml HA-o and 10 ng/ml 





factor dose of 2 μg/ml HA-o and 5 ng/ml TGF-β, at which dose combination we did see 
comparable matrix elastin production. This may signify the necessity to utilize higher 
factor doses to maximize elastic matrix stability. 
At the transcriptional level, DNA microarray provided a plethora of valuable 
information that deserves a thorough ongoing investigation. Our preliminary observations 
from this data are multi-fold. First, elastase perfusion appears to result in differential gene 
expression of EaRASMCs relative to RASMCs in culture (passage 3; Figure 5.8A). It is 
promising this differential expression is maintained ex-vivo and suggests that cells 
derived from an AAA maintain an altered gene expression in vitro. At this time, we have 
not further investigated the differentially expressed genes between the EaRASMCs 
relative to RASMCs; we have instead focused our initial efforts on understanding the 
effects of HA-o and TGF-β1 on EaRASMCs. Of interest, bone BMP-4 expression was 
decreased in EaRASMCs relative to RASMCs and HA-o and TGF-appeared to have no 
effect on that expression level. This supports our observations that there were no calcific 
deposits found within the elastase-perfused aortae or the derived EaRASMC cultures. 
Interestingly, elastin (tropoelastin) expression was decreased in EaRASMCs relative to 
RASMCs and the factors seemed to suppress this further. This suggests that increases in 
matrix elastin are caused by post-transcriptional events such as tropoelastin packaging, 
transport, and assembly into mature fibers in EaRASMC cultures. This contrasts the 
previously observed 1.5-fold increase in elastin mRNA expression observed by factor 
supplemented healthy RASMCs relative to untreated RASMCs 
215
. These results agree 







 and no significant increase in tropoelastin production by EaRASMC (at the 
2 μg/ml HA-o and 5 ng/ml TGF-β tested on cells prior to microarray analysis). Also, of 
note is that aHASMC cultures had a 5-fold increase in tropoelastin in response to the 
factors (Chapter 4), whereas EaRASMC had 1.9-fold increase. One possibility is that the 
factors influence aneurysmal SMCs differently than they do healthy cells, particularly at 
the transcriptional level, though there may be similarities in their manner of influencing 
post-transcriptional cellular mechanisms leading to tropoelastin release and extracellular 
processes of elastic matrix assembly. The second is that despite the broad etiological and 
pathological similarities between the elastase perfusion model of rat AAAs and human 
AAAs, it appears that there exist critical differences in the manner in which elastin gene 
transcription and protein synthesis, and possibly less so, elastic matrix assembly are 
impacted by the factors. A final note on differential expression of genes pertains to the 
observed decrease in MMP-12 and increase in TIMP-3 expression in EaRASMCs that 
received factors. This observation points to the possibility that the factors are „protecting‟ 
the elastic matrix from enzymatic breakdown. This data is extremely interesting, yet the 
design of future experiments to further assess the mechanistic role of HA-o and TGF-β1 
on elastin matrix formation in AAA models is necessary.   
 
5.5 Conclusions 
1.   The elastase perfusion-injury model exhibits pathological characteristics similar to 
human AAAs, such as medial elastic matrix disruption, increased MMP activity, 





2. EaRASMC phenotypic analysis revealed a significant number of EaRASMCs 
exhibited decreased contractile phenotypic marker expression and enhanced MMP 
activity relative to healthy RASMCs, suggesting an activated phenotype. 
EaRASMCs in general proliferated much faster than that of healthy RASMCs and 
HA-o and TGF- suppressed cell proliferation relative to control EaRASMCs 
 
3.   EaRASMCs were sensitive to TGF-β and HA-o in the context of elastic matrix 
regenerative responses (at an optimal dose of 2 μg/ml HA-o and 5 ng/ml TGF-β). 
Tropo- and matrix elastin production was increased (at factor doses ≥ 2 μg/ml HA-o 
and 5 ng/ml TGF-β) and elastolytic MMP-2 activity was attenuated (at a factor dose 
of 20 μg/ml HA-o and 10 ng/ml TGF-β).  
 
4. There was significant differential gene expression of EaRASMC relative to 
RASMCs, indicating the AAA-derived cells maintain altered gene expression in 
vitro, even at passage 3.  Differential gene expression as a result of supplanted HA-
o and TGF-was observed and further assessment of functional groups is 
necessary.   
 
5. The elastase perfusion-injury model of AAAs may be suitable as a surrogate in the 
context of elastin regeneration within advanced human AAAs, yet a shortcoming is 
the unparalleled increases in tropoelastin production by aHASMCs in response to 






IMPACT OF PRE-EXISTING ELASTIC MATRIX ON INDUCED  
REGENERATIVE REPAIR BY RASMCS 
 
6.1 Introduction 
The results presented in Chapters 3-5 demonstrate the utility of HA-o and TGF-β1 
for matrix engineering elastic tissue constructs within elastin-compromised tissues (e.g., 
peri-adventitial CaCl2 and elastase perfusion-derived experimental AAAs). Yet, it is not 
known as to how the severity of proteolytic elastic matrix degradation alone and hence 
quality/ content of the pre-existing elastic matrix, would impact subsequent basal- and 
induced- cellular elastin regenerative outcomes. This is relevant since cell phenotype and 
remodeling of the ECM are influenced by the biochemical and biomechanical stimuli 
cells perceive from their microenvironments. In fact, numerous parameters such as the 
etiology of an aneurysm, size and location, proximity to site of injury, stage in 
development, and inflammatory cell and thrombus involvement can impact proteolytic 
activity and generate temporal- or location- specific variability in cell phenotype and 
matrix degradation properties within aneurysms 
110-112
. In the current study, these 
individual parameters will be studied step-wise in a cell culture model of porcine 
pancreatic elastase (PPE)-injured aortal SMCs. This model has been previously shown to 
degrade intact elastic structures, and reduce elastin content in cell cultures to mimic the 
diseased state 
224
. Though simplistic, this cell culture model is advantageous because it 





cellular factors, etc.) on elastin degradation and cell phenotype, including their basal- and 
induced- elastic matrix synthesis responses. 
  
6.2 Materials and methods 
 
6.2.1 Cell Isolation and culture 
Aortae were harvested from adult Sprague-Dawley rats. All animal protocols 
were approved by the Institutional Animal Care and Use Committee at Clemson 
University. Aortae were opened lengthwise and the intima scraped gently with a scalpel 
blade.  The medial layer was dissected out from the underlying adventia, and was then 
chopped into ~ 0.5 mm-long sections, rinsed with sterile phosphate buffered saline 
(PBS), pooled, then enzymatically degraded in DMEM-F12 medium (Thermo Scientific, 
Logan, UT) containing 357 U/mg collagenase (Worthington Biochemicals, Lakewood, 
NJ) and 4.5 U/mg elastase (Worthington Biochemicals, Lakewood, NJ) for 45 min at 37 
C. The digestate was centrifuged at 400 g for 5 min, the tissue segments then 
reconstituted and cultured in 6-well plastic plates with minimal volumes of DMEM-F12 
medium containing 10% v/v fetal bovine serum (PAA, Etobicoke, Ontario) over 4-6 
weeks.  Primary rat aortic SMCs (RASMCs), derived by outgrowth from these tissue 
explants, were cultured until confluence and passaged.  Low passage (2-8) RASMCs 
were then seeded onto 6-well tissue culture plates (area = 10 cm
2
) at a density of 3 × 10
4
 
cells/well and cultured in DMEM-F12 medium containing 10% v/v FBS and 1% v/v 





6.2.2 Experimental design and time points 
Table 6.1 summarizes the experimental cases, and corresponding conditions of 
culture and treatments. Briefly, RASMCs (Passage 2-8) were cultured within 6-well 




) for 21 days, over which time the cells deposited a robust 
matrix. Select wells (n = 3/case) were then incubated for 45 min with 2 mL of porcine 
pancreatic elastase (PPE) (Worthington Biochemicals, Lakewood, NJ), prepared at doses 
of 0.15 U/ml (PPE15) and 0.75 U/ml (PPE75) respectively, to proteolytically degrade the 
elastin matrix to different degrees of severity. Cultures designated as injury controls (No 
PPE) instead received PPE-free medium.  One set of cultures (n = 3/treatment) was 
harvested before, and after proteolytic injury to assess the effects of proteolytic injury on 
cell viability and elastin matrix amounts. Other cell layers (n = 3/case) were cultured for a 
further 21 days with or without factors (0.2 μg/ml of HA-o, 1 ng/ml of TGF-β1; see 
below) with medium changes performed twice weekly. In this study, the effects of these 
factors alone were not assessed due to our previous findings with healthy cells that the 
factors, delivered individually at the present doses, had limited effect, and were much 
more effective when delivered together
225
. Spent medium aliquots removed from each 
well, at the time of each medium change, were pooled and frozen, and biochemically 









Group Name  Culture Period Enzymatic Treatment Media Supplements 
No PPE_21 day 21 day - - 
No PPE_42 day 21 day - - 
No PPE_42 day_+factors 21 day - HA-o & TGF-β1 
PPE15_21day 21 day 0.15 U/ml PPE - 
PPE75_21day 21 day 0.75 U/ml PPE - 
PPE15_42 day 21 day + 21day 0.15 U/ml PPE - 
PPE75_42 day 21 day + 21day 0.75 U/ml PPE - 
PPE15_42 day_+factors 21 day + 21day 0.15 U/ml PPE HA-o & TGF-β1 
PPE75_42 day_+factors 21 day + 21day 0.75 U/ml PPE HA-o & TGF-β1 
 
Table 6.1 Experimental groups with corresponding treatments and conditions of culture. 
RASMCs were cultured within 6-well plates for 21 days, over which time the cells 
deposited a mature elastic matrix. Select wells (n = 3/case) were then incubated for 45 
min with 2 mL of PPE, prepared at doses of 0.15 U/ml (PPE15) and 0.75 U/ml (PPE75) 
respectively, to proteolytically degrade the elastin matrix to different degrees of severity. 
Cultures designated as injury controls (No PPE) instead received PPE-free medium.  One 
set of cultures (n = 3/treatment) was harvested before, and after proteolytic injury to 
assess the effects of proteolytic injury on cell viability and elastin matrix amounts. Other 
cell layers (n = 3/case) were cultured for a further 21 days with or without factors (0.2 
μg/ml of HA-o, 1 ng/ml of TGF-β) with medium changes performed twice weekly. 
 
HA-o mixtures used in this study contained ~ 75 ± 15% w/w of HA 4-mers 
(tetramers), with 6-mers and 8-mers forming the balance, and were prepared using our 
priviously-described protocols based on digestion of HMW HA (>1 MDa; Genzyme 
Biosurgery, Cambridge, MA), with testicular hyaluronidase (20 mg hyaluronidase, 40 U 







and TGF-β (Peprotech, Rock Hill, NJ) dissolved in serum-free DMEM-F12 medium, 
were syringe-filtered and supplemented to DMEM-F12 culture medium containing 10% 
v/v FBS and 1% v/v Penstrep. Final serum levels were normalized to 10% for all culture 
groups, so the TGF-β content in the serum would not be a confounding factor. The 
presence of FBS was deemed necessary since these poorly elastogenic cell types, produce 
even less elastic matrix, at the threshold of detection, when cultured in the absence of 
FBS. A 5 mL-volume of medium was added to each well. As with the above cultures, 
spent medium from each of these wells was also changed twice weekly. The spent 
medium collected from each well was pooled with prior collected aliquots from the 
respective wells and stored frozen at –20 ˚C until biochemical analysis was performed. 
 
5.2.3 Immunoflourescence detection of SMC markers 
Immunofluorescence techniques were used to confirm the isolated cells as SMCs.  
RASMCs were cultured in sterile, 2-well glass chamber slides (Nalge Nunc International, 
Naperville, IL) at a low cell density overnight.  They were fixed with 4 % w/v 
paraformaldehyde for 10 minutes (4 °C), and detected with polyclonal rabbit antibodies 
for SM22α and α smooth muscle actin (Abcam, Cambridge, UK), and visualized with 
FITC-conjugated goat anti-rabbit IgG secondary antibodies (Chemicon, Temecula, CA). 
Cell nuclei were visualized with Vectashield hard-set mounting medium with DAPI 





6.2.4 DNA assay for cell proliferation 
The DNA content of the RASMC cultures listed in Table 6.1 were compared to 
determine the impact of PPE and the elastogenic factors on cell viability and 
proliferation. Select cell layers were harvested at 21 days (before and after PPE injury) 
and 42 days of culture, sonicated, and their respective DNA contents quantified using a 
fluorometric assay described by Labarca and Paigen
202
. Actual cell counts were then 




6.2.5 Immunoflourescence detection of elastic matrix 
Immunofluorescence techniques were used to visualize and confirm PPE-induced 
elastic matrix loss within treated cell layers.  RASMCs were cultured in sterile, 2-well 
glass chamber slides (Nalge Nunc International, Naperville, IL) under identical 
experimental conditions as described for cultures meant for biochemical analysis, though 
the seeding density and treatment doses were adjusted proportionally to the substrate 
surface area and the cell number respectively.  At 21 days post-seeding, when the cell 
layers were either treated with PPE75 or were untreated with PPE, they were fixed with 4 
% w/v paraformaldehyde for 10 minutes (4 °C), and elastin and fibrillin in the matrix 
then detected with polyclonal mouse antibodies (courtesy of Dr. Robert Mecham, St. 
Louis, Missouri), and visualized with FITC-conjugated donkey anti-mouse IgG 
secondary antibodies (Abcam, Cambridge, UK). Cell nuclei were visualized with the 






6.2.6 Fastin assay for elastin 
A Fastin assay (Accurate Scientific and Chemical Corporation, Westbury, NY) 
was used to quantify the total amount of elastin deposited within cell layers (matrix 
elastin), and that released into the culture medium as a soluble precursor (tropoelastin). 
For each treatment group, tropoelastin in the spent medium was collected and pooled 
over the culture period and frozen at -20 ˚C. The spent medium fractions collected from 
individual wells were pooled separately for the pre- and post-injury phases of cell culture. 
To isolate matrix elastin following either 21 days, or 42 days of culture, the cell layers 
were trypsinized, scraped, re-suspended in NaCl/Pi buffer, and centrifuged (2500 rpm, 10 
min). The cell pellet was digested with 0.1 N NaOH (98 ˚C, 1 h), and centrifuged to yield 
a less crosslinked, alkali-soluble supernatant fraction (soluble elastin), and a mature, 
highly crosslinked, insoluble pellet (insoluble elastin). Since the Fastin assay quantifies 
only soluble α-elastin, the insoluble elastin was first converted to a soluble form prior to 
quantification. To do this, the insoluble elastin pellet was dried, solubilized with 0.25 M 
oxalic acid (95 ˚C, 1 h), and the pooled digests then centrifuge-filtered (3000 RPM, 10 
min) in microcentrifuge tubes fitted with low molecular weight (10 kDa) cut-off 
membranes (Millipore, Bedford, MA). All three elastin fractions (tropoelastin and soluble 
and insoluble matrix elastin) were quantified using the Fastin assay. Between each of the 
cases, the ratios of matrix elastin (soluble + insoluble elastin) to total elastin (tropoelastin 
+ matrix elastin), and the ratios of the soluble and insoluble fractions of matrix elastin 
were compared to gauge efficiency of crosslinking into a structural elastin matrix, and the 





6.2.7 SEM analysis of elastic matrix 
Scanning electron microscopy (SEM) was used to visualize proteolytic 
degradation of elastin matrix by PPE and its subsequent regeneration, under basal and 
induced conditions. Spent medium was removed from atop cell layers after 21 or 42 days 
of culture. The cell layers were rinsed with PBS, and fixed with 4% w/v 
paraformaldehyde in 0.1 M phosphate buffer (4˚C, 15 min). After fixation, the cell layer 
was rinsed several times with 0.1M phosphate buffer, then submersed in 25% w/v KOH 
(60 ˚C, 5 min) to remove cellular and ECM debris and yield relatively pure, matrix 
elastin structures. Following a phosphate buffer rinse, the isolated elastic structures were 
then treated with 1% w/v tannic acid (1 h) and stained with 1% w/v osmium tetroxide (1 
h). The osmium tetroxide was used as an alternative to sputter coating in order to create a 
high electron emission without the need for a metal coating. The samples were 
dehydrated successively in graded ethanol (70-100% v/v 1 min each) and finally 
hexamethyldisilazane (Sigma Aldrich, St. Louis, MO) (3 min), under a fume hood. The 
samples were finally mounted on aluminum stubs and imaged using a Hitachi SEM 
TM1000 (Hitachi Technologies, Pleasanton, CA). 
 
6.2.8 LOX enzyme activity assay 
Frozen aliquots of spent culture medium, pooled over the respective periods of 
culture (21 and 42 days) were assayed for the elastin crosslinking enzyme, lysyl oxidase 
(LOX), using a fluorometric assay (Amplex® Red Assay, Molecular Probes, Eugene, 





monoamines and diamines 
226
.  The fluorescence intensities were measured at λexcitation = 
560 nm and λemission = 590 nm. 
 
6.2.9 Assay for elastase activity  
Elastase activity following proteolytic injury of the cell cultures was assayed 
using an EnzChek® Elastase Assay kit (Molecular Probes, Eugene, OR).  Aliquots (50 
L) of spent medium (collected and pooled over the 21 or 42 days, after injury or 
recovery) were mixed with diluted bovine neck ligament elastin, incubated for 30 min at 
37 ºC, and the fluorescence intensity measured at λexcitation = 485 nm and λemission = 510 
nm.  One unit of elastase was defined as the amount of porcine pancreatic elastase 
required to solubilize 1 mg of elastin at pH 8.8 and 37 ºC. 
 
6.2.10 Gel zymography for MMP-2, 9 activity 
Proteins from spent medium fractions collected from control and test cultures (at 
21 days post-seeding, and between 21 and 42 days post-seeding with and without PPE-
treatment at 21 days) and from cell layers themselves (before and after PPE-treatment at 
21 days of culture) were extracted in a RIPA buffer, dialyzed, and analyzed by gelatin 
zymography using 4 μg of protein per lane (as per BCA assay) as described previously
227
. 
Intensity of the MMP bands were quantified and expressed as relative density units 






6.2.11 Statistical analysis 
Although non-parametric tests (e.g., Mann-Whitney Test) are less powerful than 
parametric tests based on Gaussian distribution, especially for smaller sample sizes, they 
are still recommended for analyzing biologic data since these data typically do not follow 
Gaussian (bell-shaped) distribution. Accordingly, we used non-parametric methods for 
statistical analysis in the current study.  The Kruskal-Wallis test was initially used to 
broadly assess differences between cell layers with or without proteolytic degradation 
and cell layers with or without the exogenous supplementation of TGF-β and HA-o. 
Subsequently, more detailed, pair-wise analysis between specific groups was conducted 
using the Mann-Whitney (Rank-Sum) test. Assumptions were that the data was 
representative, observations were independent, and the matrix elastin distributions were 
identical except for a shift in location. Statistical significance was deemed for p ≤ 0.1. 
This level of significance is different than the typical α = 0.05, representing a 5% type I 
error rate, because the current sample size of n = 3/case, selected in consideration of the 
large number of test cases, long-culture times, and high cost of analysis, is inadequate to 
demonstrate significance with greater than 90% confidence level.  Further analysis on the 
most promising results from this study will be subsequently conducted at a higher 











6.3.1 Experimental design and time points 
The cells harvested from rat aortae expressed SM22α and α smooth muscle actin 
confirming their identity as SMCs (Figure 6.1A). At 21 days of culture prior to PPE-
treatment, the cells were confluent and exhibited a spindle-like phenotype. The cell layers 
were elastolyzed with two different strengths of PPE (0.15 U/ml: PPE15 and 0.75 U/ml: 
PPE75; 45 min) to degrade the elastin matrix to different levels of severity. Following 
incubation with PPE, the majority of the cells in both sets of cultures remained viable and 
spindle-shaped, with a small number of rounded cells (Figures 5.1B and C). 
 
6.3.2 DNA assay for cell proliferation 
 A fluorometric DNA assay was used to quantify cell proliferation of each of the 
three replicate cell layers from each treatment group listed in Table 6.1. In the PPE-
untreated group, cell layers cultured for 42 days (with and without factors) contained a 
slightly lower number of cells relative to 21 day cultures (p = 0.001 and 0.00004 for 42 
day and 42 day + factors vs. 21 day cultures; Figure 6.2). There were no significant 
differences in cell proliferation between cell layers cultured for 42 days with HA-o and 
TGF- β factors and those that were not (p-value = 0.8). Additionally, there were no 
differences in cell proliferation between No PPE, PPE15, and PPE75-treated groups 







Figure 6.1 Immunofluorescence (IF) of SMC markers (SM22α and α smooth muscle 
actin) was used to confirm isolated cells from rat aortae as SMCs (A). A count of these 
RASMC was conducted after 21 days of culture following variable PPE injury (B) and 
the elastic matrix degradation after treatment with PPE was validated with IF and 
scanning electron microscopy (SEM) (C). Representative 21day RASMC cultures with 
no PPE injury and severe PPE injury (PPE 75) are shown. Scale Bars: (A) 150 µm (B) 








6.3.3 Immunofluorescence detection of elastic matrix 
 Figure 6.1C illustrates the decreased elastin content found in cell layers treated 
with PPE75 as compared to controls. With cell numbers both before and after PPE 
treatment at 21 days of culture appeared constant (Figures 6.1B, C), the elastic matrix 
was significantly decreased after PPE75 treatment.  
 
Figure 6.2 Cell proliferation ratios of RASMC culture groups as described in Table 1. 
Data shown represent mean ± SD of cell count determined by DNA content of cell layers 
after 21 and 42 days of culture, normalized to 21 day control cultures that received no 
PPE treatment or elastogenic additives (n = 3/case). * indicates significance (p ≤ 0.05). 
 
6.3.4 Elastin production 
 Prior to PPE-treatment at 21 days of culture, all cell layers contained similar cell 





Similarly, regardless of whether they were treated with PPE or not, cell layers also 
synthesized similar amounts of tropoelastin in the time period between 21 and 42 days of 
culture, leading to very similar totals when measured at 42 days (Figure 6.3). Culture of 
cell layers (with or without PPE injury) for a further 21 days in presence of HA-o and 
TGF-β, did not enhance tropoelastin synthesis relative to the corresponding cell layers 
cultured without any factors (Figure 6.3). Matrix elastin content was also identical in all 
cultures prior to PPE-treatment. Incubation with PPE (PPE15 and PPE75) at 21 days of 
culture was found to cause a significant reduction in matrix elastin content relative to 
untreated control cultures (Kruskal-Wallis, p-value = 0.002); matrix elastin content in cell 
layers treated with 0.15 U/ml of PPE (PPE15) was 74 ± 9% of that in non-injured cell 
layers, while that treated with 0.75 U/ml of PPE was only 31 ± 13% (Mann- Whitney, p = 
0.1 vs. non-injured cell layers for both cases) (Figure 6.4).  
In the PPE-untreated cultures, at 21 days, approximately 88% of the total elastin 
in the cell layer was crosslinked into an alkali-insoluble form (Table 6.2). This proportion 
was maintained over longer-term culture, both in presence and absence of TGF-β and HA 
factors. In cell layers that were only moderately proteolyzed (PPE15), the fraction of 
matrix elastin in the alkali-insoluble form was initially no different than in PPE-untreated 
cell layers, though the value gradually decreased to approximately 71% following 21 
days of post-injury culture in the absence of any stimulating factors (Table 6.2). 
Differently, however, in those PPE-treated cell layers that were cultured with factors, the 
fraction of matrix elastin in the alkali-insoluble form, as analyzed at 42 days of total 





layers subject to more severe proteolysis (PPE 75), such injury to elastic matrix caused an 
immediate reduction in to the absolute content of fractional alkali-insoluble elastin. 
Regardless of further culture with HA-o and TGF-β factors, the maturation levels of the 
elastic matrix as exhibited within cell layers prior to PPE treatment, was not reinstated.  
 
 
Figure 6.3 Tropoelastin measured from each individual sample outlined in Table 5.1 are 
shown. The mean and standard deviation are compared for each case (n = 3/case). There 
are no statistically significant differences. 
 





Figure 6.4 Matrix elastin data measured from each sample outlined in Table 6.1 are 
shown (A). The mean and standard deviation are compared for each case (n = 3/case). * 
indicates significance (p ≤ 0.1). Representative scanning electron micrographs of 
RASMC cultures following PPE15 and PPE75 injury and supplementation with factors 
are shown (B). Regeneration of elastic fiber networks is confirmed with the addition of 
HA-o and TGF-β. 
 
Broad statistical comparison of matrix elastin amounts between 21 day cultures 
and 42 day cultures (culture with or without added factors, and either following PPE-
treatment at 21 days or not), indicated significant differences (Kruskal-Wallis, p = 0.04). 
More specifically, in PPE-untreated cell layers, cumulative accumulation of elastin 
matrix over 42 days of culture in the absence of added factors, was no different than that 





increased by a further 23% (p = 0.1 for 42 day + factors vs. 21 day, no PPE group). 
Culture of PPE-treated cell layers for a further 21 days without any supplemented factors 
failed to enhance elastic matrix amounts (Figure 6.4). However, when instead cultured 
with TGF-β and HA-o factors, elastic matrix amounts in PPE15 and PPE75-injured cell 
layers was increased by 58 ± 20% and 100 ± 0%, respectively. In the PPE15 group, 
induction of injured cells with the supplemented factors enhanced cumulative matrix 
elastin amounts to levels beyond that measured in 21 day-old cell layers prior to PPE-
treatment, just as was observed for the no PPE-treatment group (p-value = 0.1 vs. no PPE 
treatment, 21 day cultures in both cases) (Figure 6.4).  
 
Table 6.2 Basal and induced elastic matrix synthesis. Shown are cumulative, mean 
amounts of alkali-soluble and insoluble matrix elastin per well (n = 3/group), quantified 
in RASMC cultures either prior to or following PPE-treatment at 21 days post-seeding, 
and following culture of these cell layers for 21 more days (i.e., 42 days post-seeding), in 
the presence or absence of TGF-β (1 ng/ml) and HA-o (0.2 μg/ml) factors. Yield of 
   Total Matrix Elastin (Ave μg/sample)  
  Insoluble Elastin Soluble Elastin Total Matrix Elastin Insol/Total Matrix 
No PPE 21d 230.3 32.4 262.7 0.88 
 42d 200.9 35.1 236.0 0.85 
 42d + factors 285.4 38.4 323.8 0.88 
PPE15 21d 167.9 26.3 194.2 0.86 
 42d 79.9 33.2 113.1 0.71 
 42d + factors 259.1 49.3 308.4 0.84 
PPE 75 21d 60.6 21.6 82.2 0.74 
 42d 69.1 27.5 96.6 0.72 





alkali-insoluble matrix elastin, i.e., insoluble elastin /total matrix elastin is indicative of 
the efficiency of crosslinking and hence, matrix maturation.  
 
5.3.5 SEM analysis of elastic matrix 
Figure 6.1C shows representative scanning electron micrographs of elastic 
matrices isolated from 42 day cultures of RASMCs prior to and following proteolytic 
degradation with PPE75. These images show that elastic matrix structures are severely 
degraded upon treatment with PPE. Figure 6.5A shows elastic fibers deposited by 
RASMCs over 21 days of post PPE-injury culture in the absence of HA-o and TGF-β1 
factors; elastic matrices in cell layers that were not PPE-injured at 21 days (A, B) 
contained more crosslinked, elastic matrix structures than cell layers treated with PPE15 
(C, D) or PPE75 (E, F). Figure 6.5B shows scanning electron micrographs of elastic 
fibers deposited by RASMCs over 21 days of post PPE-injury culture  (C, D for PPE15 
and E, F for PPE75), in the presence of HA-o and TGF-β1 factors. A comparison of 
panels in Figures 6.5A and 6.5B indicates that culture of RASMCs with HA-o and TGF-
β1 factors, following injury with PPE15 (panels C, D) and PPE75 (panels (E, F) 
enhanced cellular deposition of crosslinked elastic fibers relative to culture without the 
factors.  
 
6.3.6 LOX enzyme activity  
  There was no difference in LOX activities between the different treatment groups. 
On average, the LOX activity was (1 ± 0.24) x 10
-4






Figure 6.5 For SEM, the cell layers were incubated with KOH to digests away non-
elastin ECM and cellular components. (A) Scanning electron micrographs of elastic 
fibers deposited by RASMCs over 21 days following proteolytic injury in the absence of 
elastogenic factors (42 days of culture, overall). Few highly-crosslinked elastic fibers 
remained after KOH digestion in PPE-injured cultures. (B) Micrographs of elastic fibers 
deposited by RASMCs over 21 days following proteolytic injury (42 days of culture, 
overall), in the presence of HA oligomer and TGF-β supplements. Relative to cell layers 
that did not receive the HA-o and TGF-β supplements during post-injury culture (see 
images in Figure 6.5A), these supplements enhanced cellular deposition of mature, 
crosslinked fibers that could survive KOH digestion. Black arrows and white arrows 
indicate elastic fibers and undigested cell debris, respectfully. Magnification: 1000 Χ (A, 






6.3.7 Elastolytic activity 
 As shown in Figure 6.6A, there was no difference in endogenous elastase activity 
in cultures representative of each of the tested groups. Gel zymography (Figure 6.6B) 
also indicated that the activities of MMPs 2, 9 measured in spent medium fractions 
collected from 21 day-old cell layers, before and after PPE-treatment were similar. 
Further, activities of MMPs 2, and 9 measured in the pooled spent medium aliquots 
collected from PPE-treated cell layers over 21 days of culture in the presence and absence 
of elastogenic factors, were no different from that measured immediately following PPE-
treatment. No error bars are present on Figure 6.6B because the data was collected from a 
single gel with n = 1/ condition. This gel served as a secondary confirmation of the data 
collected with the elastase assay, therefore was not completed in triplicate.  
 
Figure 6.6 Endogenous elastolytic activity was measured using an elastase activity assay 
(n = 3/condition) (A) and gel zymography (n = 1/ condition) (B) for all treatment groups.  
 
6.4 Discussion 
A gradient of proteolytic enzymes and matrix proteins has been shown to exist 
within AAAs as a function of distance from the rupture site
110-112
. In such cases, vascular 






receptors; the impacted behavioral patterns can include their own synthesis and 
organization of matrix proteins, responsiveness to growth factors and cytokines, altered 
Ca
2+ 
ion uptake to possibly promote matrix calcification
228
, and importantly the type and 
extent of matrix (e.g., collagen, elastin)- degrading enzymatic activity they exhibit. Thus, 
establishing the utility of elastogenic protocols, and the need for their customization is 
contingent on understanding of inter-relationships between extracellular matrix 
content/quality, and cell phenotype, and hence the nature of basal and induced 
elastogenic responses. This study seeks to explore these aspects. 
Established aneurysmal tissues represent disease outcomes and thus do not allow 
us to distinguish between disease causes and secondary degenerative changes, and to 
isolate the standalone impact of individual factors that influence inherent or induced 
matrix repair and/or regeneration. Small animal models of AAAs also rely on artificial 
hemodynamic manipulations that influence cellular behavior 
229
. Such in vivo models 
also render it difficult to distinguish the effects of matrix content and quality/extent of 
degradation on one hand, and matrix architecture, and the incidence and extent of matrix 
debridement by inflammatory cells recruited to the site of tissue/matrix injury on 
subsequent elastic matrix regeneration or repair. In vitro cell culture models, such as one 
previously described by Thompson et al. 
230
, may be usefully adopted to circumvent these 
problems. Such models have been previously studied to understand progression of elastic 
fiber injury by elastases and inherent cellular mechanisms for repair of degraded elastic 
fibers. They have never been adapted to the study of elastin regenerative processes, either 





existing ECM and assessing the subsequent matrix repair and regeneration, such models, 
though simplistic, are superior to ones based on culture of aneurysmal cells, which 
represent a terminal outcome of a disease.  
In the present study, we have sought to specifically investigate the impact of 
elastic matrix degeneration, independent of leukocyte debridement, on its subsequent 
repair possible via regeneration of new elastin, and if/how this phenomenon may by 
stimulated by exposure to factors we have deemed „elastogenic‟ based on prior study of 
effects on healthy  and AAA derived SMCs. While it may exhibit minimal, non-specific 
proteolytic activity, PPE was selected for this study, since it specifically targets and 
rapidly degrades elastic matrix structures, unlike post-inflammatory cell-mediated matrix 
degradation that gradually, and simultaneously degrades elastin, collagen, and other ECM 
structures due to the collective action of multiple matrix metalloproteases (MMPs) 
exhibiting diverse substrate specificities.  
Mature RASMC layers were incubated with two different concentrations of PPE. 
The lack of change in cell counts before and after enzyme treatment attested to the lack of 
any immediate deleterious effects on the SMCs; yet, DNA analysis at 21 days post-PPE-
treatment (42 days post-seeding) showed the cell numbers to have nearly halved. One 
possibility is that the PPE-treatment had no short-term (i.e., 45 minutes) effect on the 
cells, yet triggered degenerative effects that compromised their viability in long-term 
culture. However, the occurrence of a similar decrease in cell number in control cultures 
that were not treated with PPE, eliminated this hypothesis. Rather, a likely explanation 





already-confluent cell layers at 21 days, further proliferated to form multi-layers with the 
cells in the interior possibly succumbing to limitations to diffusional supply of essential 
nutrients/ gases. 
Identical tropoelastin amounts synthesized in all (test and control) cell layers prior 
to PPE-treatment suggested deposition of identical elastin matrix amounts as well, 
although this was only measured in one set of cell layers (n = 3) that was harvested at 21 
days of culture, and prior to PPE-treatment.  With this assumption as a basis, we deemed 
PPE-treatment to induce an enzyme dose-dependent decrease in elastic matrix amounts, 
particularly of insoluble matrix elastin relative to non-treated cultures, as confirmed via 
biochemical assays and electron microscopy (Figures 5.1, 5.4, and 5.5). Elastase activity 
and gel zymography analysis for MMP activities performed on medium aliquots drawn 
from the PPE-treated cultures (both doses) following 1 hr of recovery after PPE treatment 
and after 21 days (i.e., 42 days post-seeding) did not indicate any increase in values 
beyond that measured in non-treated cultures (Figure 5.6). This suggests that PPE-
treatment likely does not result in sustained injury to cells, beyond the actual 45 minute 
period of incubation of the PPE with the cell layers. These results lend credence to our 
above explanation that decreased cell number in long-term culture post-PPE treatment is 
not due to any sustained effects of the treatment, but rather due to nutritional limitations. 
However, the lack of any measured increase in elastase activities in the culture medium 
removed from cell layers as early as 1 hr after PPE-treatment, relative to control cultures, 
was unexpected. To assess this further, an independent set of experiments was performed, 





and following 1 hour of recovery, the cellular, rather than the medium fraction was 
analyzed using gel zymography. These results (not shown) again indicated no differences 
in activities of the MMPs-2, and 9 between PPE-treated and –untreated cell layers.  
Collectively, these results suggest that PPE-treatment at the present doses/duration is 
effective from the standpoint of inflicting elastic matrix damage, but does not 
significantly activate cells, to be able to quantify temporal increases in activities of 
elastolytic MMPs.  
Although tropoelastin production by PPE-untreated (control) cell layers between 
21 and 42 days of culture was less than that in the first 21 days of culture, the lack of 
elastic matrix accumulation during the same period could be possibly attributed to either 
(a) a decrease in LOX-mediated crosslinking activity or of LOX protein itself, (b) 
sustained elastolysis due to PPE, MMP release by cells, or (c) spatial limitations for 
matrix deposition, imposed by high cellularity and already dense matrix in cell layers at 
42 days of culture. Since elastase and LOX activity assays showed no change in cell 
layers at 42 days of culture relative to cell layers at 21 days of culture, the lack of any 
significant accumulations of elastic matrix between 21 and 42 days of culture may be 
purely due to a contact inhibition of the SMCs within the super-confluent and dense cell 
layers. Although, we did not specifically quantify other mature elastic fiber proteins such 
as fibrillin and microfibril-associated glycoprotein (MAGP) it is quite possible that 
cellular synthesis of these and other proteins critical to elastic fiber formation could have 
also been inhibited when cell layers attained super-confluence. This will be elucidated in 





In light of the multi-fold increases in tropo- and matrix elastin production that we 
previously showed TGF-β and HA-o to induce in healthy cells
225
, here, 21 day culture of 
PPE-untreated (control) cultures with these very factors only modestly improved matrix 
elastin production (23%), and had no effect on tropoelastin synthesis. We believe that this 
muted effect is due to our high cell count, due to which factor doses on a per cell basis 
were rendered very low. Although the cell seeding densities in both our earlier and 




), in this study, the factors were not 
provided to the cell layers immediately, but only after 21 days of culture, and by which 
time the cell counts had exponentially increased. Thus, effectively, the TGF-β and HA 
oligomer doses on a per cell basis were orders of magnitude lower than that provided in 
the prior study. It is thus likely that providing greater doses of HA-o and TGF-β on a per 
cell basis, to be equivalent to that provided in our prior study (0.2 μg/ mL per 40,000 
cells and 1 ng/mL per 40,000 cells; 5 mL per well) would much more dramatically 
enhance tropo-and matrix elastin production in the control cell layers in this study also. 
Our biochemical analysis clearly demonstrated that in absence of any provided 
factors, proteolytically-injured cell layers were incapable of regenerating the lost elastin 
matrix, though they continued to produce tropoelastin. As SEM analysis indicated, PPE-
treatment resulted in etching of elastic fibers (see degenerated fibers vs. intact fibers in 
Figure 1C), their fragmentation and sometimes complete degeneration, particularly at the 
higher PPE dose. Prior studies have emphasized the importance of intact elastic fibers to 
the process of tropoelastin nucleation, crosslinking, and fiber formation 
87
, and the 






6-10, 70, 82, 91
. Thus the reduced presence of intact fibers in PPE-treated cell 
layers, could likely have deterred further elastin matrix deposition. Perhaps for the same 
reason, we observed elastic matrix accumulation in PPE-treated cell layers cultured with 
HA-o and TGF-β factors. Likely, the provided HA-o interacted with cell surface 
receptors (Toll like Receptor 4 (TLR-4) for HA 4mers and CD44 for larger oligomers) to 
localize at the cell layer and further coacervate tropoelastin precursors through opposite 
charge interactions and facilitate their lateral aggregation and crosslinking with lysyl 
oxidase, to for mature fiber structures. Though likely muted in its effects, due to the low 
HA-o dose/cell (~0.2 μg/2 × 10
6
 cells), it is clear that HA-o do benefit elastin matrix, 
specifically fiber formation (compare Figures 5A and 5B), in a manner that mimics our 
prior observations, though those outcomes were more significant. As we noted in a prior 
publication 
225
, TGF-β likely interacts with cells independently via TGF-β receptors to 
elicit enhanced elastin synthesis, through changes to intracellular signaling pathways that, 
due to synergy between them and HA-o, likely show some degree of commonality. TGF-
β may also enhance LOX production/activity to benefit tropoelastin crosslinking into a 
matrix. The lack of any perceivable increase in LOX activities in cell layers, post culture 
with TGF-β, and the absence of any significant increase in tropoelastin production over 
non-additive cultures may be again due to the low provided dose on a per cell basis. 
Our results indicate that the provided elastogenic factors induce greater percent 
increase in elastic matrix synthesis within cell layers that are subject to more severe 
proteolytic injury. This could be due to a less dense matrix in the more severely 





in the interior of the cell multi-layer. Although cell counts immediately after PPE-
treatment were similar in both PPE15 and PPE75-treated cell layers, cell numbers after an 
additional 21 days of culture ended up slightly lower in the latter case. It is thus possible 
that the somewhat lower cell numbers in PPE75-treated cell layers resulted in higher 
effective factor doses on a per cell basis, and accounted for the greater percent increase in 
matrix elastin relative to PPE15-treated cultures. Nevertheless, the provided dose of 
elastogenic factors was deemed insufficient to restore elastic matrix amounts to pre-
injury levels within the more severely proteolyzed cell layers. These results suggest that 
the greater the severity of elastic matrix injury, the greater the dose of elastogenic factors 
that must be provided to induce complete recovery of lost elastic matrix. Fractional 
content of alkali-insoluble elastin in the matrix showed immediate and substantial 
(PPE75), or gradual and mild (PPE15) decreases from that in PPE-untreated (control) cell 
layers. In the absence of any added growth factors, there was no recovery after even 21 
days of culture. As mentioned before, likely, more severe the PPE-injury, the greater the 
deterioration and removal of existing elastic matrix structure, and more afflicted the 
subsequent process of tropoelastin coacervation and crosslinking. The fact that the HA-o 
and TGF-β factors are able to restore fractional content of insoluble matrix elastin in 
PPE15 but not PPE75-treated cultures clearly demonstrates the vital involvement of the 
HA-o and TGF-β in the tropoelastin crosslinking process, and yet inadequacy of these 
factors (at the current doses) in overcoming the effects of severe elastic matrix injury. 
The study thus illustrates the importance of customizing factor doses to the severity of 






1.  In vitro elastase (PPE) treatment to established RASMC cultures with robust matrices 
induced an enzyme dose-dependent decrease in elastic matrix amounts, particularly of 
insoluble matrix elastin relative to non-treated RASMC cultures. 
 
2.  The ability of cell layers to self-repair and regenerate elastic matrices following their 
proteolytic damage was limited, particularly when elastic matrix injury is severe.  
 
3.   HA-o and TGF-β together can elastogenically stimulate RASMCs in elastic matrix-
degraded cultures to restore both elastic matrix amounts and elastic fiber deposition to 
levels of accumulation observed in healthy cultures.  
 
4.  Doses of the elastogenic factors must be enhanced and optimized based on the 
severity of elastic matrix damage. These studies suggest that with early clinical 
diagnosis of AAAs and therefore moderate elastic matrix degeneration in the vessel 










HYDROGEL-COATED GRAFT SYSTEM FOR DELIVERY  
OF ELASTOGENIC FACTORS 
 
7.1 Introduction 
Endovascular aneurysm repair (EVAR) involves the deployment of a stent-graft 
within the lumen of an aneurysmal aorta using a balloon catheter and guide wire. The 
stent-graft is designed to isolate the aneurysm sac while providing a conduit for normal 
blood flow. The first successful EVAR for abdominal aortic aneurysm repair was 
reported in 1991 
231
. This technique is currently used as a relatively safe and less invasive 
alternative to open surgical repair, that yields acceptable clinical results 
232
. The skeleton 






, while the graft material is 
typically Dacron
™
 (polyethylene terephthalate or PET) or poly(tetrafluoroethylene) 
(PTFE).  
Though EVAR has numerous benefits (reduced blood loss and complications 
(such as cardiac events, congestive heart failure, respiratory failure, myocardial 
infarction, limb ischemia, post-op bleeding, graft thrombus, wound infection) during 
surgery or following surgery and decreased duration of hospital stay and recovery time) 
over open repair, a number of late (>1 year post-implantation) problems occur, which 
may require secondary interventions. Endoleaks, which occur when the stent-grafts fail to 
completely exclude blood flow to the aneurysm sac, are the most common cause of 
secondary intervention 
233
, with a typical incidence of 10-50% 
234





further distension of the aorta and the eventual rupture of the vessel wall. To ensure 
optimum fixation of the device, most devices use barbs, hooks, and radial force applied 
during deployment at the proximal and distal ends of the stent. Although the currently 
marketed stent graft designs address the issue of fixation, endoleak still remains one of 
the main causes of device failure 
234
. 
One hypothetical way of reducing endoleak is to induce local, cell-mediated 
regeneration of elastic matrix-rich vascular tissue. A strategy of incorporating elastogenic 
factors (e.g., HA-o and TGF-β as discussed in previous chapters) into currently applied 
EVAR systems to deliver them to aneurysmal tissue for the purpose of regenerating an 
elastic matrix is thus attractive. Theoretically, the ability of this a newly regenerated 
elastic matrix to restore native elastic mechanics to the treated vessel segment would 
encourage sustained intimate contact of the expanded stent graft with the vessel wall, 
eliminating the occurrence of endoleak. This strategy broadly resembles that published by 
Kajimoto et al. who examined the efficiency of stent-grafts with a basic fibroblast growth 
factor delivery system in the canine thoracic aortic aneurysm model with endoleaks 
189
. 
The current study will provide preliminary data as to the feasibility of coating 
hyaluronan-based hydrogel systems (with loaded elastogenic factors) on ePTFE graft 
material for sustained release of the elastogenic factors at the site of AAA.  
Aeos
™
 ePTFE (Zeus, Orangeburg, SC) is used as the graft material in this study; 
it is micro-porous, biocompatible, implantable, flexible, hydrophobic, has a high linear 










delivery vehicle for factors, in the form of a graft coating; it contains thiol-modified HA 
and thiol-modified gelatin chemically crosslinked with polyethylene glycol diacrylate and 
small amounts of thiolated heparin which can ionically bind a wide variety of growth 
factors to allow slow release 
237-238
. Specifically, the manufacturers have shown with 0.2 
ng/μl of TGF-β1 incorporated within their hydrogel releases 31.6% of this amount over 7 
days and 41.5% over 21 days 
179
.  
In this study, we loaded different concentrations of TGF-β1 into the Extracel-HP
™
 
gels at variable doses, evenly coated the formulations on the ePTFE graft surface, 
dehydrated these gel coatings into a thin film (to demonstrate the feasibility of packaging 
and storage for clinical applications), and assessed the factor release rate over a 2 week 
period. Although this body of work is too premature in development to be able to 
evaluate induced elastic matrix regeneration within AAAs, it will serve as a proof-of-
concept that currently used grafts for EVAR can be modified to deliver elastogenic 
factors, for interaction with/ uptake by endogenous SMCs. This study will serve as a first 
step toward demonstrating that growth factor delivery in this manner can evoke 
elastogenic responses from SMCs within intact aneurysms, ultimately leading to elastic 












7.2.1 Surface modification of ePTFE graft  
 Since ePTFE is highly hydrophobic and inert, we functionalized our ePTFE graft 
(Aeos
™
 ePTFE; Zeus, Orangeburg, SC) surface by introducing reactive amines by NH3-
plasma treatment. Plasma treatment was performed at the lab of our collaborator, Dr. 
Marian McCord at NCSU. Flattened ePTFE grafts (2 mm diameter, 2 cm in length, and 
0-50 µm pore diameter) were ultrasonically cleaned with acetone and methanol. They 
were vacuum-dried and treated with a helium/ forming gas (H2, N2) mixture (base 
pressure: 2.67 Pa, He gas and forming gas flow rates: 10, 0.3-4 l/ min; < 12 min) while 
vertically oriented within a Pyrex glass plasma reactor so as to treat both exterior sides of 
the flattened graft.  
 
 
7.2.2 XPS validation of amine functionalization on ePTFE  
X-ray photoelectron spectroscopy (XPS) was used to determine the efficacy of the 
plasma treatment (to introduce amine groups on the surface of the ePTFE). Using this 
technique, we compared the elemental composition and chemical structure characteristics 
of the plasma-treated and untreated ePTFE. Samples were analyzed using an Axis 165 
XPS system (Kratos, Chestnut Ridge, NY) with a monochromatic aluminum target x-ray 
source (15 kV and 10 mA). Samples were analyzed at a pressure of 1 X 10
-9
 torr and 
temperature of 23 ºC with a takeoff angle close to 0º. Scans between 1200 eV and 0 eV 





Higher resolution spectra were also generated to monitor the formation of functional 
groups upon plasma treatment.  
 
7.2.3 Loading factors into the hydrogel  
Under sterile conditions, the ePTFE graft material was cut into rectangles (6.3 
mm x 66.7 mm) and individually placed, with the plasma-treated side up, in the wells of a 
24 well plate. Hydrogel films for coating ePTFE were prepared with thiolated derivatives 
of GAGs (HA) and gelatin (Gtn). Michael addition between these thiolated derivatives 
and diacrylate PEG at neutral to slightly basic pH was used to crosslink the hydrogel 
(Figure 7.1). HA-o & TGF-β (reconstituted in 50 µl PBS at the different concentrations 
listed in Table 7.1) was added to a mixture of Heprasil (carboxymethyl hyaluronic acid-
thiopropanoyl hydrazide with heparin-thiopropanoyl hydrazide (CHMA-S with HP-
DTPH) & Gelin-S (carboxymethyl gelatin-DTPH (Gtn-DTPH); Extracel-HP
™
 Hydrogel 
Kit, Glycosan Biosystems, Salt Lake City, Utah; 2 µl/ 3 samples; n = 3 samples/ 
condition) before crosslinking with Extralink (poly(ethylene glycol) diacrylate (PEGDA); 
25 µl/ 3 samples, yielding a total of 150 µl/ 3 samples).  
 











Table 7.1 TGF-β1 concentrations of each hydrogel test group (n = 3/ group). The doses 
correspond to the dose equivalent of the total TGF-β delivered to previously assessed   
healthy and aneurysmal SMC cultures over 21 days for elastogenic regeneration (0, 1, 5, 
10 ng/ml TGF-β; Chapters 4 and 5). The TGF-β release from the hydrogels was 
quantified at 1, 3, 7, and 14 days. 
 
7.2.4 Hydrogel coating on ePTFE  
The respective Extracel-HP
™
 hydrogel formulations (Table 7.1) were carefully 
pipetted onto the surface of the ePTFE (50 µl/ 420 mm
2
 sample; n = 3 samples/ group) 
and allowed to air-dry overnight in a standard cell culture hood, to create a thin film. 
 
7.2.5 SEM confirmation of hydrogel coating on ePTFE 
Scanning electron microscopy of the ePTFE surface before and after hydrogel 
coating was conducted to confirm uniform coating with the hydrogel and the absence of 
the hydrogel delaminating upon drying. The dried samples were mounted on aluminum 
stubs and imaged using a tabletop Hitachi SEM TM1000 (Hitachi Technologies, 
Pleasanton, CA), which is capable of direct stereoscopic observation of the surface 
topography of non-conductive samples. 
Group ID TGF-β (ug/ sample) Dose Equivalent (ng/ ml) 
A Control 0 
B 0.025  1 
C 0.125  5 





7.2.6 Factor release 
 Following re-hydration (5 min in phosphate buffered saline; PBS) of the hydrogel 
on the ePTFE samples, 1 ml of PBS was added to each sample well. The samples were 
stored at 37 °C and the PBS supernatants were replaced at 1, 3, 7, and 14 days; the 
removed PBS aliquots were stored at -20 °C until analysis. The TGF-β released from the 
hydrogel was measured using the TGF-β Emax
® 
ImmunoAssay System (Promega, 
Madison, WI), which measures biologically active TGF-β. A 96-well place was coated 
with TGF-β coat mAb (Promega) in coating buffer (1:1000 v/v; 100 µl/ well; Biolegend, 
San Diego, CA) and incubated overnight at 4 °C. The plate was then returned to RT and 
excess coating buffer removed.  Wells were blocked with TGF block buffer (35 min at 37 
°C; Promega) and vigorously washed with TBST wash buffer (Millipore, Billerica, MA). 
Standards were prepared and samples were added to wells (90 min; 500 RPM shaking at 
RT). 50 µl of diluted anti-TGF-β1 pAb was added to each well (2 hr; 500 RPM shaking 
at RT) followed by TBST washes. 100µl of HRP conjugate (Promega) was added to each 
well (2 hr; 500 RPM shaking at RT) followed by TBST washes. 100 µl of TMB One 
Solution was added to each well (15 min; RT; Promega) and the reaction stopped by 












7.3.1 XPS of surface amine groups  
 As illustrated in Table 7.2, XPS spectra show that gas plasma treatment of ePTFE 
introduces reactive amine/amide groups on the surface (compare increased N and O 
concentrations in cases 3 or 6 over case 1). There was a significant increase in % C, O, N 
in XPS spectra of HA-coated gas-plasma-treated ePTFE (7, 8) over non-coated and HA-
coated unmodified ePTFE (1, 2). Yet, treatment parameters need to be optimized to 
maximize surface functionalization of reactive functional groups. 
 
 
Table 7.2 XPS analysis of untreated and plasma-treated ePTFE with and without 








7.3.2 Hydrogel coating on ePTFE 
 The Extracel-HP
™
 hydrogel formulations with loaded factors (Table 7.1) were 
coated on plasma-treated Aeos
™
 ePTFE samples, dehydrated overnight, then rehydrated 
prior to assessment of factor release (Figure 7.2). The films appeared slightly crystalline 
upon dehydration, yet rehydrated fully to an even coating (with no cracks visible). 
 
Figure 7.2 (A) Aeos
™
 ePTFE alone (following plasma treatment); (B) ePTFE with 
Extracel-HP
™
 Hydrogel film; (C) Initial rehydration (30 sec) of hydrogel; (D) Complete 
rehydration (5 min) of hydrogel coating on ePTFE. 
 
7.3.3 SEM of hydrogel coating on graft  
The ePTFE was analyzed via scanning electron microscopy (SEM) before and 
after hydrogel coating. As illustrated in Figure 7.3, the ePTFE had an intermodal 
diameter of 0-50 μm. Upon coating with the hydrogel film, the hydrogel filled the ePTFE 
surface pores and there was a distinct film interface between the non-coated and 






7.3.4 Sustained TGF-β release  
 Slow TGF-β release was measured using the TGF-β Emax
® 
ImmunoAssay System. 
As demonstrated in Figure 7.4, over 14 days there was steady release of TGF-β beginning 
at 1 day post incubation; only 0.04% w/w (of the total TGF-β released over the 14 days) 
was released over 1 day, 13.8% w/w over 3 days, and 48.4% w/w over 7 days. The total 
active TGF-β released over the 14 days (1377 ± 93.7 pg/ sample), represented only a 
small fraction of the theoretical TGF-β loading amounts into the hydrogels (0.025, 0.125, 
and 0.25 µg/ sample). Thus, TGF-β release kinetics, at least at over the initial 14 days, 







Figure 7.3 SEM images of (A) ePTFE prior to hydrogel coating and (B) following 
hydrogel coating and dehydration. White arrows indicate the interface between uncoated 
and coated ePTFE. 
 
Figure 7.4 TGF-β (active) release over 14 days as measured by TGF-β Emax
® 
ImmunoAssay System. Data points and error bars are based upon values measured from 
all the hydrogel formulations listed in Table 7.1.  
 
7.4 Discussion  
In this study, we examined the efficiency of Aeos
™
 ePTFE graft materials coated 
with a factor-releasing hydrogel, Extracel-HP
™
. This study served as an in vitro 
assessment of hydrogel-coated graft delivery of our elastogenic factors, which can later 
be applied to endovascular delivery in vivo at the site of AAA for elastin regeneration, 

































provides a preliminary assessment of feasibility of endovascular elastogenic factor 
localized and sustained delivery to a diseased vessel segment.  
As mentioned previously, PTFE is a common EVAR graft material. Aeos
TM
  
ePTFE is micro-porous, biocompatible, implantable, flexible, hydrophobic, and has a 
high linear strength, excellent radial expansion, and has been shown to allow 
endothelialization 
235-236
. This material was chosen due to these ideal characteristics. A 
graft diameter of 2 mm was selected for study to facilitate future translation of this 
technology for study of therapeutic regression of AAAs, in rats, where the abdominal 
aorta typically measures ~2 mm in diameter. The graft material was made up of a number 
of solid ePTFE nodes inter-connected by a matrix of thin fibrils with 0-50 µm spacing 
between the nodes (IND) to eliminate passage of red blood cells through the graft. Due to 
the hydrophobicity of ePTFE, chemical modification of the graft surface was conducted 
to render it more reactive for adherence of the hydrogel coating. The results show that we 
effectively introduced reactive amines on the outer surface of the ePTFE (by NH3-plasma 
treatment), that could potentially bind to –COOH groups on the modified HA and thus 
bind the hydrogel coating.  
 The Extracel-HP
™
 hydrogel allowed for effective incorporation of TGF-β and its 
sustained release over a 14 day period in vitro (Figure 7.4). The hydrogel formulations 
assessed were loaded with TGF-β  amounts (0, 0.025, 0.125, and 0.25 µg/ sample) that 
represented equivalents of the TGF-β doses tested in Chapters 4 and 5 for elastogenic 
inductibility of aneurysmal SMCs in vitro (0, 1, 5, 10 ng/ml TGF-β, 5ml media/ well, 5 





we did not see a any dependence of kinetics of TGF-β (active-form) release from the 
hydrogels on TGF-β loading amounts, at least over 14 days of incubation in a non-
enzymatic aqueous medium. This suggests increasing the loaded TGF-β amounts in the 
hydrogels may only serve to prolong the duration of factor release. It is important to 
acknowledge that in the in vivo environment enzymatic degradation in addition to 
hydrolytic degradation is likely to occur more rapidly, therefore releasing the TGF-β at a 
more rapidly. It is also important to note that the -β Emax
® 
ImmunoAssay System only 
measures active TGF-β, so for future analysis it may be important to activate TGF-β 
(using an acid treatment procedure) prior to quantification to be sure to quantify both the 
active and inactive TGF-β released from the hydrogel.   
There is evidence that hyaluronan oligomers (HA-o) could be similarly released 
from the hydrogel due to hydrolytic and enzymatic degradation in vivo. Studies have 
shown that Extracel-HP
™
 is naturally degraded in vivo by endogenous hyaluronidases 
and collagenases produced by cells to form hyaluronan fragments 
179
. Degradation/ 





 with standard Extracel-HP
™
  formulations persisting in vivo for up to 4 weeks, 
and lyophilized sponges of the same material lasting as long as 8 weeks 
239-240
. 
Degradation times and therefore HA-o and TGF-β release can be altered based upon 
experimental requirements by controlling crosslinking within the hydrogels, which can in 
turn impact their water content. 
Additional work is necessary for demonstration of cellular uptake/interaction and 











graft materials. An in vitro experiment wherein factor delivery to EaRASMCs (elastase-
perfusion derived AAA SMCs) from Extracel-HP
™
-coated grafts would be a first step 
toward demonstrating elastogenic inductibility of these cell types. The hydrogel-coated 
graft could be mounted in cell culture wells to allow immersion in the culture medium 
without direct contact with the EaRASMCs. The elastic matrix deposition by the cells 
could be biochemically quantified and ultrastructurally assessed after 3 weeks of culture 
to validate the efficacy of factors delivered in this manner for elastogenic induction.  
There is a concern that the size of the hyaluronan degradation products from 
Extracel-HP
™
 may adversely influence the cellular response, with larger, non-oligomeric 
size fragments eliciting undesirable outcomes (e.g., inflammation). However, in prior 
studies, we have shown that non-oligomeric HA fragments do not impact tropoelastin 
synthesis and cellular proliferation, but in fact may improve elastic matrix deposition 
through coacervating tropoelastin by opposite charge interactions (a mostly physical 
effect) to facilitate efficient crosslinking into matrix structures 
180
. Future studies will 
thus need to evaluate the effects of these degradation products in the context of aneurysm 
repair, particularly from the standpoint of potentially inciting inflammatory responses. 
The modes of hydrogel degradation are discussed further below. 
Non-enzymatic hydrolysis and enzymatic hydrolysis (mainly resulting from 
MMPs, including collagensases, hyaluronidases, and chondroitinases) contribute to the 
degradation of Extracel-HP
™
. Figure 7.5A illustrates the non-enzymatic degradation of 
the HA-Gtn-based hydrogel, which interestingly is approximately four times longer than 
the predicted half-life for ester bond hydrolysis 
241





hyaluronidase (bovine testicular hyaluronidase) and collagenase (from Clostridium 
histolyticum) degradation of the hydrogel. These data suggest that the hydrogel is quite 
stable against hydrolytic degradation, yet degrades in an activity-dependent manner in an 
enzymatic environment. These characteristics can be taken advantage of in the future 
modification of this gel-based system for delivery of elastogenic factors in vivo. The 
factor-hydrogel formulations can be altered to take into account the enzymatic activity of 
the endogenous AAA environment. For example, increasing the hydrogel crosslinking 




Figure 7.5 (A) Nonenzymatic degradation in vitro of hydrogels: (a) 50:50 HA-Gtn 
hydrogel. Open circles indicate wet weights; open triangles indicate dry weights 
239
. (B) 
Enzymatic degradation in vitro of 50:50 HA-Gtn hydrogel in DMEM medium containing 
different concentrations of hyaluronandase plus collagenase. Open diamonds: no 
enzymes; open squares: 50 U/mL each enzyme; open triangles: 100 U/mL each enzyme; 








Another consideration is the mechanical forces seen by this delivery system in 
vivo; the modified EVAR system must have excellent fixation and the hydrogel-coating 
must be sustained for weeks to allow for appropriate delivery of elastogenic factors. 
Other groups have conducted numerical modeling of aneurysms and stent grafts using 
finite element analysis and computational fluid dynamics to evaluate the stresses on the 
aneurysm wall 
242-243
 and flow patterns and drag forces around stent grafts 
244
. Figure 7.6 
illustrates the wall stress in an aneurysm prior to and following EVAR treatment. 
Following EVAR, the highest stresses are seen at the sites of anstomoses, therefore, 
fixation approaches (high deployment pressure, hooks, or barbs) are extremely important 
to ensure the hydrogel coating of the stent are not eliminated due to the high pressures.   
 
 
Figure 7.6 (A) A computer-generated image illustrating a modular bifurcated graft. The 
main component comprises a body and one limb, introduced from the left femoral artery 
in this case (curved arrows). There is a short limb in the main component on the side 





docked with this short limb to complete the bifurcated device 
245
. (B) Von Mises stress of 
Pre-op, Post-op and Follow-up AAA models at time of maximum wall stress. Pre-op 
model (left), Post-op model (center), and Follow-up model (right) showing peak wall 
stress. Stresses are normalized to the pre-operative peak stress. The peak stress on the 




 Finally, an important consideration for the proposed mode of elastogenic factor 
delivery is intraluminal thrombus that would limit diffusion of the elastogenic factors to 
medial SMCs. It has been reported that in fact ~75% of all AAAs have intralunimal 
thrombus 
247
. In this context, elastogenic factor delivery would not be recommended for 
those AAAs with a thick thrombus. Alternatively, for thrombus-rich AAAs, other local 
delivery techniques could potentially be utilized. The Angiotensin II (Ang II) infusion 
AAA model may be useful to test additional delivery modes because the model yields 
thrombus formation in combination with aortic wall ECM degradation and expansion.  
 
7.5 Conclusions 
1.   This study provides a preliminary assessment of the feasibility of localized, 
endovascular elastogenic factor delivery to an aneurysmal vessel segment. It serves 
as a preliminary in vitro assessment of hydrogel-coated graft delivery of our 
elastogenic factors, which can later be applied to endovascular delivery in vivo at 
the site of AAA for elastin regeneration, elimination of endoleak, inhibition of 






2.      The Extracel-HP
™




 ePTFE graft and sustained TGF-β 
delivery over weeks is promising, yet much further work addressing functional 









OVERALL CONCLUSIONS FROM THIS PROJECT AND FUTURE DIRECTIONS 
 
8.1 Overall conclusions 
The objectives of this project were to (a) assess the utility of the extracellular 
matrix-derived factors, hyaluronan oligomers (HA-o) and TGF-β1 (elastogenic factors), 
to stimulate aneurysmal SMCs (from CaCl2-injury and elastase-perfusion AAA models) 
to regenerate biologically and ultrastructurally faithful mimics of native vascular elastin 
networks, (b) identify a working range of effective elastogenic factor doses, which may 
serve as a basis for model-independent prediction of in vivo delivery doses, (c) 
demonstrate that clinical translation of this elastogenic induction approach is feasible, (d) 
predict if and how basal and induced elastic matrix repair and new elastic matrix 
regeneration by activated vascular SMCs depends on their location within AAAs, and (e) 
provide preliminary studies toward developing a strategy for localized delivery of 
elastogenic factors within intact AAAs, and demonstrate the feasibility of sustained 
release of these factors. 
Here, we will summarize the conclusions we have drawn from this project as a 
whole towards the above outlined objectives.  The CaCl2-treatment and elastase 
intralumenal perfusion models were successful in inducing expansions in the abdominal 
aorta of rats (~45% and ~120% diameter increase within 28 days and 14 days, 
respectively). Specifically, the CaCl2-injury model of AAAs exhibited pathological 





calcification, and enhanced MMP activity and CaCl2-injury-derived SMCs (aRASMCs) 
had similarities to aneurysmal human SMCs (aHASMCs) in terms of decreased 
contractile activity, enhanced proliferation, increase elastolytic activity, and reduced 
elastogenic capacity (relative to healthy SMCs). Compared to healthy RASMC cultures, 
aRASMCs proliferated less and produced less collagen, tropoelastin, and matrix elastin. 
The protein synthesis within these aRASMC cultures was not up-regulated by adding 
either HA-o or TGF-β alone. Yet, concurrent delivery of the factors resulted in slight 
suppression of proliferation, significant increases in lysyl oxidase (LOX), desmosine, 
collagen, tropo- and matrix elastin, and reduced calcification and MMP activity in 
aRASMC cultures, which was not achieved by the presence of either factor alone. 
  The CaCl2-injury model differed from human AAAs in cellular responses to 
elastogenic stimulation; aRASMCs appeared to be less sensitive to TGF-β and HA-o in 
the context of elastin regenerative responses relative to aHASMCs, though trends were 
maintained.  Factors attenuated elastolytic MMP-2 activity in aRASMCs; interestingly, 
no significant decrease was seen in aHASMC cultures, yet an overall decrease in MMP 
and TIMP expression was seen with factor supplementation. The differences in cell 
responses to factors may likely be due to differences in the stage of maturation of the 
AAAs studied. Therefore, the CaCl2-injury model of AAAs may not be the most 
appropriate as a surrogate in the context of elastin regeneration within human AAAs, 






The elastase perfusion-injury model induced pathological characteristics similar 
to human AAAs, such as medial elastic matrix disruption, increased MMP activity, and 
~120% increase in aortic diameter, similar to more advanced human AAAs. EaRASMC 
phenotypic analysis revealed a significant number of EaRASMCs exhibited decreased 
contractile markers relative to healthy control RASMCs, suggesting an activated 
phenotype. There was significant differential gene expression of EaRASMC relative to 
RASMCs, supporting that the AAA-derived cells maintain altered gene expression in 
vitro (even at passage 3). The EaRASMCs proliferated much faster than healthy 
RASMCs and HA-o and TGF- suppressed cell proliferation significantly, relative to 
control EaRASMCs. EaRASMCs were sensitive to TGF-β and HA-o in the context of 
elastic matrix regenerative responses and elastolytic MMP-2 activity was attenuated. In 
support of these findings, differential gene expression (e.g., MMP, TIMP) as a result of 
supplemented HA-o and TGF-was observed, yet further assessment of functional gene 
groups is necessary.  Overall, the elastase perfusion-injury model of AAAs may be 
suitable as a surrogate in the context of elastin regeneration within advanced human 
AAAs, yet a shortcoming is the unparalleled increases in tropoelastin production by 
aHASMCs in response to factor supplementation.  
Table 8.1 shows the biochemical data obtained from study of the SMCs derived 
from the different AAA models. This compiled data illustrates our observations that 
aRASMCs, EaRASMCs, and aHASMCs with factor supplementation produced absolute 
amounts of tropoelastin quantities beyond that produced by healthy RASMCs and 





supplementation produced absolute amounts of matrix elastin quantities at or beyond 
amounts produced by healthy RASMCs, while aHASMCs with factor supplementation 
did not produce absolute amounts of matrix elastin to the level of healthy HASMCs, 
although they did have a dramatic 8.5-fold increase in matrix elastin as normalized to 
DNA and non-supplemented aHASMC control levels (Table 8.1C).  
 
Table 8.1 Biochemical data collected from the AAA-derived SMC cultures as compared 
to one another and their respective controls. (A) Cell sources and proliferation relative to 
healthy SMCs. Maximum absolute tropoelastin (B) and matrix elastin (C) amounts 
(average µg/ sample) produced by SMC layers and tropoelastin (B) and matrix elastin (C) 






Figure 8.1 illustrates the effects of the factor doses on elastin production and 
matrix formation. The same HA-o and TGF- doses appear to have more or less 
exaggerated effects on tropoelastin production and matrix elastin crosslinking by the 
AAA-derived SMCs from different models, with the most obvious difference being the 
bi-modal effect of TGF-β at low HA-o doses on aHASMCs. This indicates to us that the 
aHASMCs are more sensitive to the factors than the aRASMCs and EaRASMCs. At 
higher (than tested) TGF-β doses, we would anticipate a similar characteristic bi-modal 
response of the aRASMCs and EaRASMCs.  
It was important to assess if the increase in elastin production by SMCs with 
factor supplementation was accompanied by an increase in other proteins within these 
SMC cultures. Table 8.2 illustrates the minimal differences in protein content (as 
quantified using a BCA assay on spent medium from the cultures) indicating there is not 
a dramatic influence on overall protein production by these SMCs due to factor 
supplementation. Further study of SMCs from stage-matched elastase perfusion-injury 
generated aortal expansions and human AAAs will be necessary to more rigorously 







Figure 8.1 Trends of tropoelastin and matrix elastin production by AAA-derived SMCs 
with the addition of elastogenic factors. Data points represent the mean elastin 







Table 8.2 Protein amounts quantified (BCA assay) from spent medium samples of the 
SMC layers listed (average µg/ sample ± standard deviation). No/minimal increases in 
overall protein in spent medium was observed with the additional of factors.  
 
The observations from our in vitro elastase-injury studies illustrated the ability of 
cell layers to self-repair and regenerate elastic matrices following their proteolytic 
damage is limited, particularly when elastic matrix injury is severe. Our results also 
provide evidence that HA-o and TGF-β factors together can elastogenically stimulate 
RASMCs in elastin-degraded cultures to restore both elastic matrix amounts and elastic 
fiber deposition to levels of accumulation observed in healthy cultures. Doses of the 
elastogenic factors must be enhanced and optimized based on the severity of elastic 
matrix damage.  
 We conducted preliminary in vitro assessment of hydrogel-coated graft delivery 
of our elastogenic factors, which can later be applied to endovascular delivery in vivo at 





growth, and possibly even AAA regression. The Extracel-HP
™




 ePTFE graft and sustained TGF-β delivery over weeks is promising, yet much 
further work addressing functional efficacy is necessary.  
 
8.2 Future outlook 
 This thesis details the progress made regarding cell-mediated elastic matrix 
regeneration toward regression of AAAs. Despite the many positive outcomes of the 
project, there are still several issues that need to be addressed/ resolved. We have begun 
to investigate the gene expression profiles of elastase perfusion AAA-derived cells 
(EaRASMCs) and those that have been supplemented with HA-o and TGF-β factors, 
relative to healthy RASMC; this has provided us with a great deal of information to 
investigate the mechanism at work, yet extensive follow-up work is necessary. In 
additional to gaining a mechanistic understanding of HA-o and TGF-β  effects on elastic 
matrix assembly, in vivo delivery of the factors and functional analysis in the complex 
AAA environment is crucial. Suggestions for future study include:  
  
1. Identification and quantification of specific genes and cell surface-receptors 
modulated by HA-o and TGF-β1in elastic matrix assembly. 
 
2. Design and fabrication of a customized bioreactor for long-term (6-8 week) in situ 
aortae tissue culture to optimize factor formulations for hydrogel-graft delivery (and 






3. Hydrogel coating and deployment studies to address challenges of the hydrogel-graft 
delivery modality. 
 
4. Controlled, local delivery of these optimized elastogenic factors to elastase-perfused 
AAA sites in vivo. 
 
 
5. Mechanical testing of aorta burst strength following elastic matrix regeneration.  
 




































Functionally categorized differential gene expression: 
effects of elastase perfusion and HA-o and TGF-β 
Gene Symbol 
          Functional Group Elastase vs Healthy Elastase+Factors vs Control Elastase+Factors vs Elastase 
 
SMC Fold change P value   Fold change P value   Fold change P value   
Il6 0.60 0.401626   1.21 0.76317   2.01 0.387412   
Ptgs2 0.91 0.643641   1.79 0.05619   1.97 0.022163   
Igfbp5 0.37 0.068968   0.64 0.30545   1.72 0.250517   
Edn1 1.14 0.363659   1.71 0.01044   1.51 0.042894   
Igfbp5 0.42 0.074371   0.64 0.31369   1.51 0.374809   
Pdgfa 1.17 0.214759   1.69 0.01301   1.44 0.008892   
Igfbp5 0.55 0.101609   0.76 0.4801   1.39 0.379792   
Calcrl 1.29 0.516066   1.80 0.0839   1.39 0.429106   
Plau 2.28 0.186726   3.10 0.11168   1.36 0.631705   
Rcan1 0.53 0.006866   0.69 0.02226   1.29 0.092128   
Aamp 1.21 0.56031   1.54 0.20896   1.27 0.271108   
Plau 1.96 0.186801   2.41 0.08187   1.23 0.670651   
Igfbp3 8.34 0.046284   10.20 0.02542   1.22 0.79115   
Pdgfa 1.26 0.065877   1.53 0.00145   1.21 0.100302   
Flt1 0.45 0.005677   0.54 0.02167   1.19 0.334386   
Ang1 1.42 0.185657   1.71 0.06752   1.19 0.502653   
Tgfbr2 1.39 0.5072   1.65 0.248   1.18 0.659857   
Jun 1.37 0.022319   1.61 0.01379   1.18 0.048104   
Flt1 0.45 0.030265   0.52 0.03798   1.17 0.235144   
Fgfr2 1.37 0.388995   1.57 0.25503   1.15 0.461533   
S1pr1 0.30 0.045423   0.34 0.01622   1.13 0.740314   
Jun 1.45 0.017525   1.64 0.01306   1.13 0.155523   
Plat 0.52 0.007598   0.56 0.00042   1.09 0.421657   
Igfbp3 8.63 0.047674   9.38 0.01786   1.09 0.910991   
Bmp4 0.34 0.191973   0.34 0.13864   1.01 0.987394   
Wnt4 0.44 0.002765   0.44 0.00164   0.99 0.892201   
Cdh13 0.52 0.053067   0.50 0.02814   0.95 0.844594   
Cdh13 0.46 0.008636   0.37 0.00793   0.81 0.324185   
Abcc4 0.70 0.02322   0.57 0.0047   0.81 0.073253   








          
Functional Group Elastase vs Healthy Elastase+Factors vs Control Elastase+Factors vs Elastase 
 
ECM Fold change P value   Fold change P value   Fold change P value   
Col11a1 0.99 0.92619   1.88 0.00532   1.89 0.006218   
Col12a1 1.27 0.569232   2.27 0.03027   1.79 0.208378   
Col12a1 1.21 0.536214   2.01 0.02334   1.67 0.178639   
Col11a1 0.80 0.167469   1.33 0.13562   1.66 0.036941   
Acan 2.03 0.181373   3.25 0.00834   1.60 0.327825   
Acan 1.75 0.09966   2.01 0.02172   1.15 0.60649   
Col24a1 0.52 0.10521   0.55 0.05511   1.06 0.858478   
Col27a1 1.58 0.195917   1.61 0.17863   1.02 0.85531   
Col4a5 0.59 0.000945   0.51 0.01079   0.86 0.254557   
Col4a2 0.66 0.075698   0.57 0.04138   0.86 0.400526   
Eln 0.71 0.7619   0.28 0.125   0.39 0.41874   
          
           
Gene Symbol 
          
Functional Group Elastase vs Healthy Elastase+Factors vs Control Elastase+Factors vs Elastase 
 
Apoptosis Fold change P value   Fold change P value   Fold change P value   
Il1b 1.16 0.466254   3.32 0.08766   2.89 0.104409   
Sod2 1.10 0.852202   2.43 0.09699   2.20 0.237827   
Il6 0.60 0.401626   1.21 0.76317   2.01 0.387412   
Ptgs2 0.91 0.643641   1.79 0.05619   1.97 0.022163   
Tgfb2 0.63 0.1584   1.09 0.678   1.74 0.126365   
Rarb 0.49 0.037748   0.79 0.2864   1.61 0.005104   
Tcf7 2.66 0.030365   4.14 0.00891   1.56 0.233474   
Sod2 1.07 0.837145   1.57 0.1281   1.46 0.331139   
Slc2a3 1.49 0.381544   2.17 0.11957   1.45 0.29719   
Rarg 1.14 0.74717   1.64 0.19031   1.43 0.324017   
Sh3kbp1 1.41 0.234334   1.91 0.05178   1.35 0.334126   
Cdkn1a 1.68 0.087314   2.27 0.03164   1.35 0.110026   
Nuak2 1.24 0.19803   1.64 0.07311   1.32 0.208639   
Dusp1 1.54 0.126132   1.97 0.06009   1.28 0.180143   
Sh3kbp1 1.85 0.185964   2.38 0.05098   1.28 0.555288   
Psen1 1.29 0.451495   1.65 0.19463   1.27 0.261339   
Bcl2l1 1.22 0.317295   1.55 0.07276   1.26 0.162954   
Fgfr1 1.46 0.377823   1.80 0.09336   1.23 0.631933   
Igfbp3 8.34 0.046284   10.20 0.02542   1.22 0.79115   
Dedd 2.51 0.008473   3.01 0.0036   1.20 0.365891   





Aldh1a3 0.09 0.016994   0.10 0.02204   1.16 0.79035   
Sphk1 1.61 0.102913   1.87 0.13006   1.16 0.671907   
Cdkn1b 1.80 0.210276   2.06 0.13656   1.14 0.654001   
Slc2a3 1.44 0.004452   1.65 0.01098   1.14 0.253205   
Jun 1.45 0.017525   1.64 0.01306   1.13 0.155523   
Il1rn 1.65 0.206985   1.83 0.25262   1.11 0.836328   
Igfbp3 8.63 0.047674   9.38 0.01786   1.09 0.910991   
Sgk1 1.43 0.250665   1.54 0.12924   1.07 0.824026   
Pla2g4a 0.54 0.01162   0.57 0.01865   1.06 0.538588   
Krt18 1.45 0.445778   1.51 0.25905   1.04 0.937859   
Cx3cl1 0.46 0.035913   0.45 0.03149   0.97 0.90341   
Bdkrb2 /// 
RGD1308470 1.51 0.345011   1.46 0.25747   0.97 0.946584   
Fosl1 1.56 0.057282   1.49 0.19673   0.97 0.892607   
Scg2 0.55 0.436181   0.49 0.38369   0.90 0.900874   
Casp12 0.54 0.026857   0.47 0.01923   0.88 0.404009   
Arnt2 0.66 0.020512   0.57 0.00681   0.88 0.259162   
Bcl11b 1.77 0.128676   1.55 0.19129   0.87 0.705116   
Dedd 0.66 0.033757   0.55 0.01677   0.83 0.064734   
Casp4 0.68 0.039668   0.56 0.00521   0.82 0.184381   
Cd74 0.59 0.220776   0.45 0.05074   0.76 0.440143   
Rbm5 0.79 0.643049   0.47 0.16589   0.60 0.24002   
Rbm5 0.85 0.808848   0.49 0.25023   0.58 0.355954   
Pabpn1 0.87 0.856259   0.44 0.23259   0.50 0.295728   
 
Gene Symbol 
          
Functional Group Elastase vs Healthy Elastase+Factors vs Control Elastase+Factors vs Elastase 
 
Inflammatory Fold change P value   Fold change P value   Fold change P value   
Cxcl1 1.23 0.841887   6.23 0.03932   5.06 0.204318   
Calca 5.43 0.070802   19.56 0.01789   3.61 0.1597   
Il1a 1.15 0.595764   3.46 0.11739   3.01 0.135762   
Il1b 1.16 0.466254   3.32 0.08766   2.89 0.104409   
Il1a 1.51 0.251524   4.06 0.06718   2.69 0.11757   
Ccl20 3.56 0.310902   9.51 0.05306   2.68 0.444948   
Lbp 0.45 0.253799   1.21 0.71938   2.66 0.207958   
Ccl11 9.71 0.142542   24.08 0.05125   2.48 0.509848   
Calca 1.48 0.235877   3.34 0.09209   2.25 0.169999   
Il6 0.60 0.401626   1.21 0.76317   2.01 0.387412   
Ptgs2 0.91 0.643641   1.79 0.05619   1.97 0.022163   
C3 3.03 0.187732   5.74 0.07868   1.89 0.484129   





Calca 1.00 0.98212   1.69 0.14741   1.69 0.140456   
Bdkrb1 1.77 0.312226   2.95 0.13583   1.67 0.454037   
LOC687992 1.21 0.30849   1.92 0.1843   1.59 0.295729   
Olr1 0.79 0.250987   1.19 0.16532   1.51 0.089561   
Ccl7 2.79 0.16366   4.23 0.02493   1.51 0.529097   
Ccl2 1.28 0.61751   1.83 0.12531   1.41 0.527683   
Tollip 1.13 0.745545   1.60 0.26364   1.41 0.159779   
Bmp2 1.97 0.027986   2.77 0.01055   1.40 0.191856   
F3 1.29 0.516002   1.80 0.09918   1.39 0.439078   
Calcrl 1.29 0.516066   1.80 0.0839   1.39 0.429106   
Fabp4 1.47 0.261607   2.00 0.12372   1.36 0.468983   
Bmp2 1.78 0.062863   2.39 0.0251   1.35 0.305759   
Masp1 3.53 0.038798   4.72 0.05446   1.34 0.610745   
Tnfrsf1b 1.77 0.233661   2.36 0.14132   1.34 0.588102   
Adora2b 1.65 0.320441   2.07 0.17654   1.26 0.680103   
Il4ra 0.54 0.006689   0.65 0.13898   1.20 0.452939   
Fcgr2b 1.42 0.185508   1.67 0.11147   1.16 0.582423   
Sphk1 1.61 0.102913   1.87 0.13006   1.16 0.671907   
Ptafr 1.56 0.111794   1.78 0.03452   1.13 0.602021   
Masp1 3.84 0.026681   4.35 0.02817   1.13 0.766825   
Serpina3n 0.09 0.015888   0.10 0.02046   1.12 0.267368   
Il1rn 1.65 0.206985   1.83 0.25262   1.11 0.836328   
Ccr1 1.75 0.147837   1.91 0.18291   1.09 0.842117   
Igfbp4 1.45 0.415808   1.57 0.29398   1.08 0.880775   
Pla2g4a 0.54 0.01162   0.57 0.01865   1.06 0.538588   
Spp1 0.58 0.105861   0.60 0.01861   1.04 0.871083   
Il17b 1.62 0.004118   1.59 0.00835   0.98 0.709508   
Pdpn 3.32 0.093758   3.25 0.04055   0.98 0.973203   
Cx3cl1 0.46 0.035913   0.45 0.03149   0.97 0.90341   
Aif1l 1.52 0.032087   1.42 0.04783   0.94 0.644912   
Ednra 0.56 0.136364   0.49 0.07152   0.87 0.673086   
Ggt5 1.71 0.16035   1.47 0.24661   0.86 0.698545   














          
Functional Group Elastase vs Healthy Elastase+Factors vs Control Elastase+Factors vs Elastase 
 
MMP Fold change P value   Fold change P value   Fold change P value   
Mmp3 1.30 0.393566   3.03 0.14918   2.31 0.221094   
Timp3 0.98 0.8921   1.65 0.034   1.68 0.020215   
Mmp13 1.00 0.987619   1.64 0.1646   1.64 0.176342   
Timp3 1.10 0.5638   1.55 0.04   1.40 0.071918   
Adam19 1.18 0.54488   1.57 0.09974   1.33 0.26884   
Spg7 1.33 0.4387   1.69 0.20801   1.27 0.218382   
Adam10 1.21 0.589963   1.53 0.1662   1.26 0.480745   
Mmp15 1.47 0.325779   1.85 0.10088   1.26 0.485582   
Mme 1.27 0.347804   1.53 0.10062   1.21 0.330783   
Adamts9 0.31 0.160119   0.31 0.05271   0.97 0.96868   
Mmp12 2.03 0.1526   1.61 0.136   0.80 0.575757   
Mmp23 0.72 0.447467   0.54 0.16614   0.75 0.392478   
LOC314655 0.66 0.204466   0.46 0.01977   0.70 0.254939   
Bmp1 0.72 0.370985   0.45 0.05648   0.63 0.213692   
Adam33 0.90 0.856548   0.48 0.21874   0.54 0.228588   
 
Gene Symbol 
          
Functional Group Elastase vs Healthy Elastase+Factors vs Control Elastase+Factors vs Elastase 
 
TGF Fold change P value   Fold change P value   Fold change P value   
Tgfb2 0.63 0.158   1.09 0.678   1.74 0.126   
Tnfaip6 1.79 0.049   2.87 0.011   1.60 0.118   
Acan 2.03 0.181   3.25 0.008   1.60 0.328   
Fos 0.55 0.005   0.84 0.153   1.54 0.024   
Pdgfa 1.17 0.215   1.69 0.013   1.44 0.009   
Ccl2 1.28 0.618   1.83 0.125   1.41 0.528   
Hapln3 1.73 0.009   2.22 0.039   1.29 0.290   
Bmpr2 1.42 0.025   1.74 0.006   1.22 0.076   
Pdgfa 1.26 0.066   1.53 0.001   1.21 0.100   
Tgfbr2 1.39 0.507   1.65 0.248   1.18 0.660   
Jun 1.37 0.022   1.61 0.014   1.18 0.048   
Acan 1.75 0.100   2.01 0.022   1.15 0.606   
Jun 1.45 0.018   1.64 0.013   1.13 0.156   
Vcan 1.62 0.329   1.83 0.012   1.12 0.796   
Ltbp4 0.51 0.124   0.54 0.055   1.05 0.891   
Vcan 1.54 0.216   1.55 0.020   1.00 0.993   
Vcan 1.65 0.163   1.57 0.014   0.95 0.859   






Differentially expressed genes: symbols and names 
Gene Symbol Gene Title 
Aamp angio-associated, migratory cell protein 
Abcc4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 
Acan aggrecan 
Adam10 ADAM metallopeptidase domain 10 
Adam19 a disintegrin and metallopeptidase domain 19 (meltrin beta) 
Adam33 ADAM metallopeptidase domain 33 
Adamts9 a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 9 
Adora2b adenosine A2B receptor 
Aif1l allograft inflammatory factor 1-like 
Aldh1a3 aldehyde dehydrogenase 1 family, member A3 
Ang1 angiogenin, ribonuclease A family, member 1 
Arnt2 aryl hydrocarbon receptor nuclear translocator 2 
Bcl11b B-cell CLL/lymphoma 11B (zinc finger protein) 
Bcl2l1 Bcl2-like 1 
Bdkrb1 bradykinin receptor B1 
Bdkrb2 /// RGD1308470 bradykinin receptor B2 /// similar to RIKEN cDNA 4933433P14 gene 
Bmp1 bone morphogenetic protein 1 
Bmp2 bone morphogenetic protein 2 
Bmp4 bone morphogenetic protein 4 
Bmpr2 bone morphogenetic protein receptor, type II (serine/threonine kinase) 
C3 complement component 3 
Calca calcitonin/calcitonin-related polypeptide, alpha 
Calcrl calcitonin receptor-like 
Casp12 caspase 12 
Casp4 caspase 4, apoptosis-related cysteine peptidase 
Ccl11 chemokine (C-C motif) ligand 11 
Ccl2 chemokine (C-C motif) ligand 2 
Ccl20 chemokine (C-C motif) ligand 20 
Ccl7 chemokine (C-C motif) ligand 7 
Ccr1 chemokine (C-C motif) receptor 1 
Cd74 Cd74 molecule, major histocompatibility complex, class II invariant chain 
Cdh13 cadherin 13 
Cdkn1a cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
Cdkn1b cyclin-dependent kinase inhibitor 1B 
Col11a1 collagen, type XI, alpha 1 





Col24a1 collagen, type XXIV, alpha 1 
Col27a1 Collagen, type XXVII, alpha 1 
Col4a2 collagen, type IV, alpha 2 
Col4a5 collagen, type IV, alpha 5 
Cx3cl1 chemokine (C-X3-C motif) ligand 1 
Cxcl1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 
Cxcl2 chemokine (C-X-C motif) ligand 2 
Dedd Death effector domain-containing 
Dusp1 dual specificity phosphatase 1 
Edn1 endothelin 1 
Ednra endothelin receptor type A 
Eln elastin 
F3 coagulation factor III (thromboplastin, tissue factor) 
Fabp4 fatty acid binding protein 4, adipocyte 
Fcgr2b Fc fragment of IgG, low affinity IIb, receptor (CD32) 
Fgfr1 Fibroblast growth factor receptor 1 
Fgfr2 fibroblast growth factor receptor 2 
Flt1 fms-related tyrosine kinase 1 
Fos FBJ osteosarcoma oncogene 
Fosl1 fos-like antigen 1 
Ggt5 gamma-glutamyltransferase 5 
Hapln3 hyaluronan and proteoglycan link protein 3 
Igfbp3 insulin-like growth factor binding protein 3 
Igfbp4 insulin-like growth factor binding protein 4 
Igfbp5 insulin-like growth factor binding protein 5 
Il17b interleukin 17B 
Il1a interleukin 1 alpha 
Il1a interleukin 1 alpha 
Il1b interleukin 1 beta 
Il1rn interleukin 1 receptor antagonist 
Il1rn interleukin 1 receptor antagonist 
Il4ra interleukin 4 receptor, alpha 
Il6 interleukin 6 
Jun Jun oncogene 
Krt18 keratin 18 
Lbp lipopolysaccharide binding protein 
LOC314655 Similar to a disintegrin-like and metalloprotease with thrombospondin type 1 motif, 10 
LOC687992 similar to Serum amyloid A-3 protein precursor 
Ltbp4 latent transforming growth factor beta binding protein 4 





Mme membrane metallo endopeptidase 
Mmp12 matrix metallopeptidase 12 
Mmp13 matrix metallopeptidase 13 
Mmp15 matrix metallopeptidase 15 
Mmp23 matrix metallopeptidase 23 
Mmp3 matrix metallopeptidase 3 
Nuak2 NUAK family, SNF1-like kinase, 2 
Olr1 oxidized low density lipoprotein (lectin-like) receptor 1 
Pabpn1 poly(A) binding protein, nuclear 1 
Pdgfa platelet-derived growth factor alpha polypeptide 
Pdgfrb platelet derived growth factor receptor, beta polypeptide 
Pdpn podoplanin 
Pla2g4a phospholipase A2, group IVA (cytosolic, calcium-dependent) 
Plat plasminogen activator, tissue 
Plau plasminogen activator, urokinase 
Psen1 presenilin 1 
Ptafr platelet-activating factor receptor 
Ptgs2 prostaglandin-endoperoxide synthase 2 
Rarb retinoic acid receptor, beta 
Rarg retinoic acid receptor, gamma 
Rbm5 RNA binding motif protein 5 
Rcan1 regulator of calcineurin 1 
S1pr1 sphingosine-1-phosphate receptor 1 
Scg2 secretogranin II (chromogranin C) 
Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N 
Sgk1 serum/glucocorticoid regulated kinase 1 
Sh3kbp1 SH3-domain kinase binding protein 1 
Slc2a3 Solute carrier family 2 (facilitated glucose transporter), member 3 
Sod2 superoxide dismutase 2, mitochondrial 
Spg7 spastic paraplegia 7 homolog (human) 
Sphk1 sphingosine kinase 1 
Spp1 secreted phosphoprotein 1 
Tcf7 transcription factor 7, T-cell specific 
Tgfb2 Transforming growth factor, beta 2 
Timp3 TIMP metallopeptidase inhibitor 3 
Tnfaip6 tumor necrosis factor alpha induced protein 6 
Tnfrsf1b tumor necrosis factor receptor superfamily, member 1b 
Tollip toll interacting protein 
Vcan versican 
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